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Abstract
The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and develop-
ment, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete 
steps that can be individually evaluated and quantified by a large number of bioassays. These independent assessments hold 
advantages but also have limitations. This article describes in vivo, ex vivo, and in vitro bioassays that are available for the 
evaluation of angiogenesis and highlights critical aspects that are relevant for their execution and proper interpretation. As 
such, this collaborative work is the first edition of consensus guidelines on angiogenesis bioassays to serve for current and 
future reference.
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1 Introduction
The process of angiogenesis—the formation of new blood 
vessels from preexisting ones—is a hallmark of tissue repair, 
expansion, and remodeling in physiological processes, such 
as wound healing, ovulation, and embryo development, and 
in various pathologies including cancer, atherosclerosis, 
and chronic inflammation [1–5]. Many of these conditions 
share characteristics, for example the occurrence of hypoxia 
or inflammation, recruitment of inflammatory cells, angio-
genic growth factor production, basement membrane deg-
radation, endothelial cell (EC) migration, proliferation and 
differentiation, and modulation of vascular support cells. 
However, depending on the tissue or disease under inves-
tigation, important details may differ considerably. Moreo-
ver, EC in different vascular beds exhibits organ-specific 
heterogeneity associated with the differentiated specialized 
functions of the tissue. It is often not possible to accurately 
visualize the process of angiogenesis and its molecular 
players. Therefore, different in vivo, ex vivo, and in vitro 
bioassays and techniques have been developed to investi-
gate the specific stages of the angiogenesis. However, the 
use of bioassays that study a part of the process, with the 
intention to extrapolate and understand the full process of 
angiogenesis, inherently implies accepting specific limita-
tions. It is therefore crucial to understand the full potential 
of these bioassays during their specific applications. These 
assays have been instrumental in the study of vascular biol-
ogy in growth and development [6–8] but also play a key 
role in the design, development, and evaluation of drugs 
that positively or negatively modulate vessel function for 
the treatment of many diseases [9–11]. Some examples of 
where the use of such bioassays has been imperative are: 
(1) the development of angiostatic drugs for the treatment 
of cancer, ocular diseases, and other pathologic conditions 
where angiogenesis is implicated and also angiogenic treat-
ment strategies in ischemic cardiovascular disease [12, 13], 
(2) screening of natural anti-angiogenic compounds [14], (3) 
the efforts to design combination therapies including angio-
genesis inhibitors [15–20], (4) the unraveling of mechanisms 
regulating lymphangiogenesis [21, 22], (5) the interrelation-
ship of angiogenesis and immunity [23–25], (6) the develop-
ment of imaging as diagnostic strategy [26], (7) the study 
of drug resistance mechanisms [27–29], (8) development 
of compounds and strategies for the revascularization of 
ischemic injuries [30, 31], and (9) to improve the vascular 
fitness in aging vessels [32, 33]. The current paper describes 
a large collection of assays and techniques for the evalua-
tion of angiogenesis and aims at explaining their respec-
tive advantages and limitations. In addition, we included 
strategies to study angiogenesis in tissues, through means 
of assessing and quantifying microvessel density (MVD), 
vessel co-option, pericyte coverage, and tip cell behavior.
2  Endothelial cell and monocyte migration 
assays
EC migration is one of the hallmarks of angiogenesis and 
one of the earlier steps in the angiogenic cascade. This 
process is characterized by cell-autonomous motility prop-
erty but in some cases, it acquires the features of collective 
migration [34–37], in which a group of cells coordinate their 
movements toward a chemotactic gradient and by estab-
lishing a precise hierarchy with leader and follower cells. 
Therefore, dissection of the molecular mechanisms of EC 
migration is critical to understand and to therapeutically 
manipulate the process to either inhibit sprouting (e.g., in 
tumors) or stimulate vessel formation (e.g., during tissue 
regeneration or wound healing).
Likewise, migration assays have been successfully used 
to assess the migratory responsiveness of monocytes. 
Monocytes are actively involved in angiogenesis, and their 
migratory response or potential correlates well with that of 
endothelial cells. Most importantly, CD14-positive mono-
cytes can easily be isolated and obtained from any individ-
ual, not only humans [38, 39], but also mice [40]. A number 
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of 2D and 3D cellular migration assays have been estab-
lished as relatively simple in vitro readouts of the migratory/
angiogenic activity of EC in response to exogenous stimuli. 
Depending on the specific scientific question, a range of 
assays is available to quantitatively and qualitatively assess 
EC migration. The most widely employed assays include 
variations of the wound closure and the Boyden chamber 
assays.
2.1  Types of assays
Cell culture wound closure assay Lateral migration assays 
are performed to investigate the pro- or anti-migratory effect 
of compounds, as well of specific gene perturbations, or to 
describe phenotypes resulting from genetic manipulation 
of EC. Although these assays can be used to characterize 
chemokinesis (unidirectional migration) in response to a 
given compound added to the cell culture medium, they do 
not allow determination of directed migration rate toward or 
away from a compound. Assessment of chemotaxis can only 
be determined when a gradient is also provided.
The cell culture wound closure assay is one of the basic 
readouts for characterizing the migratory activity of cells. 
It is a measure of the lateral 2D migration of EC in cell cul-
ture to test compounds for pro-migratory or anti-migratory 
activity. Depending on the migratory effect of the tested 
substances, the assay is performed over 2–4 days. ECs are 
grown to confluency in a cell culture dish and then scraped 
with a razor blade/pipette tip [41], allowing the EC at the 
wound edge to migrate into the scraped area. To really exam-
ine the motility contribution to the healing and to exclude 
the component related to cell proliferation, ECs are incu-
bated with the antimitotic agent mitomycin [42]. Large 
genome-wide screens can also be assessed with the scratch 
wounding technique. The use of precision wounding replica-
tors with floating pins and a workstation robot enables large 
numbers of scratches to be made with reduced coefficients 
of variation [43, 44].
Wound healing assay connected with video-lapse micros-
copy allows studying in 2D dimension the role of collec-
tive migration in angiogenesis and vascular development 
[34–36]. The use of aortic rings (see below) and that of spe-
cific microfluidic devices represent a further tool to describe 
this process in a 3D architecture [45]. For instance, wound 
healing assay exploited by single-cell analysis and by using 
chimeric EC sheets obtained by infecting cells with different 
fluorescent proteins [34, 45, 46] was instrumental to describe 
the following steps of EC collective migration: (1) In resting 
state, ECs undergo random cell motility in the monolayer 
with a regulated dynamics of homotypic cell junctions; (2) 
the presence of cell-free space (i.e., the wound) and a chem-
otactic gradient results in the appearance at the sheet mar-
gin of leader cells, which is characterized by an aggressive 
phenotype with prominent stress fibers, ruffling lamellipodia 
and enlarged focal adhesions, formation of peripheral actin 
cables, and discontinuous adherens junctions, which indicate 
mechanical coupling between leader and follower cells in 
the migrating cluster [47]; (3) as leaders start to migrate in 
the free space, a follower phenotype appears within cells of 
the monolayer.
Trans-well cell migration assay—Boyden chamber 
assay The Boyden chamber assay is a useful tool to study 
chemotaxis and cell invasion. It was originally introduced 
by Steven Boyden in the 1960s for the analysis of leukocyte 
chemotaxis [48], and a modified version of the assay has 
recently been used extensively for the assessment of mono-
cyte migration [39]. Indeed, today, a large range of Boyden 
chamber devices, adapted to individual needs, are commer-
cially available. The assay is based on a chamber of two 
medium-filled compartments separated by a microporous 
membrane of defined pore size and can be used to distin-
guish positive chemotaxis (migration toward the attractant) 
and negative (migration away from a repellent) chemotaxis. 
Briefly, ECs are placed in the upper compartment and are 
allowed to migrate through the pores of the membrane into 
the lower compartment. The chemotactic agent of interest or 
cells-secreting chemotactic agents are present in the lower 
compartment. The membrane between the fluid-filled com-
partments is harvested, fixed, and stained after a defined 
incubation time, and the number of cells that have migrated 
to the bottom side of the membrane is determined by stain-
ing and subsequent microscopic analysis. Because a chemi-
cal gradient cannot be maintained for extended periods, 
Boyden chamber assays are limited to 2–6 h.
Boyden chamber assays are also utilized to measure dif-
ferent types of chemotaxis, including haptotaxis, transmigra-
tion, and cell invasion. Angiogenesis and transendothelial 
migration are special forms of haptotaxis, as the trigger 
for migration requires not only a chemokine, but also the 
presence of cell surface or extracellular matrix (ECM) 
molecules. In this case, the insert on the bottom of the 
Boyden chamber is coated with purified cell surface ligands 
(e.g., ICAM1, VCAM1) or ECM proteins (e.g., collagens, 
fibronectin), evaluating the migration of cells exposed to 
specific adhesion sites. Transmigration describes the migra-
tion of cells, such as leukocytes or tumor cells, through the 
vascular endothelium and toward a chemoattractant. There-
fore, the assay measures transmigration of cells through a 
confluent, tight EC layer. Angiogenesis requires the inva-
sion of EC through the basement membrane to form sprout-
ing capillaries. Invasion processes can also be modeled in 
a Boyden chamber assay by coating the well membrane 
with a layer of Matrigel or collagen. In this case, cells must 
secrete matrix metalloproteases to degrade matrix proteins 
and migrate (invade).
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The bioactive molecules in Boyden chamber assays can 
be provided directly by adding recombinant proteins or small 
molecule compounds or by plating cells-secreting specific 
factors in the bottom chamber. Manipulation of test cells 
(gain-of-function/loss-of-function) can be introduced into 
the assay. Migration assays are often performed in co-culture 
with tumor cells, pericytes or fibroblasts.
The real-time random migration assay The use of video-
lapse microscopy allows measuring migration not only as 
an endpoint result, but gives information on single-cell 
parameters, on morphological changes, and on the influence 
exerted by specific substratum. Subconfluent ECs are plated 
on plastic surface coated with specific extracellular matrix 
proteins (i.e., collagens, fibronectin, vitronectin) allowed 
to adhere and then observed with an inverted microscope 
equipped with thermostatic and  CO2-controlled chamber 
(e.g., Leica, DMi8 platform; Nikon, TE microscope). Images 
of motile ECs are captured with a 5 min time interval over 
4 h. Images were then processed with DIAS software (Sol-
ltech). A recent review on tracking algorithms offers a wide 
and comprehensive selection of the available tools to analyze 
cell motility [49]. Generally, data are displayed as a centroid 
plot showing the location of the geometrical center of the 
cell as a function of time. Directional persistence was cal-
culated by determining the ratio between the net path length 
and the total path length. Furthermore, other parameters 
such as the total and net distance, the speed, the feature of 
turning angle can be calculated. Single-cell trajectories were 
plotted using MATLAB software and displayed in windrose 
graphs [50, 51].
2.2  Limitations and challenges
Standardization of techniques is one of the most critical 
issues to ensure the reproducibility of experimental results, 
and one has to be aware that cellular in vitro systems rep-
resent only a surrogate of the in vivo conditions. Neverthe-
less, compared to in vivo experiments, in vitro assays are 
relatively simple to perform and they offer the possibility to 
pursue high-throughput screens of compounds or superna-
tants of tumor cells affecting EC migration, e.g., superna-
tants of tumor cells. Nonetheless, the assay has limitations. 
The cell culture conditions must be standardized, and pure 
populations of EC are required. More frequently than not, 
human umbilical vein ECs (HUVECs) are used for these 
assays; however, these are derived from a large vessel, 
whereas angiogenesis occurs in microvessels. HUVECs are 
primary cells and are only viable for a limited time, and like 
other cells in culture, they change their expression profile 
and therefore their phenotype and behavior over time and 
through repeated passage events. Furthermore, reproducibil-
ity of scratch assays relies strongly on the initial degree of 
confluency [52]. In addition, scratch assays must be carefully 
evaluated to rule out the possibility that experimental condi-
tions have influenced proliferation of EC, rather than their 
migration (this can be easily done using cell proliferation 
assays such as expression of pHH3, see below). Another 
important consideration is that ECs in vivo are exposed to 
shear stress as well as hypoxia gradients, i.e., the drag force 
induced by blood flow to the endothelium, which are absent 
in the standard static cell culture models. While the scratch 
assay is a straightforward cell culture assay to analyze EC 
chemokinesis, it does not have a high degree of sensitivity, 
but it is a useful tool to perform large-scale screening experi-
ments. One downside of this method is that the width of the 
scratch introduced into the cell layer is difficult to control 
and cannot be easily standardized. Moreover, wounding of 
the monolayer with a sharp object may scratch the surface 
of the cell culture dish and additionally damage the EC at 
the migration front.
To obtain more reliable and reproducible results, fenc-
ing techniques that allow for controlled release of a conflu-
ent monolayer have been developed. These enable lateral 
migration without wounding of the cells or the underlying 
matrix [53]. Cells are grown as a monolayer in a culture dish 
containing a silicon template of defined size prior to seeding 
the cells. Once the culture reaches confluency, the silicon 
template is removed, thus allowing the cells to migrate lat-
erally into the area previously occupied by the silicon tem-
plate. Precise microscopic quantification of lateral migration 
is then possible over 2–4 days. Ideally, the duration of the 
assays should be kept under 2 days, because over longer 
incubation times, cell proliferation will contribute to wound 
closure, thereby confounding the migration effect.
As previously mentioned, a potential drawback is the dif-
ficulty of standardizing the wound areas, but this can be 
overcome using silicon templates [53]. Likewise, several 
commercial suppliers have developed robust assays that also 
circumvent this problem. For example, Essen Biosciences 
marketed a mechanical pin tool, the WoundMaker™, 
which applies equal pressure to create 96 homogeneous 
700–800 µm scratches in each microplate well (www.essen 
biosc ience .com/en/produ cts/incuc yte). Wound healing is 
visualized in real time using the IncuCyte ZOOM™, and 
cell tracing is fully automated, thus facilitating analysis and 
reproducibility. A similar device, providing automated hard-
ware and analysis software, is provided by Peira Scientific 
Instruments (Beerse, Belgium) [54]. Electric cell-substrate 
impedance sensing (ECIS, Applied Biophysics Inc, New 
York, USA) can also be used to automatically create wounds 
and simultaneously measure cell migration in multiple wells, 
and V&P Scientific has developed a wounding replicator 
using floating pins that deliver a precise scratch (www.vp-
scien tific .com/wound ing_tissu e_cultu re_exper iment s.php) 
by a Sciclone ALH 3000 workstation robot (Caliper Life 
Sciences, Hopkinton, MA). The additional precision of the 
429Angiogenesis (2018) 21:425–532 
1 3
scratches using the robot over manual wounding replica-
tors makes the latter instrument the method of choice when 
performing the scratch wound assay for large-scale screens 
on drug or genome-wide siRNA/sgRNA screens [43, 44].
It should be stressed that the Boyden chamber assay is 
somewhat delicate and it requires experience in handling. 
The most critical issue is the possible trapping of air bub-
bles in the lower and upper chambers during assembly. Air 
bubbles appear as empty spaces on the filter at the conclu-
sion of the assay, because they hinder cell migration. For 
manual analysis, this may not be of major importance, but 
it becomes relevant if an automated analysis is performed 
since trapped cells would be undistinguishable from the 
absence of migration. It is important to invest substantial 
time into the setup and troubleshooting of the assay in order 
to yield robust and reliable results. It is also recommended 
to include a checkerboard analysis to distinguish between 
chemotaxis and chemokinesis effects. To this end, different 
dilutions of the compound to be tested should be titrated in 
the upper and lower chamber. Equal concentrations in the 
upper and lower chamber should lead to the same migra-
tion behavior as in the control for a compound that strictly 
responds to a gradient (i.e., chemotaxis).
2.3  Concluding remarks
In summary, the lateral scratch wound assay [55] and the 
Boyden chamber assay are both robust and reliable platforms 
to study EC migration. They are suitable for scaled-up pur-
poses in order to perform manual or automated large-scale 
compound screens. Various vendors provide scratch and 
transwell assay systems. Although these systems offer good 
reproducibility and adequate throughput capacity, variation 
between individual EC isolations can occur resulting in vari-
able results. Pooling several EC isolates may reduce this 
variability. In combination with time-lapse microscopy, it 
is also a powerful tool for tracing the migratory behavior of 
individual EC.
3  Endothelial cell proliferation assays
Many regulators of angiogenesis have been identified, vali-
dated, and developed based on their effects on EC prolifera-
tion. ECs are among the most quiescent cells in the body, 
with proliferation rates approaching zero under steady-state 
conditions. Only after stimulation, usually as a consequence 
of injury, inflammation, or pathological processes such as 
malignant growth, can they initiate cell cycle entry [56, 57]. 
The ideal assay to measure EC proliferation should be rapid, 
reproducible, and reliable and wherever possible should 
exclude inter-operator variability, for example through 
quantitative computational readout rather than qualitative 
researcher-dependent observations [57]. This section pre-
sents different methods and elaborates on problems and 
pitfalls.
3.1  Types of proliferation assays
A number of different approaches to address cell prolifera-
tion have been developed in the last decades. In general, 
these include assessment of cell number, detection of DNA 
synthesis by incorporation of labeled nucleotide analogs, 
measurement of DNA content, detection of proliferation 
markers and metabolic assays (Fig. 1). Depending on the 
broadness of the definition of cell proliferation, which can 
range from the narrow description, for example, “the frac-
tion of cells dividing over time” to the more general “the 
doubling time of a population,” several different assays may 
be pursued. Apart from that, means and equipment avail-
able will also dictate the choice of a particular method. As 
all methods focus on a particular aspect of the process, it is 
highly recommended to verify results with a complementary 
assay.
Cell counting Cell counting is considered the gold stand-
ard for proliferation. Moreover, at least in theory, it is one 
of the most straightforward procedures for measuring prolif-
eration of a cell population. It can be done using automated 
cell counters (e.g., Beckman Coulter) or by using a hemo-
cytometer after removal of the cells from the culture vessel 
[57, 58]. More recently, different automated platforms have 
entered the market that allow analysis of cells while present 
in microplates, such as plate cytometers, automated micro-
scope, or high-content screening platforms, that are compat-
ible with cell counting-like procedures. With these, cells can 
be monitored over time but frequently require staining for 
detection, calibration, and (computation-assisted) quantifica-
tion by, for example, staining of nuclei. Moreover, real-time 
cell analysis (referred to as RTCA) platforms have emerged 
that allow label-free, automated, real-time monitoring of cel-
lular properties during incubation based on electrical resist-
ance measurements. The equipment, however, requires con-
siderable investment, beyond reach for many laboratories.
DNA labeling During S phase of the cell cycle, DNA is 
synthesized and subsequently divided between the daugh-
ter cells (2 N → 4 N → 2 N; N = number of a complete set 
of chromosomes). Addition of modified nucleotides to the 
culture medium will result in their incorporation into the 
newly synthesized DNA. Adhering to the narrow defini-
tion of proliferation as stated above, this type of assay most 
closely reflects a means of measuring the fraction of actively 
dividing cells. It should be noted that this technique does not 
directly measure cell division or population doublings, but 
exclusively incorporation of a tracer into DNA synthesis.
3H-thymidine has been used in proliferation assays for 
decades [19, 56, 58, 59]. Briefly, cells are pulsed with 
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3H-thymidine for several hours and radioactivity is meas-
ured by liquid scintillation counting. This provides a very 
accurate representation of DNA synthesis and it is highly 
sensitive since the amount of incorporated 3H-thymidine is 
directly proportional to the rate of DNA synthesis [57, 58]. 
Constraints on using radioactive compounds and the rise of 
alternative methods have limited its use. In a similar man-
ner, the incorporation of 5-bromo-2′-deoxyuridine (BrdU) or 
EdU (5-ethynyl-2′deoxyuridine) can be measured. BrdU or 
EdU can be (in)directly detected and subsequently be (semi-)
quantified using ELISA, flow cytometry, or immunohisto-
chemistry [57, 58, 60]. The latter two quantification tech-
niques allow one to determine the fraction of dividing cells. 
These uridine analogs can be combined with DNA dyes (see 
below) to gain additional cell cycle information [57].
Another approach is the measurement of cellular DNA 
content using intercalating dyes such as PI (propidium 
iodide) or DAPI (4′,6-diamidino-2-phenylindole). Using 
flow or plate cytometry, a profile of the distribution of cells 
over the different phases of the cell cycle can be visualized, 
represented by DNA contents of 2 N (G1/0), 4 N (G2/M), 
or mixed (S). In addition, this method allows for the detec-
tion of apoptotic cells that would exhibit a subG1/0 (< 2 N) 
DNA content.
An alternative method to study EC cycle is based on the 
use of Fucci (fluorescent, ubiquitination-based cell cycle 
indicator) technology (Thermo fisher). It consists of a fluo-
rescent protein-based system that employs both a red and 
a green fluorescent protein, respectively, fused to cdt1 and 
geminin, which are two regulators of cell cycle. These two 
proteins are ubiquitinated by specific ubiquitin E3 ligases in 
a specific temporal sequence. In the G1 phase, geminin is 
degraded; therefore, only cdt1 is present and appears as red 
fluorescence within the nuclei. In the S, G2, and M phases, 
cdt1 is degraded and only geminin remains, resulting in cells 
with green fluorescent nuclei. During the G1/S transition, 
when cdt1 levels are decreasing and geminin levels increas-
ing, both proteins are present, giving a nuclear yellow fluo-
rescence. More recently, Fucci probe was reengineered to 
generate a triple color-distinct separation of G1, S, and G2 
phases extending the use of this technology to quantitative 
analyze the interphase of cell cycle [61].
Fig. 1  Endothelial cell proliferation assays. a Phase-contrast image 
(left) and binarized image of HUVEC grown in a regular 96-well 
plate. Simple software solutions can be used to count features in the 
image. b Example of MTT assay, with color intensity correlating with 
cell number. c DNA staining profile of HUVEC using PI, measured 
on a plate cytometer. d Cell viability of HUVEC exposed to sunitinib, 
measured using a luminescent assay
431Angiogenesis (2018) 21:425–532 
1 3
Proliferation markers Cell division is a highly coordi-
nated process in which specific proteins act in concert with 
allow progression through different stages of cell division. 
Detection of these proteins, usually through immunochemi-
cal procedures, allows the estimation of the fraction of divid-
ing cells. This approach can be used in in vitro endpoint 
assays, but can additionally be used to evaluate active EC 
proliferation in tissue sections (see separate section). The 
most frequently used markers are phosphorylated histone H3 
(PH3), which marks cells in S phase, or PCNA and KI67, 
which label cells in all cell cycle stages except G0.
Metabolic assays Gradually, the use of cell viability 
assays has taken a dominant position in addressing cell pro-
liferation [62]. While not reflecting this property in its nar-
rowest sense, if properly conducted, these assays accurately 
represent the number of live cells. They are readily available 
and require minimal handling and infrastructure. The most 
well known is the MTT assay (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide), in which this yellow salt 
is taken up by metabolically active cells and converted by 
mitochondrial dehydrogenase to insoluble purple formazan 
crystals. As the amount of the converting enzyme is highly 
stable in a given cell population, the generation of formazan 
(and hence color intensity) is proportional to the number 
of viable cells. This is subsequently quantified by solubi-
lization of the crystal-containing cells and spectrophotom-
etry [63]. Variations in this method, for example, involving 
less toxic reagents, simplified reaction steps, or alternative 
readouts such as cellular ATP levels, have also been widely 
used [54, 58, 64]. In particular, the water-soluble tetrazo-
lium salts, such as MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), 
allowing the detection of the colored product directly in cell 
culture media without solubilization, facilitate high-through-
put and pharmacological screenings [65].
3.2  Limitations and challenges
Endothelial cell culture considerations Studying EC pro-
liferation in  vitro requires a purified population of EC 
compatible with the assay setup. As already mentioned 
before, HUVECs are a widely available source, but have 
limitations regarding phenotype and life span in vitro. There-
fore, other sources of EC are necessary for confirmation of 
results. Foreskin-derived human dermal microvascular ECs 
(HDMECs) or human dermal blood microvascular ECs 
(HDBECs) are good alternatives; however, the user should 
be aware that they represent mixed populations of blood and 
lymphatic endothelial cells [66].
It is essential to standardize the protocol of cell culture 
and propagation, by adhering to a fixed scheme of passaging, 
in order to use passage number as a surrogate for popula-
tion doublings [67]. In all cases, cell density needs to be 
carefully controlled. Assay linearity can be compromised 
when cells are plated at too high (e.g., 50,000 cells/cm2) or 
too low (e.g., 5000 cells/cm2) a density. Loss of cell–cell 
contact is a potent stimulus for EC to proliferate, whereas 
ECs enter a quiescent state upon confluency, a process 
known as contact inhibition [57, 58, 63]. Optimization of 
the dynamic performance should involve synchronization 
of cells by exposure to low serum conditions (when study-
ing pro-angiogenic molecules), or by stimulation prior to 
the addition of angiostatic factors or anti-angiogenic drugs 
[6]. Though immortalized EC can pose a helpful alterna-
tive, it should be recognized that the immortalization itself 
will likely alter growth control and survival mechanisms in 
these cells [67]. As such, care must be taken to address the 
generalizability of assay outcome.
Assay choice considerations Each type of EC prolif-
eration assay described here has limitations. Though cell 
counting is the most straightforward method, it can be prone 
to sampling error when cell detachment is required. Fur-
thermore, it can be labor-intensive and it requires relatively 
large samples [57, 58]. However, it can be executed in the 
absence of toxic, mutagenic, or radioactive compounds, such 
as metabolic, DNA labeling, and DNA incorporation-based 
assays [57, 58, 63]. Of note, the outcome of these assays 
is adversely affected by EC death. From a methodological 
point of view, each assay has its strengths and weaknesses. 
For example, the indirect detection of antigens (e.g., PCNA 
or BrdU) requires careful procedural optimization. Although 
the alternative “click” chemistry, by which the analogous 
EdU can be detected directly, circumvents this issue of 
indirect detection, making EdU preferable [57, 58, 60]. 
Nonetheless, assay readout and interpretation are important 
to consider. When measuring incorporation of nucleotide 
analogs, one should realize that DNA synthesis is not con-
fined in all situations to chromosomal duplication during S 
phase [57, 58]. For example, during DNA repair, nucleotides 
are excised and replaced, which is especially relevant when 
addressing the action of compounds with a potential DNA 
damaging effect. With DNA-intercalating dyes, care must be 
taken that doublets are excluded in the gating procedure or 
with readout in plate-based systems. By nature, this type of 
assay is mostly suited for truly diploid cells, and not for cells 
that may display alternative karyotypes. Although the latter 
is not a common trait of EC, a few reports have addressed 
this matter in tumor-derived EC [68], and personal obser-
vations also indicate this may be the case with EC lines. 
Finally, test reagents may interfere with readout chemistry; 
thus, compounds that affect mitochondrial function are less 
compatible with metabolic assays. Surrogate assays such 
as the VEGFR-BaF3 cell lines which bind VEGF ligands 
and signal through chimeric receptors in reporter cell lines 
have been very useful (both academically and in industry) 
for quantifying the presence of major angiogenic factors 
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from human, mouse, and viral sources that stimulate the 
VEGFR-2 and VEGFR-3 pathways [69, 70].
3.3  Concluding remarks
The choice for a particular EC proliferation assay is deter-
mined by a number of considerations. Endpoints, test com-
pounds, laboratory infrastructure, scale, required through-
put, convenience, and cost all influence the applicability of 
an assay system. The growth of a cell population is influ-
enced by both cell division and death, which are difficult to 
monitor simultaneously. Most important is the researchers’ 
awareness of strengths and weaknesses of each individual 
assay. Importantly, interpretation of data must be done with 
care, and whenever possible, results are validated with an 
alternative method.
4  3D models of vascular morphogenesis
The emergence of vascular networks either through vascu-
logenesis or angiogenesis requires the association of cells 
into stable 3D tubes in a process that involves differentiation, 
migration, proliferation, aggregation, and rearrangement of 
these cells to form cords that then undergo lumen forma-
tion. Taken together, this process is referred to as vascular 
morphogenesis. Subsequently, ECs recruit perivascular stro-
mal cells (pericytes) to stabilize this newly formed network 
and minimize leakage upon blood perfusion. Importantly, 
not all sprouts become functional vessels. Pruning serves to 
selectively remove redundant or non-functional vessels to 
optimize fluid flow through the network [71].
In vitro assays have played a valuable role in our under-
standing of vascular morphogenesis. These assays provide 
a simpler platform than animal models for dissecting indi-
vidual steps within the process while also incorporating 3D 
matrix to mimic native in vivo tissues. Here, we present 
several of the most reliable and informative assays devel-
oped to date and highlight the strengths and limitations of 
each (Table 1). While many types of EC can be used in these 
assays, the most commonly used are HUVEC and human 
endothelial colony-forming cell-derived EC (ECFC-EC), 
which generally have a higher proliferative potential. Mouse 
ECs are not generally used in these assays as they are notori-
ously difficult to maintain in culture. While we use “EC” to 
reference to cells derived from both species, assays using a 
specific EC source are annotated accordingly.
4.1  Types of assays
Fibrin Bead Assay Traditional Matrigel cord-forming or 
collagen I angiogenic invasion assays are insufficient to 
mimic the complexity of angiogenesis, as these assays are 
two-dimensional and ECs in these assays often form incom-
plete lumens. Moreover, lumen formation in Matrigel is not 
unique to EC as several non-EC cell types (e.g., human 
prostate carcinoma and glioblastoma cells) also form cords, 
complicating the interpretation of results from these assays 
[57]. By contrast, the fibrin bead assay provides a plat-
form for testing EC sprouting and lumen formation over an 
extended period (2–3 weeks) and incorporates a 3D, ECM, 
and multiple cell types (i.e., stromal pericytes) to model 
native angiogenesis. ECs (HUVECs) are first allowed to 
adhere to collagen I-coated Cytodex beads to generate an 
EC monolayer that mimics the vessel wall of native vessels. 
These EC-coated beads are then embedded into a fibrin gel 
with human stromal cells either embedded within the gel 
or plated as monolayer on the surface of the gel. Tip cells 
are observed 2–3 days post-plating, and elongating sprouts 
appear 2–4 days thereafter (Fig. 2a, b). When maintained 
in pro-angiogenic EGM-2 medium (Lonza), lumens form 
within a week and the cells remain viable up to 3 weeks, at 
which point anastomoses between sprouts are often appar-
ent [72]. A detailed, video protocol of this assay is available 
[73].
Angiogenic sprouting from individual beads is evalu-
ated by phase-contrast microscopy allowing for quantifi-
cation of sprout number, length of sprouts, percentage of 
sprout lumenization, and number of anastomoses. Genetic 
approaches (siRNA, lentiviral transduction, CRISPR/Cas9) 
[74] can modify gene expression in individual cell types 
to dissect cell-autonomous components of the angiogenesis 
process. Protein expression and localization are measured by 
fixing bead assays and using modified immunofluorescent 
staining techniques. More detailed gene expression analyses 
are made possible by harvesting individual cell types to track 
RNA expression changes over time through various stages 
of sprouting angiogenesis.
The use of stromal cells (e.g., lung fibroblasts) is critical 
to the success of this assay, as these cells secrete angiogenic 
factors necessary for EC sprouting and lumen formation, 
including growth factors [hepatocyte growth factor (HGF), 
transforming growth factor alpha (TGF-α), and angiopoi-
etin-1 (Ang-1)], as well as matrix molecules, matrix-modi-
fying proteins and matricellular proteins [e.g., procollagen 
C endopeptidase enhancer 1, secreted protein acidic and 
rich in cysteine (SPARC), transforming growth factor-β-
induced protein ig-h3 [βIgH3], and insulin growth factor 
binding protein 7 (IGFBP7)]. These factors act to locally 
stiffen the matrix, which supports sprouting and lumen for-
mation [75]. This assay represents a significant improve-
ment over conventional, single-cell-type angiogenic assays, 
as the inclusion of multiple cell types more closely mimics 
the physiological environment. Nevertheless, as this assay 
uses primary cultures of cells, rather than cell lines, it is 
important to remember that batch-to-batch variations in 
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stromal cells (and EC) can significantly affect assay results. 
To partially overcome these issues, it should be appropriate 
to use ECs pooled from 5 to 10 umbilical cords. Generally, 
it is crucial to identify stromal cell-HUVEC pairs that yield 
optimal angiogenic sprouts.
Collagen Lumen Assay To investigate EC lumen forma-
tion mechanisms, early assays seeded EC in monolayers on 
plastic dishes coated with ECM proteins (i.e., collagen I, 
collagen III, fibrin, or Matrigel). While these 2D assays are 
sufficient to induce EC cord formation [76–78], they cannot 
reproduce the necessary cues for true lumen formation found 
in native, 3D tissues. Collagen sandwich assays surround 
EC within a 3D matrix by seeding the cells in monolayer 
on collagen I matrix and then covering them with a second 
layer of collagen [79]. Nevertheless, tube formation fails to 
occur in a random, 3D growth pattern, forming only in the 
X–Y plane of the initial gel layer and not in the z-axis. As 
this does not adequately recapitulate normal vessel growth 
in a true 3D environment, George Davis and others further 
optimized these assays, opting instead of embedding single 
EC (HUVEC) randomly throughout a collagen I matrix. In 
the simplest version of these assays, HUVECs are seeded 
at low density (7 × 105 cells/ml) under serum-free growth 
conditions and with the addition of minimal growth fac-
tors (phorbol ester, VEGF), and fibroblast growth factor-2 
(FGF-2). After 48 h, the embedded ECs form intact tubes 
throughout the gel, with clearly demarcated lumens (Fig. 2c, 
d). Several variations on this assay have since enhanced and 
optimized lumen formation. First, the addition of several 
other growth factors, including a cocktail of stem cell fac-
tor (SCF), IL-3, stromal-derived factor-1α (SDF-1α), and 
FGF-2, further promotes lumen formation while maintain-
ing serum-free growth conditions. Second, when simulta-
neously seeded within the same matrix, stromal pericytes 
are recruited by EC, recapitulating a key step in vascular 
morphogenesis. Lastly, to understand the process of EC 
sprouting and angiogenesis, EC can be seeded on top of 
a 3D collagen gel containing the same growth factors and 
Table 1  Comparison of 
3D models of vascular 
morphogenesis
Assay Process
Sprouting Lumen 
formation
Anastomosis Pericyte 
recruitment
Perfusion Pruning
Fibrin bead assay ✓ ✓ ✓ ✓
Collagen lumen assay ✓ ✓
Retina explant assay ✓ ✓ ✓
Vascularized micro-organ ✓ ✓ ✓ ✓ ✓ ✓
Fig. 2  Three-dimensional assays of vascular morphogenesis. a A 
fibrin bead assay uses collagen I- and EC-coated Cytodex beads 
embedded within a 3D fibrin gel matrix to measure EC sprouting and 
lumen formation. b These features are readily resolved using phase-
contrast microscopy. c EC tube formation can be measured by embed-
ding EC within a collagen I matrix. d Once formed, these tubes can 
be visualized by toluidine blue staining and bright-field microscopy. 
e Whole-mount, dissected retinas from postnatal mice are mounted 
within collagen I-Matrigel matrix mix and cultured in pro-angiogenic 
medium to stimulate EC sprouting. f Sprout and lumen formation are 
resolved using phase-contrast microscopy. g The vascularized micro-
organ (VMO) approach utilizes “arteriole” (high pressure) and “ven-
ule” (low pressure) microfluidic channels to drive medium diffusion 
and flow across a cell chamber where microvasculature forms. h The 
formed microvasculature (EC, red) can be measured for leak by per-
fusion with 70 kDa FITC-dextran (green)
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invasion of the underlying gel layer can be quantified. A 
detailed protocol of the collagen lumen assay and its varia-
tions is available for further reading [80].
Real-time imaging of tube formation can be achieved 
using fluorescent protein-transduced EC. Alternatively, fixed 
vessels can be stained with 0.1% toluidine blue and imaged 
using bright-field microscopy (Fig. 2d). More in-depth anal-
yses can be carried out on these fixed vessels using immu-
nofluorescence staining of relevant protein markers or trans-
mission electron microscopy to resolve structural details of 
formed lumen and remodeled ECM.
Regular users of collagen gels will note that the viscos-
ity, pH, and contraction of these gels can hinder successful 
execution of assays in the hands of new users. As a result, 
special care should be taken when pipetting (such as when 
mixing cells and growth factors) and plating gels to ensure 
even gel coating of the bottom of the well plate. Perhaps 
most significantly, early gel contraction can limit the use-
ful length of these assays. Users will note that plating gels 
only in wells within the center of the 96 half-area wells and 
adding medium or water to the outer wells of the plate will 
minimize gel contraction, by maintaining local humidity 
levels. Additionally, seeding fewer ECs within the collagen 
(1.5 × 103 cells/ml) can minimize gel contraction and pro-
long the assay.
Retinal Explant Assay Although in vitro assays are high 
throughput and can mimic major steps in vascular morpho-
genesis, they do not fully recapitulate the in vivo, whole-
organ environment [72]. Several in vivo animal models, 
such as mouse retina or zebrafish fins, are valuable tools 
for studying vascular (re)-establishment in a physiologically 
relevant context [57, 81]. However, the added complexity 
of these systems makes it more difficult to ascertain the 
role of individual proteins and growth factors and cell types 
in the vascular morphogenesis process, relying on genetic 
manipulations or system-wide administration of pharma-
cologic inhibitors to dissect molecular pathways [57, 82]. 
As such, there is a need to increase assay complexity and 
physiological relevance while developing platforms amena-
ble to ex vivo study in the laboratory. Retina explant assays 
are one such ex vivo platform, whereby dissected retinas 
are maintained and observed for vascular morphogenesis 
over several weeks in the laboratory. While multiple ver-
sions of this assay have been published, a protocol published 
by Sawamiphak et al. is most widely used for the study of 
endothelial sprouting [83]. Briefly, retina cups from embry-
onic, postnatal, or adult mice are harvested and cut radially 
to allow flat mounting of the retina interior surface onto a 
membrane insert. After recovery in media for 2–4 h, the 
explants can then be treated with stimulatory or inhibitory 
agents for up to 4 h, followed by whole-mount microscopy 
analysis to evaluate the (anti-) angiogenic effect of these 
agents on vessel sprouting (Fig. 2e). A trained researcher 
can harvest and dissect each pair of retinas within minutes. 
Unfortunately, without the support of a 3D matrix, retinal 
cells cannot survive for long periods, thus making studies 
of later stages of angiogenesis impossible. To overcome 
this, Rezzola et al. have improved the assay by embedding 
the retinas in different matrices after dissection [84]. In this 
approach, retinas can be crosscut into four equal pieces and 
left in serum-free media overnight. The retina fragments are 
then embedded in Matrigel, collagen I, or fibrin matrix and 
fed every 2–3 days. Depending on the age of the mice and 
the matrix used, sprouts can be observed between days 3 and 
6 and anastomosis of neighboring sprouts similar to what 
occurs in vivo can be observed in 10–14 days [85] (Fig. 2f). 
These explants can be maintained up to 3 weeks before the 
vessels eventually regress. When cultured for a longer period 
however, vascular sprouts also start to form toward the cho-
rioidea and not only in the retinal plane, making analysis 
more complex.
Vessel formation can be analyzed in real time using time-
lapse imaging or immunofluorescence microscopy of fixed 
explants at established experimental time points [85, 86]. 
Gene expression can be manipulated by genetic crossing of 
the donor mice or, more transiently, by treating retinas with 
lentivirus or siRNA or Crispr-Casp9 technology. Moreover, 
embedded retinas can be treated with drugs over extended 
periods to dissect individual signaling pathways.
Several factors are critical to consistently achieve sprout-
ing from dissected retina explants. Firstly, the matrix pro-
teins in which retinas are embedded can greatly influence 
how vessels sprout. Matrigel is far superior to single matrix 
proteins in inducing sprouting. However, the addition of 
10–20% Matrigel in collagen I matrix is sufficient to stimu-
late sprouting compared to pure collagen I matrix. Secondly, 
the use of pro-angiogenic EGM-2 medium yields more 
sprouts as compared to basal medium alone. Lastly, as with 
any tissue explant, the age of the mouse can influence the 
degree of vessel sprouting. As such, special care should be 
taken to select mice appropriate for the experimental ques-
tion at hand. There are many similarities between the mouse 
retinal explant assay and the traditional mouse/rat aortic ring 
angiogenesis assay or rat vena cava explant assay [87–89]. 
However, retinal explant models more closely model true 
capillary sprouting as the vasculature in these explants is 
actively developing and remodeling. This makes the retinal 
explant model uniquely suited to studying microvessel for-
mation and its underlying mechanisms.
Vascularized Micro-Organ Platform To understand all 
the steps of vascular morphogenesis in a single platform, a 
vascularized micro-organ (VMO) approach has been devel-
oped to drive formation of a perfusable vascular network 
within a 3D hydrogel matrix environment. In contrast to the 
assays described above, VMO-embedded ECs are exposed 
to and respond to shear stress, form lumenized vessels, and 
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are perfused with a blood-substitute medium that delivers 
nutrients to tissues within the matrix, just as in the body. 
Specifically, this platform utilizes “arteriole” (high pressure) 
and “venule” (low pressure) microfluidic channels that are 
joined by a living microvascular network that forms by vas-
culogenesis in an intervening tissue chamber (Fig. 2g). A 
pressure differential between the two channels is used to 
drive interstitial flow through the fibrin gel matrix during 
vessel development, induce vessel formation (through shear-
sensing), and drive convective flow through the mature vas-
culature once formed and anastomosed to the outer channels. 
This pressure difference is induced by varying the level of 
medium within fluid reservoirs at either end of the micro-
fluidic channels, thereby creating hydrostatic pressure heads 
that ensure continuous fluid convection across the cell cham-
ber. To form vessels, human ECFC-EC and human lung 
stromal cells are co-loaded within a fibrin matrix into the 
central cell chamber through an independent loading tun-
nel. When maintained in pro-angiogenic EGM-2 medium, 
vessels form within 4–6 days post-loading (Fig. 2h). When 
perfused with 70 kDa rhodamine dextran, a molecule similar 
in size to albumin, these vessels demonstrate minimal vessel 
leakage—comparable to in vivo microvasculature. For read-
ers interested in more information, a detailed protocol for 
loading and maintaining the VMO platform is available [90].
The VMO platform is fabricated from polydimethylsilox-
ane (PDMS), an optically clear, biologically inert polymer 
widely used in the microfluidics field [91]. The use of this 
polymer and the dimensions of the platform ensure that live, 
GFP-transduced endothelial progenitor cells (ECFC-EC) can 
be imaged and quantified throughout vessel formation. Spe-
cific parameters such as vessel network length, branching, 
and anastomosis can be measured in real time as can ves-
sel permeability by perfusion with fluorophore-tagged dex-
tran molecules of various molecular weights. Additionally, 
immunofluorescent staining can be used to quantify expres-
sion of specific molecular markers or RNA can be collected 
to measure changes in gene expression. Lastly, gene expres-
sion can be manipulated by treating individual cell types 
with lentivirus or siRNA prior to loading in the platform.
To ensure robust and reproducible vascular network for-
mation, several steps are critical. First, the fibrin gel matrix 
must be consistently loaded within the VMO cell chamber. 
During normal loading, perfusion burst valves at the inter-
face between the tissue chamber and the microfluidic chan-
nels ensure a gel/air interface (later a gel/fluid interface) 
is formed. To simplify loading and minimize specialized 
training for new users of the platform, current iterations of 
the VMO platform incorporate a pressure release valve at 
the loading tunnel that minimizes unintended gel bursting 
[92]. Second, robust vascular network formation requires 
that vessels within the chamber anastomose with the outer 
microfluidic channels. To facilitate the formation of these 
anastomoses, EC can be either seeded directly within the 
microfluidic channels or induced to migrate from the gel by 
coating the external channels with ECM [93]. As with the 
fibrin bead assay, optimal stromal cell–EC pairs should be 
validated to ensure assay reproducibility.
4.2  Limitations and challenges
With all EC assays, the source of EC is critical to assay suc-
cess. Although commercial versions of HUVEC and ECFC-
EC are available, cells from these sources show limited util-
ity in many 3D assays, likely due to a larger than optimal 
number of cell doublings prior to shipment and use in the 
laboratory. As a result, the use of freshly isolated EC will 
provide the most consistent results and is strongly encour-
aged. Readers will note that isolation protocols for both cell 
types are available [94, 95]. Additionally, patient-to-patient 
variation between different EC isolations can lead to incon-
sistent assay results, an issue that may be avoided by pooling 
several EC lines prior to use.
Given the many differences between the assays described 
here, the useful length of these assays varies considerably. 
Even in well-trained hands, the contraction of gels in the 
collagen lumen assay effectively limits the useful time frame 
of assays to 72 h or less. However, the other assays described 
here can continue for much longer periods of time, with the 
fibrin bead assay, retinal explant assay, and VMO platform 
all suitable for time points up to 3 weeks under appropriate 
conditions.
Lastly, the majority of these assays can be run in a rela-
tively high-throughput manner, thereby accelerating the 
speed with which genetic, molecular, or pharmacologic 
screens [96] can be conducted to understand vascular mor-
phogenesis. This is especially true with the fibrin bead and 
collagen lumen assays, which utilize multiple beads or 
multi-well culture plates to increase assay throughput. Simi-
larly, while initial versions of the VMO platform were cum-
bersome to load in high-throughput numbers, this platform 
is now used in an optimized configuration that incorporates 
up to 16 individual VMO devices within a standard 96-well 
plate [97]. This design simplifies translation to outside labo-
ratories and interfacing with existing microscope and plate 
reader infrastructure. Of all the assays described in this sec-
tion, retinal explants are most adversely affected by delays 
between initial dissection, mounting, and plating of tissue 
samples. This inherently limits the number of animals that 
can be dissected at once and, for now, limits the number of 
retinas that can be screened simultaneously.
4.3  Concluding remarks
Vascular morphogenesis requires the interaction 
between several cell types and their surrounding, 3D 
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microenvironment. The 3D vascular morphogenesis mod-
els described here provide unique in vitro culture systems 
that recapitulate this complex multi-step process. At the 
same time, the simplicity and consistency of these assays 
compared to in vivo models allow them to be conducted 
in a high-throughput fashion. Finally, the use of human 
cells in these assays improves the clinical relevance of such 
models, making them readily amenable to drug discovery 
applications.
5  Aortic ring assay
Explants of rat or mouse aorta have the capacity to sprout 
and form branching microvessels ex vivo when embedded 
in gels of ECM. Angiogenesis in this system is driven by 
endogenous growth factors released by the aorta and its out-
growth in response to the injury of the dissection procedure. 
This property of the aortic wall was first described in the 
early 1980s [98] and led to the development of the aortic 
ring assay [99], which is now widely used to study basic 
mechanisms of angiogenesis and test the efficacy of pro-
angiogenic or anti-angiogenic compounds [100].
5.1  Benefits and strengths of the aortic ring assay
The aortic ring assay offers many advantages over exist-
ing models of angiogenesis. Unlike isolated EC, the native 
endothelium of the aortic explants has not been modified by 
repeated passages in culture and retains its original proper-
ties. The angiogenic response can be inhibited or stimulated 
with angiogenic regulators and analyzed by molecular or 
immunochemical methods without the confounding effects 
of serum (Fig. 3a, b). Angiogenic sprouting occurs in the 
presence of pericytes, macrophages, and fibroblasts, as seen 
during wound healing in vivo [100]. The ultrastructure of 
neovessels at different stages of development can be evalu-
ated by electron microscopy (Fig. 3c). The different cell 
types can be identified with specific cell markers by immu-
nostaining whole-mount preparations [101] of the aortic 
cultures (Fig. 3d–g). Many assays can be prepared from the 
thoracic aorta of a single animal (approx. 20–25 cultures/rat 
aorta; approx. 10–15 cultures/mouse aorta). The angiogenic 
response can be quantitated over time, generating curves of 
microvascular growth. Aortic cultures can be used to study 
mechanisms of vascular regression, which typically follows 
the aortic angiogenic response as seen during reactive angio-
genesis in vivo. Aortic rings transduced with viral constructs 
or obtained from genetically modified mice can be used to 
study the role of specific gene products in the regulation of 
the angiogenic response [100].
Recently, rat aortic ring assay was adapted to human 
arteries by using matrigel as 3D hydrogel [102].
5.2  Assay overview
A detailed description of the aortic ring assay protocol is 
available in previous reports [103, 104]. We provide here a 
summary of key steps for the preparation of the assay. Aortic 
rings are prepared from the thoracic aorta of 1–2-month-old 
rats or mice. After excision from the animal, the aorta is 
transferred to a Felsen dish containing serum-free Endothe-
lial Basal Medium (EBM). Under a dissecting microscope, 
the aorta is cleaned of blood and fibroadipose tissue using 
Noyes scissors and microdissection forceps. Care is taken 
not to stretch, cut, or crush the aortic wall during the isola-
tion and dissection procedures. As the dissection progresses, 
the aorta is rinsed in the four compartments of the Felsen 
dish. Using a scalpel blade, the aortic tube is then cross-
sectioned into 0.5–1-mm-long rings. The most proximal 
and distal rings which may have been damaged during the 
dissection procedure are discarded. The remaining rings 
are washed through sequential transfers into eight consecu-
tive baths of serum-free medium, using compartmentalized 
Felsen dishes. Aortic rings are then embedded individually 
into thin collagen, fibrin, or basement membrane gels as 
described. Once the gel has set, 500 μl of serum-free EBM 
is added to each culture. Each experimental group comprises 
quadruplicate cultures in four-well NUNC dishes. Aortic 
ring cultures are incubated in a humidified  CO2 incubator at 
37 °C for 7–21 days.
5.3  Quantitative analysis of angiogenesis in aortic 
cultures
The angiogenic response of the rat (or mouse) aorta can be 
quantitated by visual counts or by computer-assisted imag-
ing. For visual counts, cultures are examined every 2–3 days 
and scored for angiogenic sprouting by using an inverted 
microscope with bright-field optics equipped with 4× to 10× 
objectives and a 10× eyepiece. Angiogenesis is scored by 
counting microvessel sprouts, branches, and loops accord-
ing to previously published criteria [99]. Aortic outgrowths 
can also be quantified by image analysis using low power 
images of the cultures thresholded to highlight the vascular 
outgrowths [105–108]. Standard statistical methods are used 
to analyze data and determine levels of significance between 
control and treated cultures. An internal control group with 
untreated aortic rings must be included in each experiment 
to mitigate the effect of possible interassay variability.
5.4  Critical points
For this assay, we recommend using the thoracic aorta 
because of its uniform size and intercostal artery branching 
pattern. The abdominal artery can also be used, but its vari-
able pattern of collaterals and tapering lumen may introduce 
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variability in the angiogenic response. Injury to the aortic 
endothelium may be an additional cause of uneven sprouting 
from different rings. Therefore, special care must be taken 
not to damage the aorta by stretching or letting it dry dur-
ing the isolation and dissection procedures. Dissection of 
the aorta and preparation of the aortic ring cultures are best 
performed in a tissue culture room with HEPA-filtered air to 
avoid microbial contamination. Best results with this assay 
are obtained using interstitial collagen or fibrin gels. Col-
lagen can be produced in-house, as described [103, 104], 
or purchased from commercial sources [109]. Fibrinogen 
and thrombin for the fibrin gel are commercially available. 
Matrigel, a basement membrane-like matrix of tumor origin, 
can also be used [110]. Matrigel cultures, however, require 
growth factor supplements due to the limited ability of the 
aortic rings to sprout spontaneously in this dense matrix. The 
growth medium used for the assay should be optimized for 
the growth of EC in the absence of serum. Optimal results 
in collagen and fibrin cultures can be obtained with EBM. 
When preparing individual collagen gel cultures, given the 
small volume of gel (20–30 µl), it is important to remove 
excess growth medium from the aortic rings when they are 
transferred into the collagen, fibrinogen, or Matrigel solu-
tion. This is accomplished by gently streaking the aortic ring 
onto the bottom of the culture dish while holding it from the 
adventitial side with microdissection forceps. When work-
ing with fibrin gels, which set rapidly, no more than four 
cultures at a time should be prepared, to avoid disrupting 
Fig. 3  Aortic ring assay of 
angiogenesis. a Serum-free 
collagen gel culture of rat aorta 
(asterisk) photographed at day 
6 (microvessels marked by 
arrowheads). b Aortic culture 
treated with VEGF (5 ng/ml) 
shows increased number of 
microvessels (day 6). c Electron 
micrograph of aorta-derived 
microvessel with polarized 
endothelium (E), patent lumen 
(L), and surrounding pericytes 
(P); endothelial tight junc-
tions are marked by arrows. d 
Phase-contrast micrograph of 
microvessel composed of an 
inner core of endothelial cells 
and surrounding pericytes 
(white arrowheads). e Pericytes 
highlighted with immunoperox-
idase stain for NG2. f Immuno-
fluorescent image of aorta-
derived macrophages stained 
for CD45; an isolectin B4 
(IB4)-stained endothelial sprout 
is visible in the background. g 
Confocal image of microvessel 
double stained for endothelial 
cells (IB4) and pericytes (alpha 
smooth muscle actin, αSMA). 
Magnification bars = 500 μm (a, 
b), 5 μm (c), 50 μm (d–g)
438 Angiogenesis (2018) 21:425–532
1 3
the developing gel while positioning each ring. In addition, 
for fibrin cultures, the culture medium should include a plas-
min inhibitor such as epsilon aminocaproic acid to inhibit 
fibrinolysis by the aortic rings, which would rapidly destroy 
the matrix needed for EC to sprout.
The rat aortic ring assay is robust and very reproducible 
when performed by an experienced operator. The mouse aor-
tic ring assay is more variable than the rat aortic ring assay, 
likely because of the small size of the rings. For this reason, 
at least twice as many aortic rings should be used for this 
assay. Miniaturization of the assay using IBIDI microcham-
bers [104] and a smaller volume of growth medium (50 µl) 
are recommended for the mouse aortic ring assay to ensure 
spontaneous sprouting under serum-free conditions [104]. In 
all cases, experiments should be repeated 2–3 times to obtain 
sufficient number of data points for statistical analysis. The 
growth medium can be replaced on a regular basis (3 times/
week) or left unchanged for the duration of the experiment. 
If the medium is not replaced with fresh medium, the angio-
genesis response and the stability of neovessels are enhanced 
due to accumulation of endogenous growth factors in the 
system. For immunohistochemical evaluation of the aortic 
cultures, biomatrix gels should not exceed 20–30 µl and 
should be well spread as a thin wafer around each ring. For-
malin fixation should be limited to 10 min to avoid excessive 
cross-linking of proteins. In addition, overnight incubation 
may be needed for optimal penetration of the primary anti-
body into the gel.
5.5  Limitations and challenges
The main limitation of the aortic ring assay is the lack of 
blood flow, particularly for angiogenesis-related genes that 
are regulated by mechanochemical mechanisms. An addi-
tional potential limitation is the source of angiogenic ECs, 
which are arterial and not venous, as neovessels in vivo 
primarily sprout from postcapillary venules. Many studies 
performed with this assay, however, have shown good cor-
relation of results obtained with the aortic ring assay and 
in vivo models of angiogenesis. If needed, the aortic ring 
assay methodology can be applied to veins as reported [89]. 
Some investigators have described variability of the angio-
genic response in different aortic cultures. This is due to the 
delicate nature of the endothelium, which can be damaged 
because of inadequate handling of the aorta or the aortic 
rings, drying of the explants, or their excessive exposure to 
alkaline pH. Suboptimal preparation of the gels resulting in 
a defective matrix scaffold can also result in a poor angio-
genic response. In addition, the age and genetic background 
of the animal significantly affect the capacity of the aortic 
rings to sprout spontaneously or in response to angiogenic 
factors. Aortic outgrowths in Matrigel are much denser than 
in collagen and fibrin and more difficult to quantitate by 
visual counts due to the intricate branching pattern of the 
endothelial sprouts and the tendency of mesenchymal cells 
to arrange in confounding networks, which mimic angio-
genic sprouts. Immunostaining of the aortic outgrowths 
with endothelial markers followed by image analysis may 
overcome this limitation. For quantitative analysis of the 
angiogenic response, the visual count method (described in 
detail in Ref. [104]), becomes challenging when cultures 
stimulated by growth factors produce 250–300 or more ves-
sels. Since the outgrowths of rings oriented with the lumi-
nal axis parallel to the bottom of the culture dish (recom-
mended orientation) are typically symmetrical, angiogenesis 
in these cases can be quantified by counting the number 
of microvessels in half of each culture and then doubling 
the score. Alternatively, these cultures can be measured by 
image analysis [105–108]. Finally, for the whole-mount 
immunohistochemical stain, gel thinness is critical for opti-
mal antibody penetration.
5.6  Concluding Remarks
Many of the molecular mechanisms orchestrating angiogen-
esis have been discovered, but many others remain to be 
identified, studied, and evaluated as targets for the devel-
opment of new therapies. The aortic ring assay reproduces 
ex vivo cellular and molecular mechanisms that are essential 
for the regulation of the angiogenic process. As such, this 
assay provides an invaluable platform to test new hypotheses 
and analyze the efficacy of the next generation of angiogen-
esis-targeting drugs.
6  Tumor microvessel density 
and histopathological growth patterns 
in tumors
Microvessel density (MVD) is often regarded as a surro-
gate marker of angiogenesis in tumors. Angiogenic tumors 
contain areas with a high concentration of new but inef-
ficient blood vessels, which have sprouted from existing 
vessels and are often arranged in a tortuous, glomeruloid 
tangle. In addition, to these “hot spots,” angiogenic tumors 
also contain areas of low blood vessel numbers. Weidner 
developed a method to assess MVD in vascular hot spots 
using pan-endothelial immunohistochemical (IHC) labe-
ling assays, using lectins such as WGA, Ulex Europaeus, or 
antibodies against CD31, CD34, and von Willebrand fac-
tor and less often VE-cadherin, αvβ3 integrin, CD105, or 
type IV collagen [111]. Vascular hot spots are identified by 
light microscopy at low power magnification by scanning 
the entire stained tumor section. Individual microvessels are 
then counted at high power magnification in these regions. 
As an alternative, microvessels can be counted in regions 
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defined by systematic uniform random sampling (SURS) 
[112]. These IHC staining assays are robust, fast, and easy 
to perform and to automate. Although results in individual 
studies are highly variable, meta-analyses have confirmed 
the prognostic value of MVD, for example in breast cancer 
[113] and isolated reports support the predictive value of 
MVD for anti-VEGF treatment [114, 115]. However, the 
inter-observer variability of the vessel counting algorithm 
presents a significant barrier to the use of MVD as a bio-
marker [116]. Inter-observer variability can be reduced by 
applying strict counting rules and by consensus training of 
individual observers [112].
Although the importance of angiogenesis to tumor biol-
ogy is well-established, multiple observations that primary 
and metastatic tumors develop and progress in the absence of 
angiogenesis suggest that other mechanisms are frequently 
involved in tumor vascularization [117]. This represents 
a challenge to Folkman’s hypothesis that the growth of a 
tumor is only possible when accompanied by angiogenesis 
[118]. Moreover, MVD cannot distinguish angiogenic and 
non-angiogenic tumors. In addition to the high numbers of 
blood vessels in angiogenic tumor hot spots, high MVD is 
indeed also observed in non-angiogenic tumors which have 
co-opted vessels in organs with extensive microvasculature, 
such as the liver and the lungs [117]. The differentiation 
of angiogenic and non-angiogenic tumors is, therefore, not 
related to the absolute number of vessels per surface area but 
to the growth pattern of a tumor.
6.1  Histopathological growth patterns
Histopathological growth patterns (HGPs) are defined 
according to the morphological characteristics of the tumor 
at the interface with the surrounding normal tissue. HGPs 
are identified by light microscopy in standard hematoxylin-
and-eosin stained tissue sections, and distinct HGPs have 
been described for tumors that grow in the lung, liver, skin, 
brain, and lymph node [117]. Recently, international consen-
sus guidelines for scoring these HGPs have been described 
[119, 120]. One of the important differences in the biology 
of tumors with specific HGPs is their means of vasculariza-
tion. Liver metastases may present with one of two com-
mon HGPs, replacement or desmoplastic. In the replacement 
HGP, cancer cells “replace” the hepatocytes while co-opting 
the sinusoidal blood vessels at the tumor–liver interface. 
Patients with colorectal cancer (CRC) liver metastases with a 
replacement HGP respond poorly to the anti-VEGF-A treat-
ment, bevacizumab, likely because these tumors utilize ves-
sel co-option instead of angiogenesis [119]. By contrast, in 
desmoplastic liver metastases, the cancer cells are separated 
from the liver by a rim of desmoplastic tissue in which new 
blood vessels are formed by sprouting angiogenesis. Des-
moplastic CRC liver metastases showed a better response 
to bevacizumab [119]. Taken together, these observations 
strongly suggest that HGPs can be used to guide the choice 
of treatment for individual patients with liver metastases.
Across studies, approximately 50% of patients with CRC 
liver metastases present with a predominant replacement 
growth pattern and this proportion extend to 95% when 
patients with breast cancer liver metastases are considered 
[119, 120]. This clearly demonstrates that non-angiogenic 
tumor growth is not a rare phenotype. The same applies to 
primary lung carcinomas and lung metastases for which 
angiogenic and non-angiogenic HGPs have also been 
described [121, 122]. In the non-angiogenic, alveolar HGP, 
cancer cells fill the alveolar spaces and incorporate the capil-
lary blood vessels of the alveolar walls. Approximately, 40% 
of the lung metastases from clear cell renal cell carcinoma 
(ccRCC) present with a non-angiogenic HGP despite the fact 
that nearly all primary ccRCC relies on sprouting angiogen-
esis, driven by loss of VHL protein function [122].
The prevalence of non-angiogenic tumors and their 
resistance to anti-VEGF treatment require the identification 
of a biomarker that accurately reflects this type of tumor 
growth. HGPs constitute a good candidate biomarker. The 
vascular pattern in a tumor section immunostained with pan-
endothelial antibodies and the use of antibodies that mark 
EC participating in sprouting angiogenesis are other poten-
tial histopathological methods to distinguish non-angiogenic 
from angiogenic tumors. Indeed, when the number of hot 
spots is determined by nearest neighbor analysis in whole-
slide digital images of liver metastasis tissue sections stained 
for CD31, the non-angiogenic, replacement-type metasta-
ses clearly resemble normal liver tissue. This contrasts with 
angiogenic, desmoplastic liver metastases, which show a sig-
nificantly higher number of vascular hot spots than normal 
liver tissue and their non-angiogenic counterparts (Fig. 4).
Several groups have identified “tumor endothelial mark-
ers” or TEMs [123–125]. These are proteins that are selec-
tively upregulated on tumor endothelium compared to nor-
mal endothelium. Tumor angiogenesis meta-signatures have 
been generated using gene expression data of several tumor 
types by using “seeds” of transcripts, which were known to 
participate in angiogenesis and to be expressed by EC. The 
resulting set of EC/angiogenesis-related transcripts that cor-
related with these seeds was then purified by selecting genes 
that were modulated in response to anti-angiogenic treatment 
[126]. Interestingly, several of the top ranking genes in this 
signature have been confirmed as TEM by other independent 
teams [127]. Although we do not currently know whether 
TEMs are expressed equally on both angiogenic tumor ves-
sels and co-opted vessels in tumors, it will be intriguing to 
assess the expression of these genes, for example ELTD1, 
CLEC14a, and ROBO4 in the vasculature of replacement 
versus desmoplastic liver metastases. In primary and sec-
ondary non-angiogenic human lung tumors, only preexisting 
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vessels, with an LH39-positive basal membrane and weak 
or absent αvβ3 integrin, and arising from the alveolar septa 
entrapped by the neoplastic cells, were observed [128].
The HGP is not a static phenotype: Systemic treatment of 
patients with CRC liver metastases can alter the HGP [119]. 
The fact that the HGPs can change in response to treatment 
reflects the dynamic nature of tumor vascularization driven 
by either angiogenesis or vessel co-option. This illustrates 
the necessity for longitudinal assessment of vascularization 
mechanisms in tumors during treatment and follow-up of 
individual patients. In order to achieve this, the histopatho-
logical evaluations of the tumor vasculature as described 
here must be supplemented by medical imaging techniques 
and/or assays, which utilize small biopsies, circulating 
tumor cells, endothelial cells, or circulating tumor deriva-
tives. Moreover, the importance of an accurate biomarker 
of ongoing sprouting angiogenesis or non-angiogenic vessel 
co-option is corroborated by the extensively documented 
and strong link between angiogenesis and immune sup-
pression [129–131] and the surge of clinical studies that 
combine anti-VEGF and immunotherapy strategies [132]. 
In this regard, studies suggested that interactions between 
endogenous galectins and glycans may link tumor immu-
nosuppression and angiogenesis, conferring resistance to 
anti-VEGF treatment [133].
6.2  Concluding remarks
Although the assessment of MVD has a prognostic value 
in many different tumor types, this parameter cannot distin-
guish angiogenic and non-angiogenic processes of vascu-
larization. However, the histopathological growth patterns 
of, for example, lung and liver tumors accurately reflect the 
means of vascularization, being sprouting angiogenesis or 
non-angiogenic co-option of existing blood vessels. We 
therefore propose to determine both the HGP and MVD 
when studying the vascularization of tumors. In addition, 
noninvasive surrogate markers of the HGP should be devel-
oped, for example medical imaging parameters, and these 
markers should be integrated in clinical oncology trials.
7  Assessment of intussusceptive 
angiogenesis
Angiogenesis is the de novo formation of blood vessels and 
can follow either a sprouting or a non-sprouting course. 
One important non-sprouting mechanism is intussuscep-
tion (growth within itself; known also as vascular splitting). 
Although both sprouting and intussusception lead to an 
expansion of the capillary network, the processes involve 
different cellular mechanisms, which are presumably regu-
lated by different molecules. Sprouting angiogenesis (SA) 
is characterized mainly by local vasodilatation, increased 
vascular permeability, and cell proliferation. It is initiated by 
proteolytic degradation of the basement membrane, which 
is followed by migration of proliferating EC into the ECM. 
The sprouts reorganize internally to form a vascular lumen 
and to finally connect to other capillary segments [134]. 
Intussusceptive angiogenesis proceeds through translumi-
nal tissue pillar formation and subsequent vascular splitting. 
The direction taken by the pillars delineates intussusceptive 
angiogenesis into its overt variants, namely: (1) intussuscep-
tive microvascular growth (expansion of capillary surface 
area), (2) intussusceptive arborization (remodeling of the 
disorganized vascular meshwork into the typical tree-like 
arrangement), and (3) intussusceptive branching remodeling 
(optimization of local vascular branching geometry), includ-
ing intussusceptive vascular pruning. It has been shown 
that intussusceptive angiogenesis takes place not only dur-
ing physiological processes, but also under pathological 
Fig. 4  Microvessel density and histopathological growth patterns. a 
Unsupervised spatial modeling of the blood vessel pattern in normal 
liver shows a low number of clusters per number of vessel profiles. 
A selected region of interest (ROI) at the tumor–liver interface of 
normal liver in CD31-stained tissue is shown (left). The Blood Ves-
sel Analysis algorithm of Definiens™ segments and classifies blood 
vessel objects (orange) and nuclei (blue) (mid). The Cartesian coordi-
nates (x, y) of the centroids of all vessel objects in one ROI were used 
in a simplified “SeedLink” clustering method [646] (right). Centroids 
with the same color (e.g., red) belong to the same cluster. b Unsuper-
vised spatial modeling of the blood vessel pattern in a colorectal can-
cer liver metastasis with a replacement growth pattern shows a low 
number of clusters per number of vessel profiles. A selected region 
of interest (ROI) at the tumor–liver interface of replacement growth 
pattern in CD31-stained tissue is shown (left). The Blood Vessel 
Analysis algorithm of Definiens™ segments and classifies blood ves-
sel objects (red) and nuclei (blue) (mid). The Cartesian coordinates 
(x, y) of the centroids of all vessel objects in one ROI were used in 
a simplified “SeedLink” clustering method [646] (right). Centroids 
with the same color (e.g. red) belong to the same cluster. c Unsuper-
vised spatial modeling of the blood vessel pattern in a colorectal can-
cer liver metastasis with a desmoplastic growth pattern shows a high 
number of clusters per number of vessel profiles. A selected region 
of interest (ROI) at the tumor–liver interface of desmoplastic growth 
pattern in CD31-stained tissue is shown (left). The Blood Vessel 
Analysis algorithm of Definiens™ segments and classifies blood ves-
sel objects (red) and nuclei (blue) (mid). The Cartesian coordinates 
(x, y) of the centroids of all vessel objects in one ROI were used in 
a simplified “SeedLink” clustering method [646] (right). Centroids 
with the same color (e.g., red) belong to the same cluster. d Tukey 
boxplots of the normalized number of clusters of blood vessel objects 
for the desmoplastic growth pattern, the replacement growth pat-
tern, and normal liver. There was a statistically significant difference 
between the growth patterns as determined by one-way ANOVA 
[F(2,22) = 10.8, p < 0.001]. A post hoc Tukey test showed that the 
number of clusters divided by number of vessel objects was signifi-
cantly different between the desmoplastic growth pattern and the 
replacement growth pattern (p < 0.05, ‡), but also between the des-
moplastic growth pattern and normal liver (p < 0.001,‡). However, 
no difference was found between the replacement growth pattern and 
normal liver (p > 0.05). Outliers are plotted as points (·) and extreme 
values are plotted as asterisks (*)
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conditions including tumor growth, colitis, and in neurode-
generative disease, among others [135]. Although the mor-
phological facets of intussusceptive angiogenesis as well as 
molecular mechanisms of sprouting are well described, the 
exact cellular and molecular mechanism of intussusceptive 
angiogenesis is not yet characterized.
7.1  The concept of intussusception 
and the methodological challenge
The concept of intussusceptive angiogenesis was first 
described within the rapidly expanding pulmonary capil-
lary bed of neonatal rats [136]. Morphological investiga-
tions during the last three decades have indicated that the 
transluminal pillars arise into the vessel lumen according to 
the four consecutive steps in pillar formation postulated by 
Burri et al. in 1990: (1) creation of a zone of contact between 
the opposing sides of the capillary wall; (2) reorganization of 
the junctions between endothelial cells in the contact zone, 
resulting in central perforation of the bilayer; (3) forma-
tion of an interstitial pillar core, which is invaded first by 
the cytoplasmic processes of myofibroblasts and pericytes, 
and then by collagen fibrils; and (4) the pillars expand in 
girth (≥ 2.5 μm) and transform into a capillary mesh. The 
described model with the four consecutive steps is based 
mainly on transmission and scanning electron microscopy 
methods (scanning or transmission electron microscopy), 
and these techniques do not allow dynamical observation of 
the pillar formation, fusion, and vascular splitting over time.
7.2  Limitations and challenges
Intussusceptive angiogenesis is spatially quite a complex 
process, and it is not possible to document it on isolated sec-
tions. To overcome this limitation and maintain high resolu-
tion, a 3D reconstruction based on serial ultrathin sections 
was reported for the first time in year 2000 [137]. This is a 
very laborious approach feasible only in specialized labora-
tories. Even with significant expertise, only limited numbers 
of pillars as a qualitative and descriptive illustration can be 
visualized. A new technique is now available that makes 
such task much more feasible—serial block face 3D imag-
ing. With this new technique, exact morphological informa-
tion on relatively big sample volumes (1 × 1 × 1 mm) within 
a short time can be acquired: For example, the scanning of 
a block the size of one zebrafish embryo would take around 
1 day and would provide a 3D scan of the complete embryo 
at ultrastructural level. Using the standard approaches, it 
would have taken weeks, if not months. Moreover, the out-
come from 3View is of much better quality and without loss 
of information (slices). This technique enables a quantum 
leap forward in 3D morphological studies [138].
Vascular casting has been extensively used to demon-
strate intussusceptive angiogenesis in 3D. The methodology 
is based on creating a vascular replica of the microvascula-
ture. As casting media Methylmethacrylate (Mercox, Japan 
Vilene) or PU 4ii (VasQtec, Switzerland) is used [137]. A 
few hours after perfusion, the organs are excised and trans-
ferred to 15% KOH for 2–4 weeks for dissolving the tissue. 
After washing, the casts are dehydrated in a graded series of 
increasing ethanol concentrations and dried in a vacuum des-
iccator. They are then examined using SEM. A new power-
ful methodology employing polymer-based contrast agent in 
combination with micro-computed tomography (micro-CT) 
has been reported recently [139]. Both casting and micro-CT 
are very useful for evaluation of large samples, for example 
entire mouse organs and in a subsequent step to “zoom” in 
on the area of interest. The vascular casting combined with 
scanning electron microscope has the potential to demon-
strate greatest morphological details (Fig. 5a). The micro-
CT does not provide a high level of resolution, but is very 
rapid and the epitopes are not destroyed and can be used for 
further morphological investigations [139].
Dynamic in vivo observation of the pillar formation and 
subsequent vascular splitting over time is feasible employ-
ing conventional fluorescence microscopy, stereomicros-
copy, and laser scanning microscopy (Fig. 5b). The latter 
methodologies are widespread, but often cause partially 
severe, phototoxic artefacts. Zebrafish lines with uniform 
cytosolic expression of the respective fluorescent proteins 
such as Tg(Fli1a:eGFP)//Tg(Gata1:dsRed) represent a use-
ful model for dynamic observation of vascular splitting 
and blood flow (Circulating erythrocytes). Zebrafish lines 
with uniform cytosolic expression of the respective fluo-
rescent proteins can be used, for example Tg(Fli1a:eGFP)//
Tg(Gata1:dsRed). The embryos are mounted in low-melting 
agarose in the presence of phenylthiourea and can be moni-
tored for 16–20 h. To reduce phototoxicity, imaging should 
be performed with laser scanning microscopes with a long 
working distance, using a heated chamber, fast scanning 
(less than 1 µs pixel time), lowest possible laser power (in 
a range of few percentages depending on the microscope), 
and time steps of 10–15 min. Such a dense time pattern is 
necessary to record the dynamic cellular alterations of pil-
lar formation and splitting. Using these settings, no signs of 
photobleaching or phototoxicity (membrane blebbing, cell 
apoptosis) have been observed.
7.3  Concluding remarks
Due to its 3D complexity, intussusceptive angiogenesis 
can only be properly investigated by a combined methodo-
logical approach. Matching the dynamic cellular changes 
in capillaries obtained with in vivo time-lapse studies with 
morphological data from light microscopy level up to the 
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ultrastructural level by transmission electron microscope 
can provide complex and detailed information (Fig. 5b–d). 
The sites of interest should be documented first by intravi-
tal microscopy as described above. After the in vivo docu-
mentation, the area of interest can be harvested, fixed, and 
processed either for paraffin sectioning and LM with immu-
nohistochemistry or alternatively for serial semi-thin sec-
tioning and 3D analyses using, for example, Imaris Software. 
To obtain a deeper insight into the morphological substrate 
and tissue components involved in the process, the same 
tissue should be processed for transmission electron micro-
scope (Fig. 5).
8  In vivo sprouting lymphangiogenic 
assay and AAV‑mediated gene transfer 
of vascular endothelial growth factor c 
(VEGFC)
The lymphatic system plays a key role in the body in main-
taining tissue fluid homeostasis, in lipid absorption, and in 
immune cell trafficking. In some life-threatening diseases, 
such as cancer, lymphangiogenesis, the formation of new 
lymphatic vessels, contributes to disease progression. By 
contrast, inherited or acquired insufficiency of lymphatic 
vessel development results in various forms of lymphedema 
[140, 141]. The most important receptor signal transduction 
system guiding lymphatic growth is the VEGF-C/VEGFR-3 
system. Increasing tissue concentration of VEGF-C by trans-
genic overexpression or viral gene delivery system leads to 
lymphatic overgrowth [142, 143]. By contrast, overexpres-
sion of soluble VEGFR-3 extracellular domain leads to 
suppression of lymphatic vessel growth in cancer models 
[144]. Thus, stimulation or suppression of lymphatic ves-
sel growth in experimental animals and in human patients 
can be the ultimate way to improve or inhibit lymphatic 
function. In this section, a description is provided of two 
in vivo techniques that allow studying the lymphangiogenic 
Fig. 5  Intussusceptive angiogenesis—the methodological chal-
lenge. a Scanning electron microscopy image of transluminar pil-
lars. Early stage is characterized by tinny pillar (arrow), formed 
mainly by endothelial protrusions coming from the opposing EC. At 
later stages, the pillar (arrowhead) is increasing in girth and its core 
is invaded by perivascular cells, fibroblasts, and fibers (visible in the 
lower disrupted part of the pillar). Lumen of the vessel is marked 
with asterisks. Adapted from [647]. b Dynamic in  vivo observation 
of the regenerating zebrafish fin vasculature demonstrated a newly 
formed pillar (rectangle). c Three-dimensional reconstruction based 
on serial semi-thin sections from the same area depicted in b, d trans-
mission electron micrograph demonstrates the transluminal tissue pil-
lars (rectangle in b, c) at ultrastructural level. Black asterisk indicates 
the core of the pillar, while arrowhead pointed to cell–cell contacts 
between the endothelial cells (EC). Er erythrocyte, Col collagen fib-
ers. Adapted from [648]
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process. One is called the ear sponge assay, and the other 
one describes viral gene delivery techniques to achieve the 
same goals. Several viral gene delivery vectors are known 
to date, such as adenovirus, adeno-associated virus (AAV), 
lenti/retrovirus, and baculovirus. Here, we describe as an 
example, the use of AAV for the transfer and analysis of 
lymphatic vascular growth factors.
8.1  Description of the ear sponge assay and AAV 
generation/tissue transduction
In this model, sprouting lymphangiogenesis is reproduced 
in a complex in vivo microenvironment. This application 
is based on the use of a biomaterial, gelatin sponge that is 
inserted in the mouse ear to develop a large lymphatic net-
work [145]. The gelatin sponge is cut into pieces of about 
3 mm3, which are transferred in a 96-well plate (one sponge 
piece per well) for pre-treatment (Fig. 6a). The sponge can 
be soaked with tumor cells, cell-conditioned medium, lym-
phangiogenic growth factors or inhibitors. Cell suspension 
or compound solution (20 µl) is seeded on the top of the 
sponge. The plate is incubated at 37 °C, for 30 min, to allow 
the diffusion of the solution into the biomaterial. Sponges 
are next embedded in a type I collagen solution (7.5 vol-
umes of interstitial type I collagen solution, 1 volume of 
10 × Hanks’ balanced salt solution, 1.5 volume of 186 mM 
NaHCO3, pH adjusted at 7.4 with a 1 M NaOH solution) and 
placed in a new well for 30 min to allow collagen polymeri-
zation. For sponge implantation into mice, a small incision 
is made in the basal, external, and central parts of the mouse 
ear. Ear skin layers are slowly detached with forceps to make 
a hole for sponge insertion, which is then suture shut. Mice 
are killed at different time points (2–4 weeks post-sponge 
implantation) to evaluate lymphangiogenesis in the sponge 
and lymph nodes (Fig. 6a–c).
Preparation of the recombinant AAV encoding VEGF-C 
or VEGF-D of mouse origin starts from the cloning of the 
ORF into the special AAV plasmid vector, which possesses 
flanking sequences 5′ and 3′ Inverted Terminal Repeats 
(ITRs) (Fig. 6d). Such vectors can be obtained from com-
mercial sources, for example from Addgene (www.addge 
ne.com). Next, the AAV plasmid vector is used to generate 
AAV particles by transfecting the plasmid into the host cell 
lines derived from embryonic human kidney 293 cells. We 
suggest using three-plasmid transfection system, in which 
AAV and adenovirus helper genes are administered into 
239T cells together with the VEGF-C/VEGF-D encoding 
AAV vector plasmid by simultaneous transfection. 293T 
cells are seeded at an initial density of 7.7–106 cells/145 
 cm2plate. When reaching cell confluency level of 70–80%, 
cells are transfected with three plasmids (gene encoding one 
and the two are the helper plasmids) (1:1:1 molar ratio). The 
AAV accumulating inside the cells are released from the 
cells by three consecutive freeze/thaw cycles using liquid 
nitrogen and + 37 °C water bath, respectively. AAV particles 
are then purified and concentrated by ultracentrifugation. It 
is important to run a functional test to assess the ability of 
the AAV particles to transduce mammalian cells and drive 
expression of transgenic proteins. This can be done by trans-
fecting cultured 293T cells and determining the expression 
of a transgene by any suitable method, such as Western blot-
ting, ELISA, or fluorescent microscopy in case of fluorescent 
proteins.
For the treatment of skeletal muscle (tibialis anterior, t.a., 
in mice), the volume of the AAV solution should be kept to a 
minimum and should not exceed 50 µl/t.a. for the adult mice 
of ≥ 7–8 weeks old. The AAV dose (concentration of AAV 
particles in the injected volume) for a single injection is sub-
ject to thorough consideration, taking into account various 
factors, such as susceptibility for AAV transduction in a cer-
tain tissue, biological activity and toxicity of the transgene, 
half-life of the transgenic protein in free circulation or in a 
tissue. Gelatin sponge transplantation and injection of AAV 
solutions are performed under either isoflurane or liquid 
(ketamine/xylazin) anesthesia. Transgene expression starts 
soon after the treatment and becomes detectable in 1–2 days, 
increases until it reaches the plateau (in 5–7 days), and can 
slightly decline later on, but never shuts down completely.
Fig. 6  Stimulation of lymphatic and blood vessel growth in  vivo. 
a–c Preparation of gelatin sponges for lymphangiogenic assay. a 
Small pieces of gelatin sponge are detailed with a puncher before 
to be soaked with tumor cells or a compound. Prepared sponges 
are inserted in mouse ear between the two skin layers. b, c Immu-
nohistochemical analysis of sponges (b) and sentinel lymph node (c) 
resected from mouse with control sponge (PBS or medium without 
growth factor) or from mouse with sponge imbedded with growth 
factor. Lyve-1 (lymphatic endothelial cell marker) is stained in green, 
and CD-31 (blood endothelial cell marker) is stained in red. Sponges 
soaked with growth factor showed higher lymphangiogenesis and 
angiogenesis compared to control sponge. Scale bar in b, c—250 µm. 
d–f Preparation of AAV and transduction of skeletal muscle. d Sche-
matic representation of different VEGF-C and VEGF-D isoforms, 
produced by step-by-step proteolysis, and general AAV production 
and usage protocol. e Immunohistochemical analysis of t.a. mus-
cle transduced with AAV8 encoding VEGF-C-ΔNΔC or VEGF-D-
ΔNΔC. Tibialis anterior muscles of C57BL/6 J male mice (8 weeks 
old) were injected with  109 AAV8 particles in 30 µl of PBS, and the 
mice were euthanized 2  weeks later. T.a. muscle samples were iso-
lated and analyzed immunohistochemically for the indicated markers. 
HSA human serum albumin. f Analysis of the functionality of lym-
phatic vessels. Lectin (from Lycopersicon esculentum), conjugated 
with FITC (FITC-lectin) was injected to the distal part of t.a. muscle. 
After 45 min, the mice were euthanized and t.a. muscle was isolated, 
fixed, and stained for Prox1. Lectin is visualized by FITC. Scale bar 
in e, f—50 µm
◂
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8.2  Applications, benefits, and strengths 
of the assay: analysis of lymphangiogenesis 
and angiogenesis
Lymphatic vessels are visualized by immunohistochemi-
cal staining using antibodies against, for example LYVE1, 
Prox1, or VEGFR3, which are relatively specific for lym-
phatic EC (Fig. 6b, c, e, f). As the mouse ear displays also 
a high blood vessel density, especially after angiogenic 
stimulation, angiogenesis can be analyzed by using anti-
CD-31 antibody. In addition, lymphatic function prior to 
and after the AAV treatment can be studied in mice under 
anesthesia by injecting a lymphatic tracer [such as FITC-
lectin (FL-1171; Vector Laboratories)] to the distal part of 
the muscle as the tracer is taken up by the lymphatic vessels 
and carried by lymph flow. The moving front of the tracer 
can be observed and recorded and serves as a measurable 
parameter of the functional lymphatics. The tracer can be 
also visualized by immunohistochemical staining, combined 
with simultaneous co-staining for lymphatic endothelial 
marker(s) (Fig. 6e, f).
Lymphatic remodeling in sentinel lymph node The ear 
sponge assay applied with tumor cells mimics the early steps 
of cancer progression and the establishment of lymph node 
pre-metastatic niche [146, 147]. The collagen capsule pro-
vides a barrier that retains cells in the sponge. Lymphatic 
vessels present in the ear drain factors to lymph nodes lead-
ing to a remodeling of the lymphatic vasculature in the sen-
tinel lymph node prior to tumor cell arrival (Fig. 1c). Lymph 
node metastases are detected between 3 and 4 weeks post-
implantation (depending on tumor cell types and the number 
of cells used).
AAV gene delivery provides stable transduction Because 
of low immunogenicity, AAV itself does not provoke a 
strong immune response, in sharp contrast to in vivo trans-
duction with adenovirus, which activates the NF-KB path-
way. Unlike AAV, adenovirus gene delivery is accompanied 
by a significant immune response to the adenovirus-encoded 
proteins, resulting in the shutdown of transgene expression 
due to host immune attack. This feature of AAV allows long-
lasting tissue transduction in mice for up to 2 years. If the 
transgene delivered to the mice via an AAV vector encodes 
an isogenic murine protein, it does not provoke an immune 
response either. Although the purified transgenic proteins 
can also be used for in vivo treatment, their administration 
into the tissues usually produces an inferior effect due to the 
instability and fast dilution of the injected protein when it 
diffuses out from the site of injection. It should be noted that 
lymphangiogenic and angiogenic proteins must be present 
for a prolonged period of time to allow vessel formation 
and maturation of the newly formed vessels. Immature ves-
sels often formed after adenovirus-mediated gene delivery 
are unstable and prone to regress soon after the transgene 
expression ceases [148]. Multiple injections of the protein 
to the same tissue are not desirable due to the trauma caused 
by the injections.
Analysis of various forms of lymphangiogenic factors 
Various forms of VEGF-C or VEGF-D can be used includ-
ing immature (full-length) pro-VEGF-C/VEGF-D and 
mature VEGF-C/VEGF-D-ΔNΔC forms, which are natu-
rally produced during step-by-step proteolysis (Fig. 6d). 
Only mature forms VEGF-C/VEGF-D-ΔNΔC demonstrate 
full lymphangiogenic activity in vitro and in vivo, primarily 
due to higher affinity interactions with VEGFR-3. In nature, 
they are all expressed as immature pro-VEGF-C/VEGF-D, 
which then undergo step-by-step proteolysis producing fully 
active mature ΔNΔC forms. Thus, AAV-mediated expres-
sion of ΔNΔC form of VEGF-C or VEGF-D provides some-
what artificial stimulatory conditions for lymphatic vessel 
growth.
Lymphangiogenic factors can also stimulate blood vessel 
growth The mature forms of both VEGF-C and VEGF-D 
are able to bind to and stimulate not only VEGFR-3, but 
also VEGFR-2, although the affinity toward VEGFR-2 is 
significantly lower than VEGF-A (by a factor of 20–100). 
Blood vessel growth is induced when AAV-VEGF-C or 
AAV-VEGF-D is administered to the murine skeletal muscle 
[143], which has also been demonstrated in rabbit skeletal 
muscle transduced by recombinant adenoviruses [149]. The 
angiogenic effect of VEGF-C, however, can be decreased, 
while preserving full lymphangiogenic activity, by using 
a VEGF-C156S mutant form of the growth factor [150]; 
VEGF-C156S has a reduced binding affinity for VEGFR-2, 
while binding affinity to VEGFR-3 is largely unaltered.
8.3  Limitations and challenges
Sponge preparation Steps related to sponge preparation 
are critical for the reproducibility of the assay. The addi-
tion of a drop of 20 µl with cells or factors on the top of 
the sponge is better than an immersion of the sponge in the 
solution. Moreover, it is important to turn the sponge half-
way through the incubation period to allow homogenous 
diffusion in the biomaterial. Finally, the collagen capsule 
formation is a key step to allow sponge insertion between 
ear skin layers without cell or solution loss.
Control of transgene expression To date, broad usage 
of AAV-mediated overexpression of VEGF-C/VEGF-D 
(or VEGFR-3-Fc) in mice or in human patients in clinical 
practice is hindered by the inability to efficiently regulate 
transgene expression. When a lymphangiogenic effect is 
achieved, it would be desirable to shut off the expression 
of the transgene. Long-term overexpression of VEGF-C/
VEGF-D would lead to a heavily overgrown and unstruc-
tured lymphatic vasculature, which would be poorly 
functional. Blood vessels may also respond to long-term, 
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uncontrolled VEGF-C/VEGF-D overexpression by over-
growth and increased leakiness. Currently existing ON/OFF 
switch systems, such as under tetracycline regulation, are 
either inefficient, or toxic for humans, although some have 
been adapted for in vitro use. The versatility of the CRISPR/
Cas9 delivery system may provide solutions to these prob-
lems in the near future.
Unequal transduction of target cells in the transduced 
tissue Unlike in transgenic animals, where transgene expres-
sion can be induced in virtually every cell in a target tissue 
such as muscle, viral gene delivery fails in some of the target 
cells and this can lead to tissue mosaicism and non-homog-
enous protein delivery. Cell types vary in their sensitivities 
to AAV transduction due to differential expression of AAV-
binding receptors. For example, tail vein injection of AAV9 
results in a significantly higher transduction of heart than of 
the liver or pancreas [151].
Local trauma associated with ear sponge implantation 
and viral vector delivery During surgery, the integrity of 
the ear must be assessed as perforations can result in sponge 
loss. Of note, it is not possible to identify mice using ear 
clips since both ears are used for the assay. Depending on 
the pathological context of the study, a limitation of the ear 
sponge model is local inflammation induced by the sponge 
insertion. Regarding viral vector delivery, when AAV is 
administered locally, the injection itself produces some 
trauma in the target tissue, which can lead to altered sensi-
tivity of cells along the vector injection path.
8.4  Concluding remarks
The ear sponge assay is a suitable model to study lymphatic 
vessel remodeling in the both primary tumor and sentinel 
lymph node prior (pre-metastatic state) and after tumor cell 
arrival (metastatic state). Gene delivery via AAV represents 
a reliable and relatively inexpensive approach for gene ther-
apy in inherited or acquired vascular disease models. AAV 
provides a convenient way to study biological properties of 
bioactive proteins, such as vascular growth factors in vivo 
and under conditions mimicking the natural expression of 
the endogenous genes.
9  Assay for pericyte recruitment 
to endothelial cell‑lined tubes, capillary 
assembly, and maturation
A fundamental question concerns the growth factor and sign-
aling requirements governing how human EC and pericytes 
co-assemble to form capillary tubes in a 3D matrix or tis-
sue environment [80, 152–155]. To this end, bioassays have 
been developed in 3D collagen or fibrin matrices to address 
such issues using serum-free defined conditions [156, 157] 
(Fig. 7). In either system, pericyte recruitment to EC tubes 
can be readily observed over a 72–120 h period and a conse-
quence of this recruitment is deposition of the vascular base-
ment membrane between the abluminally recruited pericytes 
and the ECs that line the branched networks of tubes [153]. 
Interestingly, EC tube formation results in the creation of 
networks of ECM spaces, which are termed vascular guid-
ance tunnels [158], where the EC tubes reside, and are also 
a physical space into which pericytes are recruited along the 
basal and abluminal EC tube surface [153, 158]. Both EC 
and pericytes migrate along each other in a polarized man-
ner within these tunnels, resulting in basement membrane 
deposition underneath the abluminal surface of the EC-lined 
tubes [152, 153, 159]. Basement membrane deposition leads 
to much narrower and elongated EC tubes in EC-pericyte 
co-cultures compared to EC-only tubes which progressively 
get wider and less elongated with time [153, 159].
9.1  Benefits and strengths of the assay
The major benefit and strength of this assay model is its high 
reproducibility and high replicate number in that it is per-
formed in half-area 96-well plates. The assay is typically set 
up in 60 wells per plate, and this can be readily established 
using one T75 flask of human EC (e.g., HUVEC) and one 
T25 flask of human pericytes (brain-derived vascular peri-
cytes) (labeled with GFP). The assay allows performance 
of siRNA suppression experiments using either cell type 
or lysates that can be prepared to assess signaling trans-
duction cascades by Western blot. Also, the recruitment of 
pericytes can be examined in time with or without blocking 
antibodies to various targets (e.g., growth factors, recep-
tors, integrins, ECM molecules, etc.) or signal transduction 
inhibitors. The consequence of pericyte recruitment to EC 
tubes can be revealed by examining basement membrane 
deposition (by immunofluorescence staining or transmission 
electron microscopy) (Fig. 7), or by measuring capillary tube 
widths and lengths. Finally, real-time video analysis can be 
used to monitor pericyte and endothelial motility as they co-
assemble to form tube networks with abluminally recruited 
pericytes in 3D matrices.
9.2  Assay overview
HUVEC or human artery endothelial cells (HUAECs) 
and human brain-derived vascular pericytes or bovine 
retinal pericytes are trypsinized and seeded within 3D col-
lagen matrices at a density of 2 × 106 cells/ml for EC and 
4 × 105 cells/ml for pericytes. Both types of EC or pericytes 
work very well in this assay system. FGF-2 and stromal-
derived factor-1α (SDF-1α) are each added at 200 ng/ml 
into the collagen gel mix (2.5 mg/ml of rat collagen type 
I). Twenty-five μl of gel is added into each individual 96 
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well (A/2 plates from Costar). After 30 min of equilibration 
in a  CO2 incubator, culture medium is added (100 μl per 
well) which is Medium 199 (100 μl per well supplemented 
with 1:250 dilution of Reduced Serum Supplement II) [160], 
and 40 ng/ml each of FGF-2, stem cell factor (SCF), inter-
leukin-3 (IL-3), and 50 μg/ml of ascorbic acid are added. 
Cultures are then placed in a  CO2 incubator for 72–120 h. 
After this time, cultures are fixed with 3% paraformaldehyde 
in PBS (120 μl per well). Cultures can then be imaged under 
fluorescence to quantify EC tube area and pericyte recruit-
ment under the various conditions of treatment. Individual 
cultures can be immunostained with various antibodies 
directed to EC or pericyte cell surfaces and/or ECM anti-
gens (i.e., basement membrane proteins such as fibronectin, 
laminin, and collagen type IV) [153]. Alternatively, cultures 
can be used to make lysates using SDS sample buffer or 
used to isolate total RNA to perform gene expression experi-
ments [153]. Real-time movies can be performed to examine 
pericyte recruitment and measure pericyte motility during 
capillary assembly and maturation [154]. In the latter case, 
nuclear GFP-labeled pericytes can be utilized to track peri-
cyte motility [154].
9.3  Critical steps in the assay
The assay system above is highly dependent on the health 
of the growing EC. To each 500 ml bottle of Medium 199, 
we add 200 mg of lyophilized bovine hypothalamic extract, 
50 mg of heparin, and 100 ml of fetal calf serum (then ster-
ile filter complete media). Tissue culture flasks are coated 
with 1 mg/ml of gelatin solution for at least 30 min. prior to 
seeding the trypsinized EC. Pericytes are grown using the 
same culture media and gelatin-coated flasks. Bovine hypo-
thalamic extracts as well as rat tail collagen preps are used 
at 7.1 mg/ml protein in 0.1% acetic acid. The assay system 
is highly robust and reproducible [153, 156, 157].
Especially for longer-term experiments (i.e., multiple 
days), it is important to completely surround each well with 
100 μl of water. This reduces dehydration of media in the 
microwells and maintains the health of the cultures. For 
cultures extending longer than 72 h, the cultures are replen-
ished by removing 90 μl of media and replacing with 100 μl 
of media per well. This medium is slightly different than 
that used above to start the assay: Medium 199 containing 
a 1:250 dilution of RS II, ascorbic acid at 50 μg/ml, as well 
as 80 ng/ml of FGF-2, and 40 ng/ml each of SCF, IL-3, and 
SDF-1α.
9.4  Limitations and challenges
The major limitations of this in vitro assay relate to how 
reflective the assay model is to the in vivo state. Overall, 
the data and conclusions obtained over the years have 
been repeatedly demonstrated to be observed using mouse, 
zebrafish, or quail in vivo models [155]. One of the interest-
ing issues is the state of differentiation of the EC that are 
Fig. 7  Serum-free defined model of human endothelial cell-pericyte 
tube co-assembly in 3D collagen matrices. a Human EC and GFP-
labeled pericytes (Peri) were seeded together at the indicated cell 
densities and after 120  h, were fixed and stained with anti-CD31 
antibodies. The immunostained cultures were imaged using confo-
cal microscopy. The serum-free defined culture system contains SCF, 
IL-3, SDF-1α, FGF-2 and insulin (a component of the RS II supple-
ment), which are required to be added in combination. b Cultures 
fixed at 120 h were immunostained with antibodies to CD31, laminin 
(LM), and fibronectin (FN) and were imaged using confocal micros-
copy or were examined by transmission electron microscopy. Arrows 
indicate the capillary basement membrane. L indicates lumen while 
Nuc indicates nuclear labeling. Bar equals 25 μm
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used in these in vitro assays, and how similar are they to EC 
in vivo that are undergoing vasculogenesis or angiogenic 
sprouting. This is a very difficult question to answer and 
needs to be addressed in future studies. Another potential 
weakness of the current in vitro systems is that flow condi-
tions have to be adapted or the gels have to be transplanted 
into a mouse model to interface the human vessels with an 
in vivo vascular system.
9.5  Concluding remarks
Here, a defined assay system is described which allows for 
the assembly of capillary tube networks, with EC-lined tubes 
and abluminally recruited pericytes in 3D collagen or fibrin 
matrices. This system has been previously utilized (and can 
be employed in future studies) for detailed investigations of 
the molecular and signaling requirements for this process, 
by independently assessing the functional role of ECs vs. 
pericytes during these tube co-assembly events.
10  EC co‑culture spheroids
Angiogenesis, the sprouting of endothelial cell capillaries 
from preexisting blood vessels, is multifactorial includ-
ing processes such as proliferation and directed migration. 
These processes in turn are influenced not only by auto-
crine but also by paracrine stimuli mediated by, for example, 
pericytes, fibroblasts, immune cells, and tumor cells in the 
case of cancer. This intercellular communication by stimuli 
includes growth factors, chemo- and cytokines as well as 
other secreted factors, like enzymes, extracellular base-
ment membrane components, and the exchange of genetic 
material (miRNA, mRNA, DNA) via extracellular vesicles 
[161–163]. Anatomically, these various cell types are fine-
tuned and orchestrated to become organized 3D structures 
to ultimately allow and control the flow of blood. However, 
the field of angiogenesis has typically focused on studying 
angiogenesis-associated processes in vitro in pure EC cul-
tures. Although studying EC in isolation has some advan-
tages in investigating certain EC-specific elements and to 
certain defined processes within angiogenesis, 3D co-culture 
spheroids allow one to study the direct intercellular cues 
and cross talk between EC and their surrounding cells. Co-
cultures with tumor cells create a simplified dynamic tumor 
microenvironment due to the changes in shape and size in 
time. As a result, the 3D spheroid assay sheds light on the 
biological conduct and communication of EC with a mul-
titude of different cell types under various stresses or treat-
ment conditions in a controlled manner. Importantly, it offers 
the possibility to investigate multiple different interventions 
(e.g., chemotherapies, radiation, experimental drugs) in a 
medium-throughput manner in an environment more rel-
evant to the in vivo situation.
10.1  Strengths and benefits 
of the three‑dimensional co‑culture EC 
spheroids
Studies on in vitro 2D monolayer cell cultures and their 
translation/extension to clinical settings have their limi-
tations, as they are not capable of mimicking the nutrient 
and oxygen gradient and an environment reminiscent of 
the in vivo setting. The preclinical 3D co-culture spheroid 
assay facilitates intra-/intercellular cross talk mimicking 
aspects of in vivo vascular architecture, for example lumen 
formation and polarization, and is particularly valuable for 
interrogating these interactions in the presence of two or 
more cell types growing together with natural adhesion and 
layering properties. Additionally, and at least as important, 
it lends itself for controlled experimental manipulation and 
replication thereof as it can be applied in the developmen-
tal/regeneration field as well as the cancer biology and the 
cancer treatment fields. Particularly in the cancer field, the 
3D co-culture tumor cell/EC spheroid assay is a valuable 
instrument for interrogating interactions between the tumor 
stroma and parenchyma to better understand the mechanisms 
of radiation and cancer therapeutics and how cells support or 
damage each other in their response to these interventions. 
Ultimately, the ability to screen a relatively high number 
of conditions against these mini-tumor microenvironments 
has potential to promote the establishment of improved drug 
pharmacokinetics, efficacy, and safety profiles [164].
Inherent in many in vitro assays, one of the strengths of 
the spheroid assay is the relative ease of focused manipula-
tion to aid in answering specific hypotheses. Namely, prior 
to the paired co-culture one of the cell types can be geneti-
cally altered by retro- or lenti-viral constructs, including 
fluorescence (gain-of-function) or by shRNA/siRNA knock-
down or CRISPR/Cas9 (loss-of-function). Additionally, the 
sensitivity or resistance to a particular pharmacological or 
radiation treatment approach can be tested. We and others 
have observed marked differences in treatment response and 
viability of tumor cells growing in the presence/in contact 
with EC and vice versa [164].
10.2  Assay overview and types of assays
Multicellular 3D spheroids can be generated by various 
methods, including the (1) spontaneous spheroid forma-
tion using (ultra) low binding plates; (2) “hanging drop” 
technique; (3) suspension cultures (e.g., by spinner flasks 
or bioreactors); (4) scaffold-based models (e.g., hydrogels), 
and (5) magnetic levitation [165]. Since spontaneous sphe-
roid formation and the hanging drop method are arguably 
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the most cost-effective and likely take the least amount of 
specialized skill set, we will focus on these two iterations 
of the model (Fig. 8). One of the pioneering approaches to 
generate self-assembling multicellular 3D tumor endothelial 
spheroids in hanging drops was by Timmins et al. [166]. 
Subsequently, this assay was validated by various groups 
and expanded on in terms of cell types tested and it evolved 
as an instrument to be transplanted into animals, devoid of 
Matrigel, to study cancer progression and ultimately metas-
tasis [164].
The initial spheroid structure is produced by pipetting a 
single-cell suspension of 1000 tumor cells in a 20-μl droplet 
on the inside of the lid of a, for example, 48-well cell culture 
plate (Greiner Cellstar, BioExpress, Kaysville, UT). Gravity-
enforced self-aggregation is facilitated by inverting the lid 
and placing it on its receptacle (i.e., the 48-well plate). The 
culture medium and incubation conditions do not need to be 
adjusted and thus can stay as preferred. After 72 h, the lids 
are set inside up and the addition of 2000 EC in a volume 
of 5 μl is added to the existing culture. The lid is then re-
inverted, and the hanging drops can be incubated and moni-
tored for growth, cell type incorporation characteristics, and 
other aspects for an additional 14 days depending on the cell 
types used (Fig. 8).
Additionally, the spheroids can be implanted in vivo and 
used in animal models or within specialized techniques 
such as the dorsal skin fold window chamber, creating an 
in vitro/in vivo assay. For decades, it has been postulated that 
growing tumor cell-only spheroids and implanting them in 
animals lead to a much higher tumor take with far fewer total 
cells inoculated. This was hypothesized to be due to the crea-
tion of a microenvironment in the spheroid as well as pos-
sibly engaging or enriching for cancer stem cell phenotype. 
Although the optimal conditions vary when co-culturing dif-
ferent cell types with EC, when using tumor-EC spheroids, 
as few as two spheroids per implantation are sufficient to 
generate tumor growth and metastasis [164]. This approach 
may be valuable in studying various treatments or aspects of 
tumor progression thought to be dependent on vasculariza-
tion and/or stimulation of metastasis or aggressiveness via 
tumor cells engaging EC.
The spheroids can be assessed by multiple readouts 
depending on the laboratories preferences, techniques 
available, and skill set. Namely, quantitative and qualitative 
evaluations include imaging techniques such as bright field 
and fluorescence microscopy, molecular marker assessment 
by, for example, immunohistochemistry or immunofluores-
cence, or functional assays such as cell viability and sur-
vival assessment with or without growth factors, biologics, 
therapeutics, or radiotherapy [164]. The functional assays 
are generally performed after transferring the spheroids into 
low-binding 96-well plates to better control and standardize 
the additions of, for example, growth factors, therapeutics, 
or reporters (e.g., viability or proliferation stains; Fig. 8).
10.3  Limitations and challenges
Although in theory this assay can be used for multiple differ-
ent co-cultures with a number of cell types, some restrictions 
arise in the use of particular cell types as well as the com-
binations thereof. Namely, primary isolates have a limited 
duplication potential and life span, but this can be bypassed 
with immortalized cells. Relatedly, cell density needs to be 
carefully controlled based on the cell type (short vs. long 
doubling times) and the planned length of the assay. A major 
challenge in pairing cells in co-culture growth is to find a 
growth medium that will supply each cell type with enough 
nutrients to survive, but that also does not overstimulate 
proliferation. Allowing cell types to interact and support 
themselves by the mere process of adhesion and exchange 
of various factors is one of the more exciting aspects of this 
model and frequently has led to new insight in the absence 
of the high serum, high nutrient mediums used in isolated 
2D cultures of the past. Depending on the chosen setup of 
cells (e.g., primary vs. immortalized) and pairing of the cell 
types (e.g., endothelial and pericytes, stroma and (tumor) 
parenchyma, same species or mouse/rat vs. human) inter-
pretation and generalization of the results must take these 
outsets in consideration.
10.4  Concluding remarks
In summary, the EC spheroid assay is an in vitro and pos-
sibly an in vitro/in vivo co-culture method assisting in the 
comprehension of initial stages of angiogenesis and angio-
genesis-associated processes in a continuum—from initia-
tion to development and progression. The system allows for 
monitoring tissue development as well as testing pro- and 
anti-angiogenesis targeted treatments with and without the 
combination of chemo/radiation therapy in a more relevant 
microenvironment than traditional 2D cultures. Thus, this 
in vitro/in vivo preclinical cell and animal model holds 
promise to not only enable the identification of authentic 
and novel biomarkers but also provide enhanced predictive 
utility for drug development and discovery.
11  Endothelial cell metabolism
Metabolism is a biochemical reaction network that catabo-
lizes nutrients into metabolic products such as energy and 
biomass that are needed to survive, proliferate, and adapt to 
environmental challenges. As such, they provide a functional 
readout of the observed phenotypic changes. Metabolomics 
is the systematic study of the aforementioned metabolic 
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products and is currently enjoying a revival (“Metabolomics, 
the apogee of the omics trilogy” [167]). The ultimate goal of 
metabolomics is to understand: (1) how cells under different 
circumstances apply and reroute their metabolic pathways, 
and (2) what are the required start and end products in rela-
tion to the observed phenotype.
The majority of EC remains quiescent for years [168], but 
upon exposure to pro-angiogenic stimuli (such as VEGF), 
they can rapidly switch to a proliferative and migratory state 
in health and disease. At the base of this switch lies a tightly 
regulated metabolic network, providing the necessary energy 
and building blocks for EC to respond accordingly [169, 
170]. ECs rewire their metabolism in a highly specific man-
ner to optimally execute these functions [171]. Indeed, ECs 
are highly glycolytic, producing large amounts of ATP and 
lactate even in the presence of ample oxygen [170].
In the following section, we will discuss three approaches 
that have been established to monitor metabolic activities of 
EC: (1) tracer metabolomics, (2) radioactive tracer-based 
metabolic assays, and (3) measurements of extracellular 
acidification rate and mitochondrial respiration by the Sea-
horse XF analyzer. These approaches are complementary, 
and it is recommended to perform these assays in parallel 
for a more complete metabolic phenotyping.
11.1  Tracer metabolomics
The interpretation of metabolic activities based on the 
(relative) abundances of metabolites under specific condi-
tions remains a formidable challenge, largely because the 
network of biochemical reactions is highly interconnected. 
For instance, an increase of intracellular serine levels can 
be due to increased uptake but also by de novo synthesis 
using 3-phosphoglycerate from glycolysis as a substrate. As 
such, the majority of metabolites can be linked to multiple 
sources and by merely measuring the (relative) abundance 
of metabolites, one cannot readily deduct the responsible 
pathways and their active interplay. This knowledge is para-
mount to understanding cellular biology. A specialized field 
in metabolomics, Tracer Metabolomics [172], tackles this 
challenge and uses labeled non-radioactive substrates (car-
rying 13C, 15N, 18O, 2H, etc.) to monitor the distribution of 
the labeled isotopes throughout the metabolic network and 
as such, provides the actual contribution of nutrients to spe-
cific metabolites and consequently the relative activity of 
metabolic pathways.
11.2  Experimental tracer metabolomics setup of EC
A possible cell culture format for EC is performed using 
a 6-well plate, in which at least 150,000 ECs are plated. 
ECs need to be grown in customized medium of which the 
substrate of choice is withdrawn and replaced by its non-
radioactive isotopically labeled counterpart (tracer). The 
majority of tracers are nutrients that are taken up by the 
cell (for instance, glucose, glutamine, palmitic acid, etc.), 
of which one of the constituent atom species (12C, 14N, 1H, 
16O, etc.) is replaced by its non-radioactive isotopologue 
(respectively, 13C, 15N, 2H, 18O, etc.). ECs take these labeled 
nutrients up and process them similarly compared to their 
unlabeled form. Consequently, all of the downstream metab-
olites and metabolic pathways linked to the specific tracer 
will incorporate the labeled atoms. It is critical that ECs 
reach isotopic steady state, a condition that is accomplished 
Fig. 8  EC co-culture spheroid assay. a Overview of the procedure 
of the hanging drop spheroid growth assay over time. Prior to initi-
ating the co-culture, tumor cells (green) are allowed to establish ini-
tial micro-spheroids by themselves. Typically, after 72 h EC can be 
introduced (red) and their incorporation monitored over time up to 
14 days. b After 7 days, the tumor-EC spheroid can be quantitatively 
and qualitatively evaluated by various techniques, such as c (fluores-
cence) microscopy, histology, functional assays or implanted in vivo. 
Breast tumor cells (green; GFP-4T1) are combined with 2H11 EC 
(red) stained with MitoTracker Red. Scale bar = 100 µm
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when the labeled isotope enrichment in a given metabolite 
is stable over time relative to the experimental error [172]. 
Practically, steady state in EC is reached in 24–48 h using, 
respectively, glucose or glutamine tracers [173, 174], for 
palmitic acid up to 72 h of incubation is required [169]. The 
difference in labeling time necessary to reach isotopic steady 
state depends on both the fluxes (i.e., rate of conversion) 
from the nutrient to the metabolite of interest, and the con-
centration of that metabolite and all intermediate metabolites 
[172]. The fractional contribution, which is the fraction of a 
metabolite’s carbon (or other atom) produced from a certain 
nutrient, in the downstream metabolites as well as their iso-
topic envelopes (isotopologues) can be quantified using mass 
spectrometry (MS). Prior to MS analysis, ECs are washed 
using a physiological (0.9%) NaCl solution and metabolites 
are extracted in an organic (50% methanol–30% acetoni-
trile–20%  H2O) extraction buffer. It is of utmost importance 
that the extraction is carried out swiftly because a cell’s 
metabolism changes within the order of seconds to minutes 
[175]. Extracts are centrifuged to remove the precipitated 
proteins and insolubilities. The supernatant, containing the 
polar metabolites, is loaded onto the MS platform.
11.3  Mass spectrometry
The instrument of choice for carrying out (tracer) metabo-
lomics is mass spectrometry (MS), mainly due to its superior 
sensitivity and speed of analysis in comparison with other 
technologies such as nuclear magnetic resonance (NMR) 
spectroscopy, as well as its flexibility in applying different 
kinds of chromatography (liquid or gas chromatography, 
LC, or GC) to study different chemical classes of metab-
olites [176]. We will only focus on the analysis of polar 
metabolites (amino acids, organic acids, hexose phosphates, 
etc.). Apolar species such as lipids are beyond the scope 
of this section. A crucial requirement for the MS in tracer 
metabolomics relates to its resolution, the ability to accu-
rately quantify the isotopologue profiles of the metabolites 
of interest. As such, the current benchtop LC–MS OrbiT-
RAPs are among the instruments of choice to conduct tracer 
metabolomics. Alternatively, GC-linked (triple) quadrupole 
MS can be used as well. For the separation of polar metabo-
lites prior to the MS, two main types of chromatography can 
be applied: (1) hydrophilic liquid chromatography (HILIC) 
[177] and (2) ion-pairing chromatography [178]. The latter 
has superior binding and separation capacities compared to 
HILIC, but it restricts any further usage of the chromato-
graph to ion-pairing mode. In this perspective, HILIC pro-
vides a better solution, despite the lesser separation capacity 
compared to the ion-pairing setup as it comes without any 
restrictions to apply different chromatography settings on 
the same platform.
11.4  Data processing
Data extraction of isotopic profiles occurs via vendor-spe-
cific software or in-house developed software platforms 
(e.g., BIOMEX™) [179]. In general, the workflow starts 
with in-house libraries containing information on the exact 
mass of the target molecule and its retention time during 
the chromatographic separation to identify the metabolite 
of interest. Next, the abundances of the isotopes of different 
metabolites of interest are quantified. Following a correc-
tion for natural abundances [172, 180] to facilitate proper 
interpretation of the labeling data, the fractional contribution 
is calculated [172].
11.5  Radioactive tracer‑based assays
As introduced above, unlabeled or labeled metabolites can 
be quantified by MS or NMR. However, these techniques 
display some limitations, as they do not quantify the abso-
lute flux, which reflects the rate of turnover of molecules 
through a metabolic pathway. Radioactive isotope labeling 
is a widely used experimental approach to analyze metabolic 
flux. This technique is based on the principle that nutrients 
labeled with radioactive tracers (e.g., 3H and 14C) at specific 
positions within the molecule release the radioactive label 
as 3H2O or 14CO2, respectively, upon specific enzymatic 
activities. Consequently, the generated 3H2O and 14CO2 
diffuse into the medium and can be measured by trapping 
its release on soaked filter paper and subsequently quanti-
fied by scintillation counting [170]. As an example, the use 
of [5-3H]-glucose enables to quantify glycolytic flux [181] 
because the single tritium at the C5 of glucose is removed 
by a condensation reaction catalyzed by enolase (Fig. 9a), 
hence releasing radioactive 3H2O in the medium. Similarly, 
by using [9,10–3H]-palmitic acid, one can measure the radio-
active 3H2O formed during fatty acid oxidation [169].
In order to map the different metabolic fates of glucose 
and other crucial substrates, a set of differently radioactive-
labeled tracers are needed to identify and quantify the ongo-
ing biochemistry. As an example, in parallel with the gly-
colytic flux measured by [5–3H]-glucose, the downstream 
oxidation of glucose can be monitored by quantifying the 
release of 14CO2 by [6–14C] glucose or uniformly labeled 
 [14C6] glucose. Notably, by using [6–14C] glucose, informa-
tion on the oxidation of glucose in the tricarboxylic acid 
(TCA) cycle is obtained, whereas the  [14C6] glucose tracer 
generates 14CO2 via two different metabolic pathways: the 
oxidative pentose phosphate pathway (oxPPP) and the TCA. 
Also, the carbon at position 1 in glucose is liberated in the 
oxPPP. Hence, using [1–14C] glucose in parallel with [6–14C] 
glucose, the oxPPP flux can be estimated by subtracting the 
rate of [6–14C] glucose from the one of [1–14C] glucose. In 
summary, assessing the choice of the tracer and its specific 
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labeling positions is essential in terms of the biological 
question that needs to be addressed. Similar approaches are 
available to investigate other “non-glucose” related fluxes, 
for example by using  [14C5] labeled glutamine to determine 
glutamine oxidation.
11.6  Measurements of extracellular acidification 
rate and mitochondrial respiration using 
a Seahorse XF analyzer
The Seahorse extracellular flux (XF) analyzer enables to 
assess different aspects of cell metabolism. Apart from 
providing an indirect readout of anaerobic glycolysis 
through measurements of the extracellular acidification 
rate (ECAR) [182], it can also assess oxidative phospho-
rylation (OXPHOS) (through oxygen consumption rate 
(OCR)). A commonly used method to determine glycolysis 
by the Seahorse XF analyzer is the measurement of acidi-
fication of the medium (pH changes) in a glycolysis stress 
test [183]. In this technique, glucose, oligomycin (inhibi-
tor of ATP synthase in the electron transport chain (ETC)), 
and 2-deoxy-glucose (2-DG, inhibitor of hexokinase) are 
sequentially administered while measurements of ECAR 
are being performed. In the first phase of the experiment, 
ECs are cultured in medium deprived of glucose or pyruvate 
(the glycolysis stress medium). Supplementation of glucose 
feeds glycolysis, which allows estimation of glycolytic rate 
by calculating the difference between ECAR before and 
after addition of glucose. ECAR, prior to glucose injection, 
is referred to as non-glycolytic acidification resulting from 
other sources of extracellular acidification not attributed to 
glycolysis (Fig. 9b). Next, oligomycin, which inhibits mito-
chondrial ATP production, lowers the ATP/ADP ratio, and 
shifts energy production to glycolysis, is supplemented to 
measure the maximum glycolytic capacity. The difference 
between ECAR before and after oligomycin supplementa-
tion is a measure of the glycolytic reserve capacity. The last 
injection of 2-deoxy-glucose (2-DG) inhibits glycolysis, and 
the resulting decrease in ECAR confirms that the ECAR 
produced in the experiment is due to glycolysis. Moreover, 
inhibition of glycolysis by 2-DG also provides information 
on non-glycolytic ECAR of cells (Fig. 9b).
Mitochondrial respiration can be assessed by using a 
modified Seahorse Cell Mito Stress Test [184]. This test 
sequentially uses modulators of respiration that target dif-
ferent components of the ETC. Oligomycin, carbonyl cya-
nide 4-(trifluoromethoxy) phenyl-hydrazone (maximizing 
OCR by uncoupling the OXPHOS), and antimycin (block-
ing OXPHOS by inhibiting complex III) are sequentially 
injected to determine basal mitochondrial OCR  (OCRBAS), 
ATP-dependent OCR  (OCRATP), maximal respiration 
 (OCRMAX) and non-mitochondrial respiration  (OCRnon-mito), 
proton leak, and spare respiration (Fig. 9c) [184].
11.7  Limitations and challenges, problems 
and pitfalls in probing EC metabolism
Tracer Metabolomics provides information on relative path-
way activities, qualitative changes in pathway contributions 
via alternative metabolic routes, and nutrient contribution to 
the production of different metabolites. In this perspective, 
a limitation of tracer metabolomics is the lack of quantita-
tively estimating metabolic fluxes, which provide additional 
quantitative and complementary information such as path-
way directionality. Nonetheless, resolving metabolic fluxes 
is time and data intensive [185] and often requires applying 
computational modeling of the data. A challenge for tracer 
analyses is the requirement of expert knowledge at the level 
of mass spectrometry and biochemistry. This relates to the 
choice of specific tracers needed to answer biological ques-
tions as well as the tools (chromatography, mass spectrom-
etry, software) available to extract and process the required 
data. The optimal cell culture experiments apply custom-
ized medium of which the unlabeled form of the tracer has 
been withdrawn. This setup maximizes the amount of label 
entering the cell and increases the likelihood to identify 
and quantify the labeled “downstream” targets. A pitfall 
occurs when the unlabeled form cannot be withdrawn; in 
this case, the labeled compound can be added in equimolar 
quantities to the medium as the unlabeled compound. This 
poses potential problems: (1) The amount of label incorpo-
rated in downstream metabolites is reduced and pathways 
using low amounts of the tracer might be overlooked; and 
(2) doubling the concentration of a specific substrate can 
induce metabolic changes into the cellular biochemistry, for 
instance doubling the glucose levels from the physiologi-
cal 5.5–11 mM places EC in a diabetic-like “high glucose” 
environment, triggering additional metabolic changes or, in 
worst case, inducing toxicity.
Not all of the metabolites present in the cell are detect-
able by MS, the major causes for this relate to the abundance 
and/or intrinsic technical challenges, such as the ionization 
potential of the metabolite of interest. To tackle this chal-
lenge and still gain information on this missing piece of 
the puzzle, one needs to look at the fractional contribution 
and isotopologue profiles of neighboring metabolites that 
reflect the labeling pattern of the missing component, for 
instance the lack of oxaloacetate detection can be accounted 
for by looking at the isotopologue profile of aspartic acid. 
Consequently, engaging on tracer analyses implies that suf-
ficient metabolites need to be taken into account ensuring 
full coverage of the pathway(s) of interest.
General limitations of (radioactive) tracer-based assays 
Cell metabolism is a very dynamic process, and the meta-
bolic needs as well as metabolic activity of EC have been 
shown to correlate with the cell cycle phases [171, 186]. 
Therefore, one should carefully control cell density while 
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performing these experiments. Moreover, the results and 
interpretation of metabolic studies using radioactive tracers 
depend on appropriate normalization of the data, as inef-
fective or poorly chosen normalization methods can lead 
to erroneous conclusions. Therefore, normalization to total 
protein concentration, cell number, or DNA content is con-
sidered as the golden standard in metabolomics.
Seahorse XF analyzer. Although assays performed on a 
Seahorse XF analyzer requires only small number of cells 
(30,000 cells/well in 24-well assay plate format), they still 
present several limitations that one should take into con-
sideration while performing these experiments. Additional 
metabolic processes, like  CO2 generated during tricarbox-
ylic acid (TCA) cycle activity, can change the pH of the 
media and interfere with the readout and interpretation of 
the results. Since ECAR is essentially a measurement of pH, 
buffering agents (e.g., sodium bicarbonate) are not included 
in the assay medium. Moreover, as bicarbonate and media 
pH play a role in regulating glycolysis, they can influence 
and confound measurements of ECAR. In order to increase 
the accuracy of the performed experiments, application 
or pre-treatment with additional chemical inhibitors (e.g., 
AR-15585; lactate export blockers) can be of use to deter-
mine whether changes in pH come from lactate excretion or 
other sources of media acidification. Optionally, glutamine 
can be also withdrawn from the media, in order to assess 
ECAR coming from glycolytic pathway and not from glu-
taminolysis [187] albeit the removal of specific nutrients 
can also induce off-target metabolic changes. In addition, 
depending on the used cell type, the concentration of each 
chemical compound must be carefully determined, in order 
to obtain the optimal result for each of these measurements. 
Fig. 9  Methods to measure EC metabolism using radioactive tracers 
and Seahorse XF analyzer. a Schematic representation of glycolytic 
flux measurements with [5–3H]-glucose. A single tritium present on 
5C glucose is released as water in the ninth step of glycolysis cata-
lyzed by enolase. b Schematic representation of the modified Gly-
colysis Stress Test. The first measurements of ECAR are performed 
while ECs are incubated in glycolysis stress test medium (without 
glucose and pyruvate). The injection of glucose leads to the satura-
tion of glucose concentration and allows measuring glycolytic rate 
(blue). Second, injection of oligomycin blocks oxidative ATP produc-
tion and shifts the energy production to glycolysis, with the subse-
quent increase in ECAR revealing the cellular maximum glycolytic 
capacity (green). The difference between glycolytic capacity and gly-
colysis rate defines glycolytic reserve. The final injection of 2-deoxyl-
glucose (2-DG) inhibits glycolysis, and the resulting decrease in 
ECAR confirms that the ECAR produced in the experiment is due 
to glycolysis. ECAR, prior to glucose injection or after 2-DG injec-
tion, is referred to as non-glycolytic acidification (pink). c Schematic 
representation of the modified Seahorse Cell Mito Stress Test. First 
injection of oligomycin blocks ATP synthase and allows the calcu-
lation of the ATP coupled oxygen consumption rate  (OCRATP; red). 
Second, injection of FCCP maximizes the OCR by uncoupling the 
OXPHOS, enabling to calculate the spare respiration (reserve capac-
ity). Third, antimycin-A treatment blocks complex III of ETC ena-
bles the calculation of the basal mitochondrial respiration  (OCRBAS; 
green), the maximal mitochondrial OCR  (OCRMAX; orange), the pro-
ton leakage (blue), and the non-mitochondrial OCR (pink)
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For instance, it has been observed that an overdose of oli-
gomycin can lead to maximal inhibition of OCR, which can 
result in a progressive increase of OCR over time [184]. 
Unfortunately, the molecular mechanism underlying this 
observation remains elusive.
12  Endothelial cell precursors
Stem and progenitor cells provide a necessary homeostatic 
source of tissue-specific mature cellular elements that 
permit appropriate cell functions through replacement of 
injured, diseased, and senescent cells in many organ systems 
throughout the life span [188]. While the identity, biology, 
and molecular regulation of hematopoietic-, intestinal-, 
skin-, and skeletal muscle stem and progenitor cells are well 
recognized, little is known of the organization of the repara-
tive cells that comprise the vascular system. In 1997, Asa-
hara and colleagues [189] reported on the identification of 
circulating progenitor cells for the endothelial lineage. Sub-
sequent studies have clarified that those putative “endothe-
lial progenitor cells” (EPC) did not possess the capacity to 
undergo a stable lineage switch to the endothelium, but were 
comprised of numerous hematopoietic cells that can serve 
paracrine pro-angiogenic functions to promote vascular 
repair and replacement but are incapable of integrating as a 
bona fide EC in the injured vasculature [190]. In fact, these 
pro-angiogenic cells can upregulate “endothelial cell” mark-
ers and thus give the impression they were becoming EC at 
sites of injury, but failed to persist as functional vasculature 
long term. A study by the Mayr lab later showed that these 
are in fact mononuclear cells and that the “endothelial” sur-
face markers were acquired by a process of membrane fusion 
with platelet microparticles [191]. Only endothelial colony-
forming cells (ECFC), also called late outgrowth or blood 
outgrowth EC (BOEC), are direct EC precursors that form 
vessels in vivo [190]. This paragraph will briefly discuss 
available evidence for and remaining controversies regard-
ing the evaluation of endothelial stem and progenitor cells 
in mouse and man.
12.1  Assays to identify endothelial stem 
and progenitor cells
A simple working definition of a stem cell is a clonal, self-
renewing cell, which gives rise to differentiated cell types 
[188]. A somatic stem cell may be multi-potent (giving 
rise to multiple types of differentiated cells) or unipotent 
(differentiating into a single lineage of mature cells). A 
progenitor cell displays clonal proliferative potential, but 
progenitor cells lack self-renewal potential. However, pro-
genitor cells can expand into a single lineage of differenti-
ated cells. Multiple assays have been developed to define 
stem and progenitor cells that reside in different organs and 
tissues [188]. Stem cells in any tissue must be interrogated 
for clonal self-renewal (most stringently proven by long-
term in vivo persistence with retained capacity for contribu-
tion to differentiated progeny [fate mapping approach] and/
or use of transplantation assays into primary and secondary 
recipient hosts). Progenitor cells are often measured with 
colony-forming assays in vitro (to prove a precursor product 
relationship). Stem and progenitor cells may also display 
distinguishing cell surface markers that can be used to pro-
spectively isolate the cells through the use of monoclonal 
antibodies and flow cytometry or magnetic bead separa-
tion. Most recently, stem and progenitor cells from some 
tissues have become definable by single-cell gene expression 
technologies to permit identification by a unique molecular 
signature [192, 193]. Presentation of some selected publica-
tions (as examples) identifying putative stem and progeni-
tor cells for the vascular system (using many of the above 
criteria) follows below.
Progenitor cell assays To identify the progenitor cells 
for the endothelial lineage, we need to decide what criteria 
should be used to define cells belonging to the endothelial 
lineage. Other paragraphs in this paper have made arguments 
as to the “best” assays used to define EC characteristics and 
their functions based on published evidence. Obviously, 
there are numerous phenotypic, morphological, physiologi-
cal, genomic, proteomic and functional parameters that 
constitute unique and characteristic behaviors of EC. How-
ever, one cannot identify cells of the endothelial lineage by 
expression of a few cell surface markers or of a few RNA 
transcripts. Several selected works that use comprehensive 
definitions for identifying progenitor cells for the endothelial 
lineage follow.
Patel et al. [194] recently proposed several features that 
can be used to define resident vascular endothelial progeni-
tor cells for the murine vasculature. Based upon the level of 
expression of vascular endothelial cadherin (VE-cadherin/
CD144), platelet EC adhesion molecule (PECAM-1/CD31), 
VEGFR-2, and leukocyte common antigen (CD45), ECs pre-
sent in blood vessels in induced healing wounds or growing 
in response to implanted tumors were identified as endovas-
cular progenitor cells (EVP), transit amplifying cells (TA), 
and definitive differentiated cells (D). Evidence for these 
distinct populations displaying different functional states 
was presented using clonogenic in vitro analysis, fate map-
ping studies in vivo, transplantation analysis, variations in 
gene expression, differences in phenotypic analysis (flow 
cytometry and immunofluorescence), and the requirement 
of certain transcription factors for the differentiation of EVP 
to transient amplifying and definitive differentiated states.
Evidence for the identification of human endothelial pro-
genitor cells (circulating or resident) has been published by 
several groups. Analysis of the circulating blood of patients 
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following a sex-mismatched bone marrow transplant indi-
cated that some of the BOEC were derived from the host, but 
the most proliferative cells were donor bone marrow derived 
[195]. Umbilical cord blood was reported to be enriched for 
clonogenic ECFC that displayed a hierarchy of proliferative 
potential and in vivo vessel formation compared to adult 
peripheral blood [196]. Furthermore, resident vascular EC 
derived from umbilical veins or human abdominal aorta con-
tained clonogenic ECFC with vasculogenic potential. Very 
recently, human-induced pluripotent stem cell (hiPSC)-
derived ECFC have been reported with properties that are 
similar to umbilical cord blood ECFC but with some distinct 
differences in gene expression [197].
Vascular endothelial stem cells Fang et  al. [198] 
reported that stem cells for the endothelial lineage 
can be isolated from lung blood vasculature. Vascular 
endothelial stem cells (VESC) expressing the phenotype 
 CD31+CD105+Sca-1+CD117+ (devoid of any mature line-
age markers for the hematopoietic system) can be isolated 
from collagenase-digested lung tissue. The VESC displayed 
clonogenic colony-forming activity in  vitro and when 
implanted in Matrigel subcutaneously in mice, gave rise to 
donor-derived blood vessels. Indeed, when 15 VESC (green 
fluorescent protein tagged: GFP) were implanted with B16 
tumor tissue, GFP-labeled blood vessels were identified in 
primary, secondary, tertiary, and quaternary tumor implants. 
Even a single VESC displayed the capacity to form donor 
blood vessels in vivo in a Matrigel implant. While some 
flow cytometric estimations of the frequency of the CD117 
expressing VESC in different tissues were reported, no 
detailed visualization of the location of the VESC in arter-
ies, veins, and capillaries in different tissues was presented. 
In addition, no fate mapping studies to identify the contribu-
tions of the putative VESC within various vascular beds in 
homeostatic endothelial turnover were reported.
Naito et al. [199] used the Hoechst staining method to 
identify resident vascular EC in the side population that were 
dormant in steady state, but possessed clonal colony-forming 
activity, produced large numbers of mature endothelial prog-
eny, and when transplanted into ischemic lesions, restored 
blood flow and reconstituted de novo blood vessels at the 
site of injection. Although the surface markers of the SP 
cells were similar to primary capillary EC, the gene expres-
sion pattern of the SP and main population that fail to retain 
the Hoechst dye was significantly different. Several unique 
cell surface markers were identified in the SP cells that may 
permit prospective isolation of these putative VESC. Use of 
Hoechst method fails to permit identification of the putative 
VESC in the organ and tissue vasculature during develop-
ment or after injury and will rely upon further studies using 
novel cell surface markers.
More recently, Yu et al. [200] identified protein C recep-
tor-expressing EC as VESC in the mammary fat pad, skin, 
and retina. These VESC exhibited robust clonal expansion 
in tissue culture, high vessel reconstituting ability upon mul-
tiple rounds of transplantation, and long-term clonal expan-
sion in lineage tracing experiments. Indeed, the VESC were 
determined to be bipotent, with contributions not only to the 
endothelium but also to pericytes throughout vessels in mul-
tiple tissues. The authors suggested that VESC underwent 
endothelial to mesenchymal transition to become pericytes 
in the examined vascular beds [200].
12.2  Limitations and challenges
Most of the > 9564 publications identified by the term EPC 
in Pubmed (endothelial progenitor cell, Pubmed, July 30, 
2017) have failed to provide sufficient evidence that the 
putative EPC under investigation display clonal prolifera-
tive potential and/or the capacity to directly form EC that 
undergo vasculogenesis in vivo to form new vessels or 
integrate long term into injured vessels in vivo as EC. If 
the EPC in question cannot directly give rise to cells of the 
endothelial lineage at a clonal level (in vitro or in vivo) or 
function as a bona fide EC in vivo, then the term EPC should 
not be applied to those cells [190]. The work of Patel et al. 
[201] has shown that endothelial progenitors can be identi-
fied by applying stringent criteria. However, several issues 
remain to be addressed such as the specific sites, localiza-
tions and contributions of EVP, transient amplifying and 
definitive differentiated cells localization in organs and 
tissues at homeostasis (artery, vein, or capillary bed), the 
contributions of EVP to transient amplifying and defini-
tive differentiated cells during homeostasis, differences in 
the EVP among different organs across the life span of the 
mouse, and, last but not least, determination of whether the 
EVP represents an endothelial stem cell. Human EPC have 
been identified [195–197]; however, no unique identifying 
markers have permitted prospective isolation of ECFC from 
circulating blood or blood vascular endothelium to permit 
identification of the site of origin of ECFC in human sub-
jects and determination of whether these cells display stem 
cell activity for the endothelial lineage. Several papers have 
published evidence for the presence of resident VESC in 
mice; however, the relationship between the unipotent VESC 
[198, 199] and the bipotent VESC identified by Yu and col-
leagues [200] remains unclear. Identification of unique and 
distinguishing characteristics of the VESC that discriminate 
these stem cells from progenitor and mature endothelial ele-
ments awaits further analysis. The difficulty in identifying 
proper VESC begs the question what the homeostatic func-
tion of these stem cells would be in tissues composed of 
differentiated endothelial and other vascular cells that retain 
a highly regenerative capacity.
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12.3  Concluding remarks
Altogether these data suggest that progress in identifying 
stem and progenitor cells for the vascular endothelium is 
possible when using multi-parameter evidence that the puta-
tive precursor cells are irreversibly differentiating into cells 
of the endothelial lineage. The use of multi-parameter ana-
lytics will be required to permit novel studies on the biology 
of vascular endothelial stem and progenitor cells and likely 
may alter our understanding of vascular development and 
the pathophysiology of vascular diseases.
13  Microfluidic assays
The use of microfluidic cell culture systems has changed 
the way in which we study and manipulate living cells, 
and numerous researchers have leveraged the capabilities 
of these systems to advance and refine our understanding 
of angiogenesis and microvascular function. Cutting-edge 
microfluidic cell culture models for studying angiogenesis 
have successfully incorporated principles from quantita-
tive analyses of vascular function, in vitro flow chambers, 
microfabrication techniques, and 3D tissue scaffolds. Con-
sequently, microfluidic approaches have enabled unprec-
edented levels of control of chemical gradients, fluid flow, 
matrix composition, and cell–cell interactions, all of which 
can be integrated to provide a physiologically relevant con-
text for studying angiogenesis.
13.1  Development and capabilities
Recent advances in microfabrication and biological integra-
tion have helped to propel the design and implementation of 
microfluidic systems, which comprise an emerging class of 
highly modular in vitro culture models of the microcircula-
tion [202, 203]. Microfabricated devices can provide cul-
tured cells with a microenvironment similar to that in vivo, 
including the correct ECM (ECM) composition, chemical 
species, associations with other cells, and mechanical signals 
to mimic tissue- and organ-level function [204]. Interest-
ingly, microfluidics allows generating chemical gradients 
and enables the study of EC chemotaxis in 3D geometries. 
These systems also contain networks of micron-scale fluid-
filled channels that are similar in size and architecture to 
microvessels in vivo [205, 206] to faithfully reproduce 
certain microvascular phenomena in vitro. Consequently, 
the application of microfluidics for studying angiogenesis 
has emerged as a major research thrust at the interface of 
microsystems engineering and biomedicine. At present, the 
majority of microfluidic systems are constructed by soft 
lithography or replica molding of an elastomeric and bio-
compatible polymer (polydimethylsiloxane or PDMS) [207]. 
This process is well suited to create structures with defined 
shapes on the micrometer scale that can be used to position 
cells and tissues, control cell shape and function, and create 
highly structured 3D culture microenvironments [208–210]. 
Researchers have used this capability to assess the influ-
ence of the host tissue environment and heterotypic cell–cell 
interactions on angiogenesis [211] by co-culturing vascular 
EC organized as an intact vessel structure with other cell 
types such as cancer cells [212–215], stromal fibroblasts 
[216, 217], vascular smooth muscle cells [218], and bone 
marrow cells [219]. Applications for these microfluidic co-
culture studies include fundamental studies of cell popula-
tion behaviors, high-throughput drug screening, and tissue 
engineering [211]. Application of microfluidic systems has 
also contributed significantly to our understanding of flow-
mediated angiogenesis (Fig. 10). For instance, multiple 
studies have shown that interstitial flow potently induces 
angiogenesis [220–222] and more recently lymphangiogen-
esis [223, 224]. These studies have also shown that the ves-
sel sprouts triggered by interstitial flow preferentially form 
against the direction of flow [220–223]. In other words, ves-
sel sprouts tend to originate from a local pressure minimum 
and seek the higher pressure vessel or source [221]. Interest-
ingly, this same sprouting behavior was recently observed 
in vivo in avian embryos [225]. In addition to interstitial 
flow, intravascular shear stress has been shown to control 
sprouting angiogenesis [221, 226] and anastomosis of ves-
sel sprouts [227]. Collectively, these findings suggest that 
the local fluid mechanical environment can both determine 
whether sprouting occurs and specify where these sprouts 
originate from the parent vessel. Moreover, the ability of 
microfluidic system to apply specific levels of fluid mechani-
cal stimuli in a highly controlled environment will be invalu-
able toward advancing the mechanobiology of angiogenesis 
[228].
One limitation to PDMS replica molding is that this pro-
cess produces microchannels and subsequent endothelial-
lined vessel structures with rectangular cross sections. To 
address this limitation, alternative fabrication techniques 
have been used to form engineered microvessels with circu-
lar cross sections. The most widely used technique to fabri-
cate this type of microchannel is to cast a 3D scaffold housed 
within a PDMS chamber around a cylindrical needle or rod 
of approx. 100 μm in diameter [229]. Once the scaffold has 
polymerized, the needle or rod cast is removed leaving an 
open cylindrical microchannel embedded within the 3D 
scaffold. Scaffold-embedded circular microchannels have 
been used to monitor focal leaks in the endothelial-lined 
microchannels, by adopting imaging techniques of fluores-
cent tracer dyes conjugated to macromolecules (e.g., albu-
min or high-molecular weight dextran) that are widely used 
in intravital microscopy techniques for measuring vascular 
permeability in vivo [230, 231]. In addition to quantifying 
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vascular barrier function, circular microchannels have been 
used to measure vessel sprouting and anastomosis [232].
Since the fabrication of circular microchannels employs 
a non-lithographic technique, it loses some of the desirable 
attributes achieved with soft lithography such as rapid pro-
totyping and scalability for high throughput [205]. In addi-
tion, circular microchannels require casting and removal of 
a cylindrical needle or rod inside a hydrogel; thus, they are 
constrained to simple linear structures [233]. To address 
the aforementioned limitations of the cylindrically casted 
microchannels, another circular lumen fabrication technique 
was recently developed that uses the principle of viscous fin-
ger patterning of pre-polymerized hydrogel specified inside 
PDMS microchannels of different geometries, including 
branched networks that mimic the topology of bifurcating 
microvessels [234]. Another hydrogel-embedded microflu-
idic model that is of significance uses micropatterned sten-
cils to produce microvascular network inside natural 3D 
hydrogels such as collagen and alginate [235, 236]. Finally, 
the recent advent of 3D printed microfluidic vessel networks 
[237] have enabled the patterning of more complex branch-
ing networks that mimic in vivo physiology [238].
13.2  Advantages of microfluidics for angiogenesis 
studies
The use of a chip supported by a microfluidic system for EC 
culture represents specific advantages. Compared to in vivo 
studies, these systems are relatively straightforward to apply 
controlled perturbations of extrinsic cues, such as fluid 
shear stress and biomolecular gradients. Furthermore, in 
contrast to conventional in vitro angiogenesis assays, vessel 
structures formed in microfluidic systems can be readily per-
fused to evaluate the effects of fluid flow on vessel matura-
tion. The feature of these systems enables the visualization 
and the precise quantification of vessel function (e.g., MVD 
and vascular permeability) in response to various extrinsic 
cues and allows the construction of distinct tissue compart-
ments (e.g., vascular and perivascular). Moreover, the cells 
that comprise each tissue compartment can be independently 
genetically modified to reproduce conditional knockout stud-
ies in vitro. Interestingly, the material that is typically used 
for microfluidic devices (PDMS) is fairly inexpensive and 
enables rapid prototyping and the total volume of biologi-
cal reagents (e.g., cells, ECM, and culture media) that is 
required for microfluidic experiments is very low and on 
the order of microliters. Finally, these devices can be further 
implemented with optical sensors for analytical measure-
ments. Altogether these features enable in vitro screening 
platforms for the efficacy of candidate drug compounds in a 
physiologically relevant setting [239, 240].
13.3  Limitations and challenges
Microfluidic technologies typically require specialized fabri-
cation techniques and make use of challenging complex 3D 
geometries that require multilayer construction. These tech-
nologies are beyond the research expertise of most biology 
laboratories. Moreover, despite the beneficial properties of 
PDMS (e.g., biocompatible, elastomeric, optically transpar-
ent, gas and water permeable), there are also several impor-
tant limitations such as leaking of non-crosslinked oligomers 
and non-specific absorption of hydrophobic molecules that 
can critically affect cell-signaling dynamics [241, 242].
Fig. 10  PDMS microfluidic device for analyzing angiogenesis. 
Fluid flow can be controlled connecting syringe pumps to the ports, 
or by imposing hydrostatic gradients. Flow can be directed through 
the endothelial lumens (green), or across the endothelial junctions, 
through the central matrix gel. Sprouting occurs through the apertures 
that flank the central 3D matrix and is easily visualized and quantified 
(Adapted from [221])
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13.4  Concluding remarks
Existing and emerging technologies for casting, molding, 
or 3D printing are changing the way we study cells in vitro. 
These methods bridge the gap between tissue culture dishes 
and animal models, allowing more informative and rep-
resentative co-culture systems. Future development may 
allow recapitulation of additional aspects of vascular biol-
ogy in vitro such as intussusceptive splitting or network 
remodeling.
14  Flow cytometry and cell sorting assays
Cancer cells modify the microenvironment at the primary 
site to favor tumor growth and dissemination [243, 244]. 
Similarly, tumor cells induce systemic alterations and mod-
ify the microenvironment at the (prospective) metastatic site 
to create a (pre) metastatic niche favorable for tumor cell 
seeding, survival, and growth [245]. The tumor microen-
vironment (TME) comprises many different cell types, in 
particular blood and lymphatic endothelial cells, carcinoma-
associated fibroblasts (CAF), myeloid and lymphoid inflam-
matory and immune cells [243, 244]. Tumor angiogenesis 
promotes local tumor growth and invasion by providing 
oxygen and nutrients, cytokines and growth factors (angi-
ocrine effects), as well as an escape route toward metasta-
sis [246]. In response to tumor-produced factors, recruited 
 CD11b+ myeloid cells polarize toward an alternative (M2) 
activation state, in contrast to the classical activation state 
(M1) [247, 248]. M2-polarized  CD11b+ cells promote tumor 
growth, invasion, metastasis, and angiogenesis through the 
release of growth and motility factors, including VEGFs, 
FGFs, tumor necrosis factor (TNF), platelet-derived growth 
factor (PDGF), and chemokines [247, 249, 250]. Diverse 
tumor-promoting pro-angiogenic  CD11b+ cell types 
have been reported, including VEGFR-1+CD11b+ [251], 
 Gr1+CD11b+ myeloid-derived suppressor cells (MDSC) 
[252], Tie-2-expressing  CD11b+ monocytes (TEM) [253], 
and  cKit+CD11b+ cells [254].
Traditionally, the TME is analyzed by immunohisto-
logical staining of tissue sections. While histological tech-
niques have the advantage to render tissue morphology, they 
nevertheless bear some relevant limitations: They require 
antibodies that work on fixed tissues; they can only detect 
one or a few markers simultaneously; stained cells cannot 
be recovered for further analysis; they are laborious, time-
consuming, and unpractical for large series of samples; and 
they do not allow precise quantification of the number of 
cells and signal intensity. To circumvent these limitations, 
alternative techniques were adopted [255]. Flow cytometry 
(often also referred to as FACS—fluorescence activated cell 
sorting) originally developed to analyze blood-borne cells 
[256, 257] is such a technique, now widely used to study the 
cellular composition of the TME. In addition, “true” FACS 
allows the isolation of cells for further analysis [258].
14.1  Types of assays
Analytical flow cytometry The critical step to analyze the 
cellular composition of the tumor microenvironment is to 
obtain a suspension of viable, single cells from the removed 
tumor tissue (Fig. 11). To avoid collecting cells circulating 
in the blood, mice are terminally perfused with physiological 
solution prior to tumor take. Also, care should be taken to 
remove the surrounding normal tissue from the tumor lesion. 
Harvested tumors are dissociated by collagenase and DNase 
treatment, and red blood cells are lysed with a lysis buffer. 
The cell suspension is passed through a 70-µm mesh filter 
to remove tissue debris and cell aggregates that can clog the 
FACS, followed by an incubation step with an anti-Fc recep-
tor blocking antibody to avoid non-specific binding of rele-
vant antibodies to immune cells. There are many commercial 
kits that perform well tumor dissociation and FcR blocking 
(e.g., from Miltenyi Biotec). Finally, cells are incubated with 
different antibodies for markers of cells of interest, for exam-
ple, for vascular endothelial cells  (CD45−/CD31+/GP38−), 
pericytes  (CD45−/CD146+/CD31−/CD34−), Type 2 pro-
angiogenic TAM  (CD45+/CD11b+/EGR2 high/CD38 low), 
or MDSC  (CD11b+,  Ly6C+/G+). By using GP38 staining, 
it is possible to separate vascular endothelial cells (GP38-) 
to lymphatic endothelial cells (GP38 +). A DNA dye can be 
added to exclude dead cells. Analysis of blood-circulating 
cells only requires a red blood cell lysis prior to incuba-
tion with antibodies of interest. Cells can also be stained for 
apoptosis [259], DNA content (to determine cell cycle state), 
for the expression of intracellular proteins such as kinases 
(including their phosphorylation state) [260], cytokines, and 
pro-angiogenic factors [261] by adding a permeabilization 
step during the staining procedure.
The advantages of FACS-based studies are manifold: 
They allow the analysis of multiple markers, routinely 6–10, 
and up to 12 or 16, depending on the machine, laser, and 
configurations. This permits monitoring multiple cell popu-
lations at once with limited numbers of cells (e.g.,  105–106). 
FACS experiments are easy and rapid to do and can be effec-
tively used as a screening platform to determine the effect 
of drugs on endothelial cells or on tumor-associated pro-
angiogenic cells. By using the right strategy and markers, 
one can determine the percentage of most cells of the TME. 
For example, we used FACS to characterize the effect of 
VEGFR/VEGFR-2 inhibition on angiogenesis and immune/
inflammatory cells [262, 263], to identify a novel pro-meta-
static/angiogenic  CD11b+cKit+ cell [254, 263] and to study 
the contribution of  CD11b+ cells to angiogenesis and lym-
phangiogenesis [247, 264, 265] in mice and human. Many 
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factors regulating angiogenesis, including soluble proteins 
and microvesicles, are released from the primary tumor site 
and can enter the systemic circulation. FACS can be used to 
quantify multiple circulating cytokines at once using bead 
arrays (e.g., BD™ Cytometric Bead Array) [266]. The assay 
takes advantage of the broad dynamic range of fluorescence 
detection offered by flow cytometry and the simplicity of 
antibody-coated beads resulting in the efficient detection of 
multiple cytokines at once. This assay allows analysis of 
smaller sample volumes and is faster compared to traditional 
ELISA. Cancer-released microvesicles, encompassing exo-
some, apoptotic bodies, and microparticles, are small cell 
membrane-derived vesicles expressing cellular proteins at 
their surface and containing DNA, RNA, miRNA and pro-
teins, and small molecules of the cell of origin. They have 
gained considerable attention recently as they allow to study 
tumor features through a so-called liquid biopsy approach 
[267, 268]. FACS can be used to study microvesicles to 
determine their level and the surface composition [269].
Fluorescent and Magnetic Activated Cell sorting (FACS 
and MACS) Virtually, all stainable cells can also be isolated 
by FACS, including endothelial cells, immune/inflamma-
tory cells, CAF, and tumor cells. Isolated cells can be used 
for functional experiments or lysed immediately to measure 
mRNA/DNA content by RNA/DNA sequencing or PCR or 
detect proteins by proteomics or antibody arrays, during 
natural tumor progression or in response to treatments, for 
example to identify pathways and their alteration by drugs 
[262, 264, 270]. A critical parameter for successful cell iso-
lation is the relative density of the to-be-sorted cells in the 
starting population: The lower the frequency (e.g., below 
1%) the longer the sorting time (which may affect viabil-
ity) and the lower the purity (which can pose problems for 
genetic, genomic, or proteomics studies). Microvesicles can 
also be isolated by FACS [269]. An alternative to cell isola-
tion by FACS is magnetic cell sorting (MACS). Cells are 
stained with antibodies coupled to nanosized superparamag-
netic particles and isolated positively or negatively with the 
aid of a column and a magnet [271]. This technique allows 
gentle separation of a larger number of cells. While negative 
selection can be performed with multiple antibodies (i.e., to 
eliminate many different cells), positive selection can only 
be done with one marker at a time. MACS is often used as 
a first enrichment step for rare cells of interest, followed by 
multi-parametric FACS sorting.
14.2  Limitations and challenges
Despite the power of FACS to analyze multiple cellular 
or molecular parameters in a single experiment, there are 
important limitations. A main one is the absence of mor-
phological information and position of cells. For example, 
the pericyte coverage of blood vessels and the organization 
of the vessels (size and diameter) as well as the relative 
positioning of immune/inflammatory cells to vessels or 
tumor cells cannot be obtained by FACS analysis. Having 
this information is important as, for example, some treat-
ments do not decrease the number of vessels but alter their 
structure (“vascular normalization”) or modify the localiza-
tion of immune/inflammatory cells but not their number. 
Thus, FACS studies should be supported by immunohisto-
logical analyses. A second limitation is that the technique 
is semiquantitative. Absolute cell numbers can be indirectly 
calculated though, by relating the relative frequency of the 
cell of interest obtained by flow cytometry analysis, to one 
main population in the test sample (e.g., CD45 + cells), 
whose cell number was previously counted manually. Cell 
sorting has limitation for viability and contamination. For 
example, endothelial cells obtained by FACS are difficult 
to culture and use for ex vivo/in vitro (functional) experi-
ments. As stated above, sorting of rare cells (< 1%) can be 
hampered by contaminating cells (in some cases, up to 50%). 
A pre-enrichment by MACS is highly recommended in such 
situations. As these technologies are rapidly evolving, new 
opportunities are emerging allowing circumventing some 
of these limitations or opening new opportunities. These 
include laser scanning cytometry for the multi-parametric 
study of tumor microenvironment in situ [272] and assess-
ment of cellular/subcellular elements in individual cells 
[258], the use of label-free spectral measurements to analyze 
native individual cells [273], or the detection and imaging 
of circulating cells directly in blood or lymph [274], to cite 
only a few.
14.3  Concluding remarks
Flow cytometry and FACS-based experiments and analy-
ses offer important (semi)quantitative, high content, and 
accurate information about tumor angiogenesis and associ-
ated cells of the TME and in the circulation. It is a remark-
able powerful and robust technique, which can be used as a 
screening platform to test the anti-angiogenic capability of 
molecules and drugs for anticancer treatment or to in-depth 
analysis of the composition of the TME during tumor pro-
gression or in response to therapeutic interventions. FACS 
analysis should always be complemented with immunohisto-
logical studies to characterize the morphology of the vessels 
and positioning of cells of interest, particularly when inves-
tigating anti-angiogenic effects of new molecules and drugs.
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Fig. 11  Representative flow-
chart of flow cytometry and cell 
sorting experiments. Overview 
of samples collection (tumors, 
organs bearing metastasis, 
and blood) from mice and the 
procedure to obtain a single-
cell suspension after tissue 
dissociation, erythrocytes lysis, 
and cell labeling with fluores-
cent or paramagnetic-coupled 
antibodies. Analysis of blood-
circulating cells only requires 
a red blood cell lysis prior to 
incubation with antibodies of 
interest. Intracellular antigens 
can be detected by adding a cell 
permeabilization step. Fluores-
cent labeled cells are analyzed 
by flow cytometry and sorted 
by FACS while cells labeled 
with paramagnetic-coupled 
antibodies can be sorted by 
MACS. MACS can be used to 
pre-enrich cells for subsequent 
FACS sorting. Cell populations 
of interest are identified in by 
dot plots analysis of collected 
data
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15  Loss‑of‑function approaches 
in the developing zebrafish
In recent years, the zebrafish (Danio rerio) has become a 
highly utilized vertebrate model system for studying vascu-
lar development and angiogenesis in vivo. Vascular develop-
ment in zebrafish is remarkably similar to that in mice and 
humans in terms of both anatomy and function. Zebrafish 
are genetically accessible with externally fertilized, opti-
cally clear embryos and larvae that permit high-resolution 
imaging of developing tissues. Fish also have large clutch 
sizes for experimentation, and their embryos can survive 
and continue to develop for several days without a functional 
circulation via passive diffusion of oxygen. Although the 
beneficial experimental attributes of zebrafish have made 
this an extremely appealing and approachable model system, 
like any model organism, there are limitations to the stud-
ies that can be performed and their interpretation. Here, we 
focus on loss-of-function approaches used to study vascular 
development in the zebrafish and address some of the pit-
falls in interpreting data generated using currently available 
approaches.
15.1  Morpholinos
Prior to the advent of genome-editing technologies in the 
zebrafish, other than mutations fortuitously isolated in 
forward-genetic screens, morpholinos (MOs) were the 
only available reasonably well-validated loss-of-function 
method. MOs are specially modified stable antisense oli-
gomers designed to block either gene translation or gene 
splicing when injected into embryos [275]. In the absence of 
reverse genetic tools, MO-based experiments rapidly gained 
popularity in the fish community. Although the advent of 
this technology was a huge step forward for the zebrafish 
community, over time many concerns have been raised about 
the specificity of phenotypes generated from MO injections, 
particularly the potential for off-target and/or pleiotropic 
effects from MO injection [275–278]. Indeed, while it is 
possible to show that a particular MO has the desired inhibi-
tory effect on the target gene, it is impossible to exclude 
that there are (latent) unspecific effects [279]. These con-
cerns have been greatly heightened by mounting evidence 
that MOs and genetic mutants for the same genes frequently 
do not yield comparable phenotypes [276]. In order to pro-
mote greater validity of experimental studies using MOs, 
attempts have been made to develop standards for their use. 
One recently promulgated set of “community guidelines” 
suggests the use of multiple MO targets, RNA/DNA rescue 
experiments, dose–response curves for titration of the MO, 
and, importantly, validation with a genetic mutant where 
possible [275]. It is generally accepted that proper MOs 
use requires rigorous confirmation of their specific block-
ing ability, either by assessing loss of protein production 
for translation-blocking MOs (if specific antibodies are 
available) or by assessing the generation of alternate splice 
variants by RT-PCR when using splice blocking MOs. MO-
based experiments can also be “rescued” by co-administra-
tion of mRNA or transgenes expressing a wild-type copy of 
the targeted gene. However, the best and generally accepted 
validation for any MO phenotype is confirmation of the same 
phenotype in a zebrafish genetic mutant. As discussed fur-
ther below, many mutants are now available from forward 
genetic ENU (N-ethyl-N-nitrosourea) mutagenesis screens, 
“TILLING” approaches [280], or genome-editing methods. 
CRISPR technologies have made it easy and straightforward 
for any laboratory to carry out reverse genetic mutation of 
virtually any gene of interest [278, 281–301]. In short, when 
possible, all MO experiments should be confirmed and vali-
dated with a genetic mutant before they are used extensively 
for experimental studies.
Common off-target effects noted in MOs-injected animals 
include p53-mediated cell death, defective circulation and 
“ballooning” (edema), and developmental delay/stunting 
of embryos and larvae. Altered vascular development and 
patterning should be interpreted with extreme caution in 
the presence of any of these phenotypes, as vessel growth 
and patterning in developing embryos and larvae are highly 
dependent on the integrity of adjacent tissues and of the 
animal as a whole (see below for further detailed discus-
sion). The recently published community guidelines noted 
above include recommendations on how to interpret MO 
phenotypes, how to validate these phenotypes, and current 
expectations in the field for MO usage [275].
Although MOs approaches, and especially their use with-
out proper validation, have justifiably come under a great 
deal of scrutiny (if not outright skepticism) in recent years 
due to well-documented frequent off-target effects and lack 
of correlation with mutant phenotypes, it is worth noting 
a few positive/beneficial features of MOs that make their 
continued use (with caution) worthwhile. First, translation-
blocking MOs can block both the zygotic and maternally 
supplied activity of target genes, whereas maternal-zygotic 
mutants can be difficult or impossible to obtain. Second, 
MOs can be used immediately with any zebrafish line or 
strain unlike mutants, which need to be crossed into the 
appropriate genetic backgrounds (when using combinations 
of mutants and transgenes, this can take many generations). 
Third, multiple MOs can be injected simultaneously to target 
two, three, or more members of a gene family with poten-
tially overlapping functions. Fourth, recent work has shown 
that upregulation of related compensating gene family mem-
bers can sometimes occur in genetic mutants (by mecha-
nisms that are not yet clear), while this does not appear to 
take place in MOs-injected animals [277], arguably making 
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MOs a better representation of targeted loss of gene function 
in these cases.
15.2  Genetic mutants
The ability to carry out large-scale forward-genetic phe-
notype-based ENU mutagenesis screens for developmen-
tal mutants has been one of the major strengths of the 
zebrafish. Large numbers of mutants have been isolated 
affecting almost every conceivable developmental pro-
cess, and these mutants have led to innumerable important 
new discoveries [302–309]. Forward genetics has been an 
extremely powerful approach for identifying genes neces-
sary for developmental processes, but until recently reverse 
genetic approaches for targeting specific genes of interest 
were not available in the zebrafish. “TILLING” approaches 
employing high-throughput next-generation sequencing of 
libraries of mutagenized fish have been used to screen for 
ENU-induced mutations in specific genes [310] but these 
approaches are relatively laborious and expensive, and some 
genes are not as easily mutagenized. More recently, genome-
editing technologies and particularly CRISPR/Cas9-based 
methods have made reverse genetic targeting of virtually 
any gene easy and cost-effective for most laboratories 
[281–283]. A number of resources now make identifying 
“ideal” CRISPR cut sites, primer selection, and mutation 
screening relatively simple [281, 311]. Generating specific 
alleles by homologous integration is still relatively challeng-
ing in the zebrafish, but the technology and resources to gen-
erate “knock-in” mutants using are also rapidly improving 
and are likely to soon become accessible to most zebrafish 
laboratories [283].
Although CRISPR mutants offer a simple and effective 
approach for loss-of-function analysis free of many of the 
caveats regarding off-target effects associated with MOs use, 
the resulting phenotypes must still be interpreted rigorously. 
Vascular phenotypes observed in animals that display signif-
icant cell death, defective circulation, edema, developmen-
tal delay/stunting of embryos and larvae—while they result 
from defects in the targeted gene—may represent second-
ary, indirect consequences of the genetic mutation and may 
not reflect a direct requirement for the targeted gene during 
angiogenesis. It is also worth noting that transient CRISPR 
approaches involving, for example, injection of guide RNAs 
into animals transgenically expressing Cas9 in specific tis-
sues (“CRISPRi”) are subject to the same general concerns 
regarding off-target effects of MOs, although the spectrum 
of off-target effects observed with the two approaches will 
likely be distinct. Phenotypes observed in either MO- or 
CRISPR-injected animals must be interpreted with caution 
and ideally should be verified using a stably transmitted ger-
mline genetic mutation.
The ease and efficiency with which CRISPR mutants can 
be generated also makes it possible to simultaneously induce 
and screen for mutations in multiple genes at the same time. 
This is advantageous for studying the role of gene fami-
lies in the zebrafish. Gene paralogues are more common in 
zebrafish than in mammals due to a genome duplication that 
occurred many millions of years ago during the evolution 
of teleost fish, and genetic compensation by alternate gene 
family members can lead to obscured phenotypes [277]. It 
has become more common to see reports in which double 
or even triple mutants have been generated in closely related 
gene family members [312]. As noted above, compensatory 
upregulation of related family members has been shown to 
occur in at least some genetic mutants [277], and pheno-
types comparable to those noted in MO-injected animals 
have been unmasked by generating double or triple mutants.
15.3  Assessing vascular phenotypes 
in loss‑of‑function models
Whether MOs or mutants are used, assessment of vascular 
phenotypes involves a number of specialized considerations, 
since proper vessel formation can be altered or disrupted by 
developmental delay or by changes in circulatory flow and 
local or generalized defects in non-vascular tissues. Below, 
we discuss some general considerations in assessing vascular 
phenotypes and point out some potential pitfalls in utilizing 
and interpreting zebrafish vascular data.
15.4  Where is the gene expressed?
One of the first considerations in assessing the vascular func-
tion of a particular gene, whether using MOs or mutants, 
is where it is experessed. This is generally assessed using 
whole-mount in  situ hybridization (WISH) of zebrafish 
embryos and early larvae [313], although in older ani-
mals in situ hybridization of tissue sections can be used. 
If a gene shows an exclusive vascular expression pattern 
(Fig. 12a, b), the gene may have a vascular-specific function, 
and vascular phenotypes observed likely reflect a vascular-
autonomous role for the gene. On the other hand, if the 
gene shows an exclusively non-vascular expression pattern 
(Fig. 12c, d), it is not reasonable to assume that the gene 
has a vascular-autonomous function, and any vascular phe-
notypes that are observed are likely indirect. In many cases, 
expression is observed in both vessels and in non-vascular 
tissues (Fig. 12e), and some commonsense judgment must 
be applied in assessing whether observed loss-of-function 
phenotypes make sense in terms of the expression pattern of 
the gene. If significant non-vascular expression is observed, 
additional experimental approaches will be needed to assess 
the cell autonomy of gene function, including transplantation 
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experiments or tissue-specific transgenic expression to “res-
cue” the phenotype (Fig. 12f–h).
15.5  Assessing general morphology 
and development in morphants or mutants
Apparent vascular-specific phenotypes often occur as sec-
ondary, non-specific consequences of general developmental 
delay and other localized or general changes in non-vas-
cular tissues or organs. Staging tables are available for the 
zebrafish [294], and it is important to determine whether 
MO injections or genetic mutants result in either overall 
delays to development or gross embryonic/larval patterning, 
or localized defects in the development and morphology of 
specific tissues or organs (Fig. 13a, b). For morphants, this 
should be done by comparing animals injected with specific 
MOs to siblings injected with a control MOs and uninjected 
siblings. For mutants, they should be compared to pheno-
typically wild-type siblings from the same clutch of eggs. In 
either case, if the overall development of the animal is sig-
nificantly delayed or readily apparent, gross morphological 
changes are noted compared to the control sibling animals 
and vascular phenotypes noted in these animals should be 
interpreted with caution. For example, reduced head size 
and/or extensive cell death in the central nervous system are 
common effects noted in both mutant and morphant models, 
and this secondarily results in vessel defects in the heads of 
affected animals (Fig. 13g, h). The timing and extent of trunk 
intersegmental vessel growth is frequently used as a conveni-
ent and quantitatively robust assay for assessing angiogene-
sis defects in zebrafish embryos, but delayed development or 
abnormal formation of the adjacent somites results in defects 
in vessel sprouting and growth that, again, are not directly 
linked to vascular-specific functions (Fig. 13c–f, i–j). Simi-
larly, the formation of the thoracic duct as a readout for lym-
phatic development is sensitive to developmental delay and 
general effects on morphology; hence, the absence of the 
thoracic duct in itself is insufficient to demonstrate a defect 
Fig. 12  Assessing EC autonomous gene function in zebrafish. a–e 
Whole mount in  situ hybridization of 24–48 hpf zebrafish embryos. 
a–b ve-cadherin labeling of the vasculature in the trunk (a) and 
head (b) of a zebrafish embryo showing vascular-specific labe-
ling. c–d tagln/sm22 (c) and vegfa [308] (d) showing labeling 
of non-vascular (somitic) tissues in the trunk. e cds2 [309] labe-
ling of both vascular (arrows) and non-vascular tissues. f Confo-
cal micrograph of a growing trunk intersegmental vessel in a 32 hpf 
Tg(kdrl:mRFP-F)y286  embryo (red vessels), mosaically expressing 
Tol2(fli1a:H2B-TagBFP-p2A-egfp-F) transgene (blue EC nuclei, 
green EC cytoplasm), showing blue, green, and red fluorescent chan-
nels and all three merged. g–h Higher-magnification images of GFP 
fluorescence (g) and merged GFP/BFP/RFP fluorescence (h) in a 48 
hpf  Tg(kdrl:mRFP-F)y286 transgenic animals mosaically expressing 
a Tol2(fli1a:H2B-TagBFP-p2A-egfp-F) transgene in a single EC in 
a trunk intersegmental vessel. Scale bars = 20  µm (f), 10  µm (g–h). 
Images in panels f–h are from Ref. [649]
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in lymphangiogenesis. Staging of embryos and excluding 
developmental delay are critical, as is monitoring the dis-
tance between dorsal aorta and PCV in phenotypic embryos. 
Importantly, lack of a lymphatic system as found in ccbe1 or 
vegfc mutant embryos [314–316] only leads to formation of 
edema after 120 dpf—any edema formation prior to 120dpf 
in experimental embryos is therefore very unlikely to result 
from a lymphatic defect.
15.6  Assessing circulatory flow and cardiac function
Even in animals with apparently normal overall develop-
ment, defective blood flow (due, for example, to heart-
specific defects) can affect the timing and extent of vessel 
growth. Assessing blood flow and cardiac function in the 
zebrafish is easily accomplished by direct imaging using a 
dissecting light microscope. For higher resolution, tracers 
injected into the blood stream such as quantum dots, fluo-
rescent microspheres, lectins, and varying molecular weight 
fluorescent dextrans can be used to assess blood flow rates, 
blood flow directionality, vascular leak, vessel drainage 
sites, and solute uptake [317–320]. Although zebrafish can 
survive a number of days in the absence of blood flow, ani-
mals lacking circulation do eventually become sick, edemic, 
stunted in growth, and die. If a mutant or MO experiment 
generates zebrafish with no blood flow or decreased cardiac 
output, assessment of vascular phenotypes should take place 
as early as possible during development, during a time frame 
in which the animal is as healthy as possible. Although 
embryos and early larvae can develop reasonably normal 
for one or 2 days in the absence of circulation (Fig. 13k, l), 
overall vascular development becomes increasingly affected 
as time goes by (Fig. 13k, p). As a general rule, pheno-
types in animals deficient in flow should be assessed prior 
to 6 days post-fertilization (dpf), and ideally before 3 dpf, 
particularly when flow is entirely absent. As noted for ani-
mals with general developmental delay or morphological 
defects, caution should also be taken in interpreting vascular 
phenotypes observed in animals that lack circulatory flow.
Quantitative assessment of blood flow and hemodynam-
ics can be accomplished using Particle Velocimetry (PV), 
in which tracer particles injected into the blood stream are 
tracked through different vessels [321] and flow speed is 
determined by calculating the displacement of the particles 
over time [322]. Due to depth and/or the decreased transpar-
ency at later stages, PV has mainly been used in embryos or 
early larvae, although recent advances in confocal micros-
copy, ultrasound, and tomography tools [323] and methods 
have facilitated deeper imaging in more opaque tissues.
15.7  Assessing vascular patterning
Visualization and assessment of vascular patterning in 
the zebrafish is easily accomplished using widely avail-
able transgenic fluorescent reporter lines labeling vessels. 
Numerous transgenic zebrafish lines are available with 
cytoplasmic, nuclear, or membrane-localized fluorescent 
proteins expressed specifically in cardiovascular cells and 
tissues [324–326]. These include lines marking the heart 
endocardium and myocardium, blood and lymphatic vessel 
endothelium, hematopoietic derived cells, and perivascu-
lar cells like pericytes and fluorescent granular perithelial 
cells. Long-term time-lapse imaging methods have also been 
developed that permit continuous, real-time imaging of heart 
and vascular development in these transgenic lines [327]. 
Together, the availability of fluorescent transgenic reporter 
lines and methods for high-resolution, dynamic imaging of 
these lines has revolutionized the study of cardiovascular 
development.
Alternatively, or in addition, intravascular injection of 
fluorescent tracers such as quantum dots, fluorescent micro-
spheres, or fluorescent dextrans, or non-fluorescent tracers 
such as India ink, Berlin blue, or Evans blue dyes can be 
used to visualize zebrafish blood vessels and their pattern-
ing [317, 319, 327–332]. Although the wide availability of 
vascular-specific transgenic lines has reduced the need for 
these traditional methods for examining the patterning of 
developing vessels, microangiography is still the method of 
choice for assessing vascular integrity [333], vessel lumeni-
zation, and flow (as noted above) in blood vessels, as well as 
permeability, drainage, and solute/fluid uptake in lymphatic 
vessels. The microangiographic techniques are fast, robust, 
and cost-effective methods for visualizing the vasculature 
and can be used to visualize vessels in non-transgenic ani-
mals or at more mature developmental stages.
The patterning of vessels in genetically or experimentally 
manipulated animals can be examined for alterations includ-
ing reduced/absent vessel growth, excessive vessel growth 
or branching, altered patterning of vessels, changes in flow 
patterns/vascular connections, etc. Changes can occur either 
broadly throughout the animal or may be localized to par-
ticular vascular beds. Up to approximately 7 dpf, the pattern 
of blood vessels observed should be compared to the pub-
lished staged atlas of vascular anatomy [328]. Although the 
positioning of major vessels (e.g., dorsal aorta, cardinal vein, 
and intersegmental vessels in the trunk, or basilar artery in 
the head) is relatively invariant in normal animals at given 
stages, the precise location and paths taken by many smaller 
and/or later forming vessels (e.g., the central arteries of the 
hindbrain) are less stereotypic, and minor changes in the 
patterning of these vessels may not be significant. As noted 
above, it is important to assess vessel defects in genetically 
or experimentally manipulated animals in the context of 
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the animal as a whole, including whether any developmen-
tal delay or gross morphological defects are present. The 
timing and extent of intersegmental vessel sprouting is fre-
quently used to assess angiogenic phenotypes in developing 
zebrafish, but their patterning can be strongly affected by 
developmental delay, non-vascular morphological defects, 
and reduced or absent circulatory flow (Fig. 13).
15.8  Concluding remarks
A variety of approaches for reverse genetic targeting of spe-
cific genes for loss-of-function analysis are now available 
in the zebrafish, most notably MOs and CRISPR-generated 
mutants. Although MOs have been somewhat discredited in 
recent years as a “first line” tool for assessment of loss-of-
function phenotypes, they remain valuable when rigorously 
Fig. 13  Assessing embryonic morphology and effects on vascu-
lar patterning. a–f Transmitted light (a, b), epifluorescence (c, d), 
and confocal (e, f) images of three dpf developmentally normal (a, 
c, e) or developmentally abnormal (b, d, f) embryos from the same 
Tg(fli1:egfp)y1 transgenic “wild-type” zebrafish population. The nor-
mal animal has a normal morphology (a) and normal vessel pattern-
ing (c, e), while the developmentally abnormal animal has a stunted, 
somewhat malformed trunk (B) and also displays trunk intersegmen-
tal vessel patterning defects (d, f). g, h Confocal images of the cra-
nial vasculature in 48 hpf wild-type sibling (g) and y284 mutant (h) 
Tg(kdrl:mRFP-F)y286 animals. The y284 mutants have small heads 
heads and eyes, accompanied by reduced and abnormal formation 
of cranial vessels and aortic arches (brackets). The vascular defects 
should be interpreted with caution, as they can be primary or solely 
a consequence of the smaller head (or possibly both). Transplanta-
tion and/or mosaic transgenic expression can be used to assess the 
vascular cell autonomy of phenotypes. i, j Confocal (top) and corre-
sponding transmitted light (bottom) images of 48 hpf Tg(fli1:egfp)y1 
wild-type sibling (i) and fused somites (fssy66) mutant (j) animals. 
Improper somite formation in fssy66 mutants (lack of chevron shaped 
somite segments, seen in the bright-field images) indirectly results 
in altered intersegmental vessel patterning (j, top). k–p Confocal 
images of the hindbrain vasculature (k, l) or trunk intersegmental ves-
sels (m–p) in Tg(fli1:egfp)y1 control (k) or cardiac troponin T type 2a 
(tnnt2a) (l–p) deficient animals at 1.5 (m), 2 (k, l, n), 2.5 (o), or 3.5 
(p) days post-fertilization (dpf). Control animals have normal blood 
flow, but tnnt2a-deficient animals have no heart beat and lack all 
blood flow. Although formation of the vasculature is largely normal 
for several days in the absence of blood flow (l, n, o), abnormalities in 
vessel growth and patterning begin to appear at later stages, such as 
enlargement of the dorsal intersegmental vessels at 3.5 dpf (p). This 
illustrates the need to analyze vascular phenotypes as early in devel-
opment as possible in zebrafish with absent or defective blood flow. 
All images are lateral views, rostral to the left, except panels k and l, 
which show dorsal views, rostral to the left. Images in panels i and j 
are from Ref. [306], images in panels k and l are from Ref. [650], and 
images in panels m–p are from Ref. [651]. Scale bars = 50 μm
467Angiogenesis (2018) 21:425–532 
1 3
validated by a corresponding mutant with the same pheno-
type. Furthermore, in some cases, mutants are susceptible 
to genetic compensation by upregulation of related genes, 
while morphants are not. Detailed “community guidelines” 
for the use of MOs were recently published and should be 
referred to [275].
Any researcher generating loss-of-function vascular phe-
notypes in the zebrafish (or in any other model organism, 
for that matter) needs to critically assess their data in light 
of some key questions. Where is the gene expressed? Do 
mutant or morphant phenotypes make sense when compared 
to the expression pattern of the gene? The more “vascu-
lar-specific” expression is, the more likely the associated 
vascular phenotypes are specific. Conversely, if a gene is 
ubiquitously expressed throughout the animal, the burden 
of proof is on the researcher to determine the vascular cell-
autonomous function of the gene, using transplantation, 
tissue-specific transgene “rescue” experiments, or other 
methods. Do mutants or morphants show significant devel-
opmental delay or gross morphological phenotypes, and do 
the vascular phenotypes most likely reflect developmentally 
“younger” animals or problems in non-vascular tissues? Do 
the mutants or morphants have absent or strongly reduced 
circulatory flow? Are vessel phenotypes being assessed in 
these animals at a time point prior to lack of flow caus-
ing significant general defects in development? Taking all 
of these criteria into consideration when assessing vascu-
lar phenotypes resulting from gene knockdown or genetic 
mutants is important to ensure that reliable, valid conclu-
sions are made when studying regulators of angiogenic 
development utilizing the zebrafish.
16  Chorioallantoic membrane assays
Although the chicken chorioallantoic membrane (CAM) 
assay (Fig. 14a) appears to have been first reported by Rous 
and Murphy in 1911 [334], more than a century ago, to 
study xenoplastic growth of mammalian tumors, the chick 
embryo itself has been a target of scientific study beginning 
with Aristotle. Due to the fact that fertilized chicken eggs 
are readily available and the embryos are easily visualized, 
chicken embryos became a favorite target for experimental 
biologists and, not surprisingly, the CAM assay became one 
of the classic procedures for students, being included in one 
form or another in virtually every college laboratory manual. 
Due to these advantageous properties, the CAM has been 
widely used not only for direct vascular biology studies, but 
also in bioengineering, cosmetics testing, transplant biology, 
drug and vaccines development, vaso-occlusive therapies, 
or cancer research [335–343]. There are certainly several 
hundreds of variations in the experimental protocol, all of 
them involving placing a test material on the CAM or an 
intraveneous injection. The variables, however, often largely 
unbeknownst to the user, lead to highly significant differ-
ences in results and a striking diversity in observations and 
conclusions. Several aspects of the diversity are described 
below.
16.1  In ovo CAM assays
The “standard” (i.e., “classic”) assay consists of exposing 
the CAM in the incubated egg by making a window through 
which the CAM can be accessed and placing a test graft, 
implant, or substance on, in, or through it. After resealing 
the window, periodical examination of the test area can be 
performed, ultimately measuring the result, frequently by 
harvesting the area for chemical or histological analysis.
Incubation temperature. The standard Hamburger and 
Hamilton stages of chick embryo development for stages 
14–35 were based on incubation at 39.4 °C using White 
Leghorn chickens [344]. The other stages were based on 
incubation temperature of 37.5 °C. Stage 33 (7 days) is when 
many investigators place a graft or sample on the CAM. This 
may sound trivial, but at stage 33 the CAM is slowing its 
growth. If the CAM is accessed on day 7 of an embryo incu-
bated at 37 °C (common in most laboratories), CAM cells 
are still rapidly proliferating [56]. Moreover, depending on 
the source and strain of eggs used, there may be a 12–18 h 
variation in developmental age.
Making a window. The original method used a handheld 
saw blade, which worked well but frequently led to debris 
falling on the developing CAM. Such debris can provide 
artifacts difficult to distinguish from results due to planned 
experimental protocols. Ed Zwilling (in 1952) had a Dremel 
drill sanding disk in his garage which worked well and is 
now used nearly universally, but even so, debris, often too 
fine to see, can materially influence the results [56].
Placement of test material/grafts. The CAM itself is, as 
indicated by its name, multilayered. Placing a filter or graft 
on the membrane is quite different from inserting it part way 
(preferred by many) or penetrating the CAM completely so 
that it projects through the entire membrane. Results may 
be completely different depending on the mode of insertion 
as well as on the physical forces used [345]. A second vari-
able is the choice of location on the membrane. The CAM 
at stage 30–35 is highly vascularized (hence, a good choice 
for transplants), but there are vessels of all sizes. Choosing 
a site near a large vessel sets up conditions quite different 
from choosing a less vascular site. Sprouting will depend 
on placement as well rate of dispersion of test substances 
and the elution from disks and filter membranes. The reader 
is referred to several excellent comprehensive reviews that 
describe a wide range of modifications and adaptations of 
the basic CAM assay [335, 346–351].
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Day 7 of the CAM incubation represents the proper time 
to place grafts on the CAM surface for investigation of angi-
ogenic responses. There are several reasons why this time 
for grafting is preferential: (1) Areas between big vessels are 
less vascularized and the assessment of angiogenic events is 
more objective, (2) the immune system is not yet developed, 
and (3) interaction between immature developing mesoderm 
of the CAM and a graft gives a proper microenvironment 
for the survival, development, and vessels acquisition by 
angiogenic grafts.
16.2  Ex ovo CAM assays
Once it was demonstrated that one can carry out CAM 
assays in shell-less egg cultures [352, 353], this modifica-
tion became a staple variant of the assay. Again, there have 
been numerous improvements and variants, but all involve 
transferring the egg content at an early stage (day 2–3) into 
a container, allowing the CAM to develop and then carry 
out procedures as in the standard in ovo protocol. The major 
modification from the original petri dish method is the use 
of a curved rather than flat-bottomed dish, and modifications 
have ranged from specially designed watch glass-type ves-
sels to plastic wrap loosely fastened over emptied food cans. 
Major advantages over in ovo methods are better visibility, 
potential to use transmitted light, ready application of sev-
eral test sites, time-lapse monitoring, and multiple manipu-
lations. Disadvantages include significant mortality, greater 
risk of infection, the need for more rigorous control of the 
incubation environment, and materially greater expense.
16.3  Angiogenesis platform using a cubic artificial 
eggshell with patterned blood vessels
One of the newest models using the chick embryo chorioal-
lantoic membrane as a tool for blood vessels assessment and 
dynamics was recently described by Huang et al. [354]. The 
authors provided a methodology to direct blood vessel for-
mation on the surface of a three-dimensional egg yolk using 
a cubic artificial eggshell with six functionalized mem-
branes. By using this method, blood vessel assessment of 
the CAM is improved by controlling their growth directions 
Fig. 14  Chorioallantoic membrane of the chicken embryo (CAM). a 
Bright-field image of the CAM vasculature presenting the functional 
vascular network from capillaries to big vessels imaged at embryo 
development day 10 (E10). Bar corresponds to 500  μm; b Vascular 
network of the CAM presented on the fluorescent angiography with 
FITC-dextran and an intravenous contrast agent. Bar corresponds to 
500  μm; c Scanning electron microscopic picture showing the cho-
rionic epithelium (CH) and two large vessels (VE) in the intermedi-
ate mesenchyme of a CAM at day 5 of incubation (reproduced from 
[652]); d A 12-day CAM incubated on day 8 for 4 days with bioptic 
specimen of ACN/neuroblastoma cell line tumor xenograft, showing 
numerous blood vessels around the graft (reproduced from [653]). 
Bar corresponds to 500  μm; e Immuno-histology of a glioma (U87 
tumor) implanted on the CAM with tumor cells in red (vimentin 
staining and vessels in green(SNA isolectin staining), magnification 
x4; with permission from [362], copyright (2005) National Acad-
emy of Sciences, USA; (f) a pancreatic adenocarcinoma (BxPC3) 
nodule (blue, Hoechst) inside of the CAM surrounded by blood ves-
sels (green, SNA isolectin staining). bar corresponds to 100  μm; 
with permission from [363], copyright, Elsevier (License number 
4307171269037); g MCF7-derived tumor implanted on CAM induces 
angiogenic response. Tip cell (red arrow) and incompletely attached 
pericytes (yellow arrow)
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in special microfluidic chambers with a width of 70, 250, 
and 500 μm. Since the blood vessels with blood flow in 
microchannels are still alive, several culture chambers for 
implanted cells/tissues can be fabricated in the patterned 
surface during one experiment. Because the cubic eggshell 
with patterned surfaces is transparent, reagent injection and 
screening is possible in each of the chambers separately, 
and the development and spreading of blood vessels into 
the cultured tissues in the chamber can be observed using a 
microscope [354].
16.4  Assessing vascular patterning
Visualization and assessment of vascular patterning in the 
CAM model is one of the most challenging aspects of the 
assay. Quantification of angiogenesis by appearance (number 
of vessels and their hierarchy, degree of branching, etc.), 
whether by simple inspection or quantitative image analy-
sis, is highly variable. To obtain statistically significant data 
requires multiple samples. Monitoring during the course of 
the experiment is often foiled by the spreading and hence 
moving of the test site from the observation window. Most 
importantly, many of the visible measurements cannot dis-
tinguish well between neovascularization and vasodilation or 
between inhibition and vasoconstriction. Several semiquan-
titative or quantitative imaging [355, 356] or immunohisto-
chemistry-based [357] methods for vascular and capillary 
pattering assessment have been developed. The descriptors 
include, for example, branching points/area, vessel or capil-
lary density, or mean mesh size. Apart from intravenous 
injection of fluorescent dextrans (Fig. 14b) [358, 359] or 
non-fluorescent tracers such as ink [360, 361], MRI and PET 
imaging, scanning electron microscopy (Fig. 14c), or opti-
cal Doppler tomography are now available to facilitate the 
visualization of the CAM vasculature (see a comprehensive 
review [335]). For some of these techniques, however, the 
resolution might be an important limitation and should be 
considered prior to imaging technique selection. Another 
point to take into account in imaging technique selection 
is the vascular development stage, vascular permeability, 
and lymphatic uptake. Recently, imaging was facilitated by 
the replacement of the original eggshell by an artificial one 
[354].
16.5  The experimental chicken embryo tumor 
model
Tumor cells can easily be grafted on the chicken CAM and 
develop vascularized tumor (Fig.  14d). The way tumor 
implantation is done is dependent on the tumor type that 
is studied, see Table 2. In the case of glioblastomas, when 
implanted onto the CAM [362] (Fig. 14e), a plastic ring 
is placed on the surface of the chorioallantoic membrane 
at embryo development day 10 (E10). Gentle lacerations 
of the CAM surface are carried out with scalpel blades in 
order to facilitate and promote tumor engraftment. Implan-
tation of four million tumor cells inside of the plastic ring 
in serum-free culture medium is usually used with daily 
monitoring over seven to 8 days. At E17 or E18, remove the 
plastic ring by cutting out the CAM area and proceed for 
analysis (OCT inclusion, snap-frozen, etc.). Tumors such as 
the highly angiogenic glioblastomas (U87 etc.) are growing 
very well with an angiogenic response that starts at day 3–4 
post-implantation.
In case of highly metastatic tumors such as pancreatic 
ductal adenocarcinomas (PDAC), the procedure is a lit-
tle different [363]. In this case, tumor cells are deposited 
directly inside the plastic ring without previous laceration 
of the CAM. Tumor nodules are invading deeply the CAM 
tissue and are surrounded by blood vessels [363] (Fig. 14f). 
CAM tumor samples can then be analyzed using various 
methods (qPCR, Western blot, immunolabeling, etc.).
Another variant is the CAM metastasis assay [364]. This 
assay can be used either to determine spontaneous metastasis 
of cells deposited on the CAM or to determine experimental 
metastasis after intravenous injection of tumor cells in the 
chorioallantoic vein. If the metastasis assay is not strictly 
speaking an angiogenesis assay, it allows, however, the study 
of tumor cell dissemination through the vasculature.
16.6  Functional genomics analysis using 
the chicken CAM model
Transcriptomic analysis of the CAM Transcriptomic analysis 
can be performed on the CAM tissue during development, 
after stimulation by exogenous factor or after tumor implan-
tation [362, 363]. CAM tissue can either be processed as a 
whole, or vessels can be micro-dissected and analyzed by 
qPCR, micro-array, or RNAseq. In case of tumor implanta-
tion, the signals coming from the tumor and the stroma can 
de differentiated because there is only 5% overlap. Bioin-
formatics analysis may help to identify the vascular cell sig-
nature of genes identified by determining vascular-specific 
ESTs and an angioscore [365].
Proteomic analysis of the CAM Proteomic studies can 
be done on the whole CAM tissue (snap-frozen after dis-
section) or can be carried out by in vivo biotinylation of 
the chick embryo using shell-less embryo cultures [366]. 
The experimental procedures can be divided into a number 
of independent steps: (1) embryo cultivation; (2) perfusion 
and biotinylation of chicken embryo and its extra-embry-
onic vasculature; (3) lysis of selected tissue or organs and 
purification of proteins; (4) deglycosylation of proteins; (5) 
proteolytic (trypsinization) digestion of proteins; (5) mass 
spectroscopy of peptides obtained from proteolytic digestion 
of proteins and measurement of peptide masses and their 
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relative representation within the sample; and (6) statistical 
identification of original proteins from known genetic data-
base after calculation of nucleotide sequence from acquired 
peptide masses. Also, in this case, bioinformatics analysis 
may help to identify the vascular cell signature of genes 
identified by determining vascular-specific ESTs and an 
angioscore. A detailed protocol can be found in [367].
16.7  Limitations and challenges
The CAM assay is a model of developmental angiogenesis. 
Exponential growth of new blood vessels and capillaries 
occurs between embryo development days 5 and 9. For test-
ing drugs or transplants, it should always be realized that 
effects are observed in the context of this developmental 
background. After Day 9, the CAM vasculature is fully 
established and allows investigation under conditions with-
out this background angiogenesis. By evolutionary point 
of view, chickens and humans are far from each other, but 
a paper published by the International Chicken Genome 
Sequencing Consortium [368] highlighted a high similarity 
between human and chicken genome, proving that 60% of 
chicken genes have counterparts in humans. Although this 
might be a an argument in favor of the use of the chicken 
CAM, we need to be conscious for species differences and 
consider other models to validate experimental results. It 
should also be realized that the chicken model is genetically 
further remote from the human system, which in some cases 
induces difficulties using the CAM. Although the model is 
very attractive for many researchers, the chicken embryos 
hatch around development Day 21. It is therefore recom-
mended not to exceed day 18 for experimental testing. In 
Table 2  Variety of applications 
with the CAM References
Developmental angiogenesis
Differentiation of vascular endothelium [352, 655]
Membrane proteome associated with the vasculature [366]
Gene transfer/global gene expression [654–658]
Metabolic profiling [659]
Transcriptome analysis in the “wound model” [660]
Vascular and endothelial cell targets from isolated chicken membranes [367]
Lymphangiogenesis
Prox-1 in the lymphatic endothelial cells [357, 661]
Ingrowth of lymphatics into the tumors [662]
Embryonic lymphangiogenesis [663]
Vasomodulating therapies
Radiosensitizing activity [662–666]
Microbeam radiation therapy [667]
Photodynamic therapy and diagnosis [666–676]
Tumor angiogenesis
Tumor growth in the CAM [348, 362, 363, 677, 678]
Experimental metastasis [677–682]
Interstitial  pO2 gradients in solid tumors [341, 683]
Accessing molecules activity
Growth factor (receptors) inhibitors; endothelium-targeting molecules [341, 684, 685]
Metal-based compounds [684–691]
Inflammatory and tumor cells or purified effector molecules [692]
Pro-angiogenic molecules [693]
Stem cells
Human mesenchymal stem cells [692–696]
Human skin-derived stem cells [697]
Drug delivery, nanoparticles
Drug delivery for cancer treatment [698, 699]
Visible laser irradiation + gold nanoparticles [700]
Screening of nanocarrier vehicles [701, 702]
Engineering
Tissue engineering and biomaterials [701–706]
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some countries, regulatory rules apply after development 
day 14–15, resulting in limitations of experimental testing 
for only 10–11 days. Nonetheless, there is little doubt that 
the classic CAM assay has produced a remarkable array 
of highly valuable information about neovascularization, 
inhibition of angiogenesis, normal xenograft behavior, and 
tumor growth and development. Its relative simplicity, its 
avoidance of many of the regulatory rules placed on live 
animal research, as well as its low cost have made it a rea-
sonable assay for preliminary screening. In the case of prot-
eomic analysis when using the biotinylation technique, there 
may be problems with biotin penetration since biotin may 
diffuse in the surrounding tissue in excess. This may lead 
in picking-up proteins not strictly linked to the vasculature. 
Thus, the duration of the biotinylation procedure is critical. 
Harsh conditions of protein elution, which can be a prob-
lem, which may lead to contamination of the protein pool 
by non-specific proteins. Despite the lack of its immunity, 
chick embryo CAM does not support implants from tissues 
rich in lymphocytes as colon and lymph nodes, nor implants 
derived from bone marrow. This is considered a limitation 
of the model, but also a challenge to find alternative ways to 
use such tissues in the CAM model.
16.8  The CAM as a screening platform
The CAM model has been used for various applications 
in various fields of research. Many excellent papers and 
reviews summarize these applications, showing that each 
application demands the use of specific protocols (Table 2).
16.9  Concluding remarks
Even in the last 3 years, close to a thousand publications 
have employed CAM assays. Whereas classically trained 
embryologists are well aware of the complexity of embryo-
genesis and are almost overly cognizant of the problems 
encountered when working with a rapidly changing target, 
researchers less acquainted with the vagaries associated with 
developing embryos may need to develop a grudging respect 
for the intricacies underlying the CAM assay. This being 
said, it is deservedly a most important technique, major con-
tributions have resulted from its use, and no doubt it will 
continue to be an important tool in angiogenesis research.
17  Murine allantois assay
The allantois is an extra-embryonic structure, which under-
goes vasculogenesis, vascular remodeling, and angiogenesis 
and is pivotal in establishing the chorioallantoic placenta 
and umbilical circulation. The allantois is characterized by 
a mesenchymal core and by an enveloping mesothelium and 
appears at E8.0. Vasculogenesis starts in the distal allantois 
and forms a plexus that connects with the dorsal aorta of 
the embryo (E8.25) before the chorioallantoic fusion (E8.5), 
which is instrumental in placenta formation (E9.5). This 
plexus undergoes a deep remodeling resulting in the forma-
tion of umbilical artery and vein, which invade the chorion 
by sprouting angiogenesis. These processes recapitulate 
the molecular and genetic distinct features of developing 
vasculature in embryo and in adult life, including the role 
exerted by signaling and transcriptional pathways triggered 
by established angiogenic inducers and modulators [369, 
370], such as VEGFs, PDGFs, ANGPTs, ephrins, NOTCH 
ligands, and WNTs.
Even if less known than other angiogenesis assays, the 
murine allantois explant assay represents a powerful tool to 
investigate general mechanisms of blood vessel formation, 
including the remodeling of a primitive vascular plexus, the 
angioblast differentiation, the arterial and venous fate, the 
sprouting angiogenesis, and the maturation of the capillary 
network by mural cell recruitment. In particular, this assay 
allowed reaching seminal contributions to vascular biology. 
For example, it was exploited to investigate the role of VE-
cadherin, vascular endothelial protein tyrosine phosphatase, 
and sphingosine-1-phosphate in angiogenesis [371–374].
17.1  Overview assay
The allantois is dissected from E8.5 mouse embryos using 
tungsten needles and is placed individually on collagen- or 
fibronectin-coated coverslips in eight-well culture dishes 
(BD Biocoat). Explants are cultured in 0.5 ml of culture 
medium (DMEM 4.5 g/l glucose, 10 mM l-glutamine, Pen-
Strep), containing 15% fetal calf serum for 18 h. Explants 
are then washed and fixed in 4% paraformaldehyde or 
methanol:DMSO (4:1) for 20 min at room temperature and 
processed for immunohistochemistry or TUNEL assay.
Pregnant female mice are killed on day 8 of gestation 
(approximately E7.75) or the following day (approximately 
E8.75). It is important to synchronize mice mating to dissect 
the allantois at the proper stage [375, 376]. Uteri are placed 
in Dulbecco’s A phosphate-buffered saline for isolation of 
decidua that is placed in Hepes-buffered DME medium 
with 7.5% fetal calf serum. With the aid of fine forceps and 
a scalpel, the embryo is isolated from the uterine tissues 
under a stereomicroscope. In the embryo, two structures 
can be recognized: embryonic tissues (clear and cylindrical 
shaped,) and the ectoplacental cone (reddish, cone shaped, 
and located at the end of embryonic tissue in the uterine 
mesometrial region). Allantoises are mouth-aspirated into a 
hand-pulled glass microcapillary (60–120 μm diameter). The 
ectoplacental cone/chorion should cleanly break off, leaving 
an opening to the exocoelomic cavity for the easy aspiration 
of the allantois. Immediately after inflating the exocoelom, 
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which allows better visualization of the allantois through 
the yolk sac, the tip of the microcapillary is aimed toward 
the distal tip of the allantois and, while gently aspirating, 
“sheathe” the entire length of the allantois with the tip of 
the microcapillary. While maintaining minimal aspiration, 
lift the allantois, still in the exocoelom, toward the menis-
cus. At the meniscus, gently suction the allantois into the 
microcapillary, thus leaving behind the embryo, which will 
drop to the bottom of the dish. The allantois can now be 
manipulated [375].
Three different methods can be used to maintain the allan-
tois in culture. It can be kept in suspension in rolling cultures 
allowing the development of a 3D spheroid characterized by 
a vascularize core enveloped by a mesothelial layer. Explants 
are cultured in 0.5 ml of DMEM medium containing 50% 
rat serum or 5% (“low serum”) or 50% fetal calf serum. 
To culture longer than 1 day, explants are given completely 
fresh gas-equilibrated medium at 24 h intervals [375, 376].
A second system is based on the hanging drop system. 
The allantois is suspended in 0.03 ml of DMEM supple-
mented with 10% FCS and located onto the underside of a 
lid of a plastic bacterial dish. The hanging drop cultures are 
placed into a 5%  CO2 incubator, and after 18 h, the origi-
nated 3D spheroids can be resuspended in the above medium 
containing angiogenic inducers (e.g., VEGF) and the hang-
ing drop procedure is repeated [377]. Finally, allantois can 
be easily maintained in adherent conditions (50% rat serum 
in DMEM medium) up to 72 h on glass surface or on plastic 
surface coated with fibronectin or poly-lysine and differ-
ently stimulated [370, 374, 378]. Allantois isolated at E8.0 
adheres within 12 h, and after 18–20 h of culture, the explant 
adopts a circular shape with a vascular plexus, which covers 
the central area.
17.2  Limitations and challenges
The main positive feature of this assay is that it can analyze 
vasculogenesis or angiogenesis dependent on the explant 
isolation. Actually, when the allantois is isolated early (E8.0, 
headfold stage), explants undergo vasculogenesis, and when 
isolated later (E9.5, 22–26 somites), undergo angiogenesis 
[370, 371]. Second, allantois explants can be imaged with 
the use of time-lapse microscopy to follow the sequence 
of events that occur during vessel formation in vitro [372]. 
Finally, cultured allantois explants can be immunostained for 
markers of vessel formation and can be sectioned for histo-
logical analysis. It is further evident that allantois isolated 
from genetically manipulated mouse models can be useful 
to understand the role of specific genes in vascular develop-
ment. Finally, because the allantois is implicated in placenta 
vascularization, this model can be specifically exploited to 
investigate pathogenetic mechanisms of placental diseases. 
Negative aspects of the murine allantois assay are the short 
time of culture viability (72 h) and a solid experience in 
manipulating embryo mice.
17.3  Concluding remarks
The allantois angiogenesis assay is not so popular and widely 
used in the vascular biology community but it is useful to 
discriminate if a vascular phenotype is primitive or second-
ary to other embryonic genetic defects, in particular when 
the genetic manipulation is early lethal. The robustness of 
the assay also validated by computer-assisted analysis [379] 
can be exploited in drug evaluation as recently reported 
[380]. Thus, the allantois is an important tool at infancy to 
address relevant issues of vasculogenesis and angiogenesis 
in development and disease.
18  In vivo angiogenesis plug assay
A widely used in vivo assay for the evaluation of pro- or anti-
angiogenic factors is the in vivo angiogenesis plug assay, 
which makes use of basement membrane extracts (BME) or 
Matrigel. This assay is reliable, easy to perform without the 
need for special equipment, reproducible, quantitative, and 
quick [381–383]. The assay is performed by injecting, for 
example, 0.1 ml BME/Matrigel in the subcutaneous space of 
an animal. The liquid solidifies to form a plug at body tem-
perature. Over time, blood vessels will sprout into the plug. 
With two plug sites per animal, the setup is quick and allows 
for multiple test compounds or concentrations to be tested. 
Thus, drug screening can also be evaluated for effects on the 
activity of angiogenic or anti-angiogenic factors [384–387]. 
The drug can either be placed in the plug together with the 
test factor by mixing with the Matrigel matrix or be given to 
the host animal. Cells or even exosomes can also be tested 
when mixed into the gel for their production of angiogenic 
factors. Furthermore, the assay is highly versatile. For exam-
ple, the role of certain genes can be evaluated using geneti-
cally modified mice (overexpressing or ablating a protein 
gene), or animal models of diseases, such as aged or diabetic 
animals. Also, the effect of certain drug treatments can be 
evaluated. Matrigel is a mixture of basement membrane 
components derived from an animal tumor [388, 389]. It 
contains predominantly laminin-111, collagen IV, heparan 
sulfate proteoglycans, and various growth factors. Matrigel 
is a liquid at 4 °C and gels at higher temperatures. It is used 
in various angiogenesis assays, including the tube formation, 
aortic ring, and plug assays.
18.1  The in vivo plug assay method
In this assay, the test compound and/or growth factor is 
mixed with a basement membrane extract at 4 °C, known 
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as Matrigel, and then injected, while still cold, subcuta-
neously into mice where it will gel. After approximately 
1 week, the plug is excised and assayed for angiogenesis 
by various methods, including histology, the Drabkin assay 
(hemoglobin content), immunofluorescence, quantification 
of fluorescent Dextran injected intravenously just before 
plug harvest, etc. [381, 382, 384–387]. Complete protocols 
have been published [382, 387].
The assay requires the use of BME/Matrigel without phe-
nol and with low content of growth factors. BME/Matrigel 
is thawed overnight on ice in the refrigerator, because it 
gels at a temperature above 4 °C and is not usable. BME/
Matrigel can be supplemented with an angiogenic inducer, 
and it is mandatory to mix it well (do not vortex as bubbles 
will form) with the BME/Matrigel at 4 °C without dilut-
ing the matrix as this reduces the gelling properties. The 
test mixture or the control without test materials should be 
cold when injected as it will gel quickly in the subcutaneous 
location due to the warmth of the animal. Injection is done 
with 1-inch 21–25 g needles, which are changed after 2–4 
injections as they may become dull. Mice (n = 3) are slowly 
injected with 0.1 ml into both groin areas (Fig. 15) with the 
tip of the needle as far as possible from the injection site to 
prevent leakage. A bump should appear at the site where 
the test material is released from the tip of the needle. It 
is preferable to hold the syringe in place for about 30 s to 
allow the test material to gel. The syringe is gently rotated to 
remove the needle to help further seal the injection site hole.
At the end of the experiments, mice are killed. For the 
harvest, a square segment of skin containing the plug is 
excised. Alternatively, the skin can be cut around the plug 
leaving plenty of space so as not to damage the plug. Then, 
the underside is exposed. The plug is small and yellow in 
color but it may also be pink or red depending on the degree 
of angiogenesis. The control plug depending on the assay 
method will be colorless. The plug is safely and gently 
removed with scissors, embedded in HistoGel, and fixed for 
histology, followed by sectioning and staining with Mas-
son’s trichrome. Most of the angiogenesis will be from the 
edges of the plug, and the quantitation can be based on the 
density of the vessels and/or extent of in growth toward the 
center of the plug. At least three fields per plug located at 
approximately the same distance from the edge of the plug 
are analyzed. Alternatively, Drabkin reagent can be used to 
assess to the amount of blood in the plug or fluorescein iso-
thiocyanate dextran (Mw 150,000–200,000) can be injected 
into the tail vein of the animals and extracted from the plug 
for quantitation. However, these approaches can be flawed by 
either the presence of compressed non-perfused vessels or 
by the presence of leaky blood vessel or hemorrhagic areas. 
Some researchers isolate RNA from the plugs and use qPCR 
of EC genes [390] as a quantitation assay.
18.2  Key steps in 3D imaging and analyses
Matrigel is very amiable to a variety of fluorescence labeling 
techniques and generation of 3D images, due to being opti-
cally translucent and highly permeable. Intravenous injection 
of large (200,000 Mw) fluorescein isothiocyanate (FITC)-
labeled dextran identifies functional vessels within Matrigel, 
while smaller (4400 Mw) tetramethylrhodamine (TRITC)-
labeled dextran can be used to highlight the permeability of 
these vessels. Figure 14 shows an example of differences in 
vascular permeability detected with this method. Stable vas-
cular networks with low permeability are induced by FGF-2 
(Fig. 14b), whilst highly permeable vessels are induced by 
VEGF (Fig. 14c). To achieve these images, labeled dextrans 
at 10 mg/ml each are mixed in a 1:1 ratio in 100 µl, and 
injected i.v. 15 min prior to euthanasia. Excised Matrigel 
plugs can be fixed in 4% PFA for 2 hours and then stored in 
70% ethanol. Using a scalpel, all skin or connective tissue is 
removed and then Matrigel plug slices of ~ 300–500µm are 
prepared for whole-mount imaging using confocal micros-
copy. Antibody labeling, such as VE-cadherin (clone BV13, 
eBioscience) and endomucin (clone V7C7, Santa Cruz) can 
be performed over-night using a permeabilization buffer 
containing 1 % BSA, 0.5 % Triton X-100. High resolution 
imaging is carried out using confocal microscopy, to acquire 
a series of Z stacks, which can be used to generate 3D pro-
jections using software such as Volocity. Permeability can 
be identified by the presence of extravasated TRITC-dextran, 
which is quantified and normalized against FITC-dextran 
[391].
18.3  Limitations and challenges
As the age and gender of mice can influence the results of 
this assay, it is important to standardize these parameters. 
Young C57BL/6 mice are recommended as Matrigel is 
derived from this mouse strain. Immunodeficient mice can 
also be used (when heterologous cells are mixed in the gel), 
but are more costly. It is important to note that there can 
be considerable variability in the plug responses under the 
same treatment; therefore, the use of 3–6 mice per data point 
is recommended, with two injections in each mouse. For 
pro- and anti-angiogenic agents that are tested as a local 
application in the gel, it is important to establish their resi-
dence time in the gel. Some known pro-angiogenic factors 
are known to leak out too fast to be effective.
The Matrigel should be handled according to the instruc-
tions. If the Matrigel has solidified or contains particulate 
matter after thawing, it should not be used, because this may 
interfere with the even distribution of the test material and 
can yield artefacts. When mixing the test material with the 
Matrigel, it is not recommended to vortex, as bubbles may be 
formed that will distort the gel in vivo. Letting the mixture 
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stand on ice for 10 min will reduce bubbles. Diluting the 
Matrigel matrix with too much test substance volume will 
reduce the gelling capacity and therefore the ingrowth of 
blood vessels. Purchasing Matrigel that is at least 12–14 mg/
ml will reduce this problem. A common problem may be that 
in certain cases the plug may be hard to see when harvesting. 
If this happens it may be best to take the larger area of skin 
around the injection site for histology. It should be noted that 
fixation can affect some antibody epitopes therefore, frozen 
sections may also be considered. HistoGel (Thermo Scien-
tific) is recommended for preservation of the fragile plug 
before fixation. Cracks or bubbles in the matrix may require 
selection of areas in the plug that are clear of these artifacts.
An adaptation of the assay is an easy to use kit: DIVAA, 
Directed In Vivo Angiogenesis Assay, Trevigen Inc., that 
avoids many of the injection and artifact problems [392].
Fig. 15  In vivo BME/Matrigel 
plug assay in mice. Injection 
of BME/Matrigel in the groin/
abdomen areas of a mouse. The 
left image is a plug without 
growth factors; the right image 
represents a plug with an 
angiogenic growth factor. b, c 
Confocal microscopy images 
of whole-mount Matrigel 
plugs, with labeled dextran 
tracers. Matrigel plug angio-
genesis induced by (b) FGF-2 
resulted in stable vessels, with 
co-localization of large FITC-
dextran and small TRITC-
dextran within the vessels, 
which appear as yellow (XYZ 
planes). Matrigel plug angio-
genesis induced by (c) VEGF 
resulted in highly permeable 
vessels, with most TRITC-
dextran extravasated outside the 
FITC-dextran positive vessels. 
Images were captured using a 
Carl Zeiss LSM510 META or 
LSM 780 confocal microscope. 
 Volocity® software (Perkin 
Elmer) was used to reconstruct 
3D images of the vessels from 
serial Z-sections
475Angiogenesis (2018) 21:425–532 
1 3
18.4  Concluding remarks
Among the various in vivo angiogenesis assays, the plug 
assay is the most widely used because it is the most versatile, 
least costly, and easiest to perform. Furthermore, results are 
available within a week. Care must be taken at all steps in 
the assay, including in the selection of the recipient mice, 
handling and injecting the Matrigel, harvesting the plug, and 
counting the vessels.
19  In vivo vascular network forming assay
In this assay, human endothelial cells (ECs) and mesen-
chymal cells are combined to form perfused vascular net-
works as rapidly as 4 days after subcutaneous injection into 
immune-deficient mice. Thus, this assay provides an in vivo 
system to study human blood vessel formation and func-
tion with the option to manipulate the human cells in vitro 
prior to implantation. Briefly, human ECs are suspended in a 
liquid extracellular matrix (ECM) or hydrogel with support-
ing mesenchymal cells and the mixture is then subcutane-
ously injected into immune-deficient mice (Fig. 16a). The 
selected ECM or hydrogel should be compatible with vascu-
lar morphogenesis and should ideally polymerize soon after 
injection to confine the cells. The vascular networks formed 
within the implant are lined with the human ECs and sur-
rounded on the abluminal side by human perivascular cells 
[393–396] (Fig. 16b). This assay is simple and essentially 
relies on three key components: (1) human ECs, (2) support-
ing mesenchymal cells, and (3) hydrogel. Nevertheless, the 
nature of these three elements can vary considerably, confer-
ring wide versatility to the assay. For example, the human 
ECs can be derived from progenitor cells (e.g., endothe-
lial colony-forming cells (ECFCs) isolated from umbilical 
cord blood or adult peripheral blood), from primary tissues 
(e.g., human umbilical vein ECs (HUVECs), human dermal 
microvascular ECs, or white adipose tissue-derived ECs), or 
from differentiated human embryonic or induced pluripotent 
stem cells [393, 394, 397, 398]. The supporting mesenchy-
mal cells may originate from a plethora of sources as well, 
including progenitor cells (e.g., mesenchymal progenitor or 
stem cells (MPCs, MSCs) from bone marrow, cord blood 
[394, 399], or adipose tissue [400]), and primary cells (e.g., 
saphenous vein smooth muscle cells (HSVSMC) [393] and 
human dermal fibroblasts [401]). Moreover, murine sources 
of mesenchymal cells can alternatively be used, including 
MSCs from bone marrow, white adipose tissue, skeletal 
muscle, and myocardium [402] as well as the murine embry-
onic mesenchymal precursor 10T1/2 cell line [403]. Lastly, 
this assay is compatible with a variety of ECMs and hydro-
gels that support formation of human vascular networks 
including Matrigel [393], Type I collagen [395], fibrin [395], 
PuraMatrix [395], and photo-crosslinkable methacrylated 
gelatin (GelMA) hydrogels [404]. In summary, this two-cell 
model for building human vascular networks in the mouse is 
versatile, rapid, and relatively simple to perform.
19.1  Background/history
Seminal studies by Schechner and colleagues [405, 406] set 
the stage for the assay described above. They suspended 
HUVECs in collagen/fibronectin gels wherein the HUVECs 
formed tubular structures in vitro within 20 h. They then 
placed the cell-laden gel pieces by incision into the abdom-
inal wall of severe combined immune deficiency (SCID) 
mice. Human EC-lined vessels were detected in the implants 
by 30 days, although the investigators found that HUVECs 
needed to be transduced with the anti-apoptotic gene Bcl-2 
to achieve meaningful survival. After 60 days, basement 
membrane deposition, EC-EC junctions, recruited host 
α-smooth muscle actin + mural cells, and TNF-α induced 
E-selectin and VCAM-1 were evident [406]. In summary, 
HUVECs formed well-developed, functional vessels, albeit 
slowly. The next logical step was to supply mural cells 1) 
to avoid reliance on host mural cell recruitment and 2) as 
a source of growth factors for the implanted ECs. In this 
regard, including the murine mesenchymal precursor cell 
line 10T1/2 was shown to significantly increase vessel den-
sity beginning at day 14 after implantation [407]. In sum-
mary, these early studies represented a “tissue-engineering” 
proof-of-concept that collectively demonstrated that pre-
assembled human vascular networks transplanted into mice 
were able to connect with host vessels.
19.2  Assay overview
We adapted these concepts to develop a rapid, simple, and 
non-surgical approach for the vascular network forming 
assay. Our prototypical assay consists of 2 × 106 human 
ECFCs + human bone marrow-derived MSCs combined 
at a ratio of 2:3 and suspended in 200 microliters of ice-
cold Phenol Red-free Matrigel for each implant. The cell/
Matrigel suspension is then injected subcutaneously using a 
26 gauge needle; two implants are placed on each dorsal side 
of 6–8-week-old athymic nu/nu mice. Soon after implanta-
tion, Matrigel forms a gel at 37 °C such that cells are con-
fined at the site of injection. Perfused vessels are detected 
as early as day 4, have a robust presence by day 7 (~ 100/
mm2), and are long lived [394, 396]. Inclusion of 1 µg/ml 
basic fibroblast growth factor (bFGF) in the cell/Matrigel 
suspension significantly increases the number of perfused 
vessels detected on day 4 [408]. Negative controls usually 
include injecting the ECM or hydrogel without cells or with 
ECs alone. Detailed descriptions of the methods including 
endothelial and mesenchymal cell isolation procedures are 
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provided in these publications from our laboratories [95, 
394, 408]. Also, a detailed video protocol of this assay is 
available [409].
19.3  Visualizing and quantifying vessels
At desired time points, the cell/hydrogel implants are 
removed by making a dorsal incision adjacent to the implan-
tation site to expose the subcutaneous space. The implants 
are 3–5 mm in diameter and easily distinguishable from sur-
rounding subcutaneous adipose tissue by shape, consistency, 
and pink/red (vascularized) color (Fig. 16). Digital photo-
graphs provide initial data on the macroscopical aspect of 
the implants. The excised specimens are then fixed in 10% 
neutral buffered formalin overnight, followed by paraffin 
embedding and sectioning (5–7 µm sections) for histologi-
cal analysis. Hematoxylin and eosin (H&E) staining is used 
to identify red blood cell-containing lumens; empty lumens 
Fig. 16  In vivo vascular net-
work formation assay. a Sche-
matic of the two-cell model. b 
Tail vein injection of rhoda-
mine-UEA-I and FITC-GS-B4 
labels perfused human (red) and 
murine (green) vessels on day 
7 after cell/Matrigel subcutane-
ous injection. c) Quantifica-
tion of lectin-labeled human 
and murine vessels shows that 
perfused human vessels present 
at day 5 and day 7
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can be counted separately to track non-perfused vascular 
tubes [396]. This analysis will capture human vessels as 
well as host vessels that have sprouted into the gel to form 
connections with the human vessels [410]. Typically, ves-
sels are counted in ten randomly selected areas from two 
H&E-stained sections, ~ 150 µm apart, for a total of 20 areas 
for each implant. Ideally, counters should be blinded to the 
experimental groups to reduce potential bias. Image analysis 
software such as ImageJ can also be used to facilitate the 
counting. As noted above, this assay typically produces a 
total vessel density between 50 and 150 vessels/mm2.
19.4  Distinguishing human from murine vessels
Three strategies have been used to visualize and quantify 
human versus murine blood vessels in the implant. The first 
is to use human-specific antibodies such as the monoclonal 
antihuman CD31 antibody (clone JC70A, Dako, Agilent) 
that has been shown by numerous groups to specifically label 
human vessels in histological sections. The second approach 
is to genetically label the human ECs prior to implantation 
with green fluorescent protein or an equivalent fluorescent 
marker using lentiviral or retroviral constructs. The support-
ing human mesenchymal cells can be labeled with a different 
fluorescent marker for dual in vivo tracking [394]. The third 
approach is to use plant lectins—Ulex europaeus aggluti-
nin I (UEA-I) which is specific for human endothelium and 
Griffonia simplicifolia isolectin  B4 (GS-B4), which binds to 
mouse endothelium but has no reactivity with human cells 
because humans lack the α-linked galactose residue needed 
for GS-B4 carbohydrate binding. For instance, tail vein 
injection of rhodamine-labeled UEA-I and FITC-labeled 
GS-B4 10 min before removing the implants has been shown 
to effectively label perfused blood vessels and shows the 
connections between human and mouse vessels within the 
grafts [410] (Fig. 16b). Using this lectin approach, three 
distinct patterns can be seen: UEA-I-positive human ves-
sels, GS-IB4-positive murine vessels, and UEA-I/GS-IB4-
double-positive chimeric vessels; each can be quantified and 
reported as vessels/mm2 (Fig. 16c) [410–412]. Alternatively, 
biotinylated forms of UEA-I and GS-B4 can be used to stain 
the vessels in histological sections.
19.5  Longitudinal analyses
Vascular volume within the implants can be measured lon-
gitudinally by contrast-enhanced ultrasonic imaging using 
a high-resolution system such as the Vevo 2100 (Visual-
Sonics Inc, Toronto, Canada) [396, 410]. This technique 
requires imaging before and shortly after tail vein injec-
tion of an echogenic microbubble contrast agent, preferably 
with a syringe pump to achieve consistent levels of con-
trast among the different animals. In addition, to assess cell 
retention over time, the human ECs can be genetically modi-
fied for luciferase expression (e.g., Lenti-pUbiquitin-firefly 
luciferase-GFP); this allows visualizing the location of the 
human ECs over time in individual mice [394, 411, 412]. 
This procedure simply requires an intraperitoneal injection 
of the substrate luciferin followed by live bioluminescence 
imaging 30–40 min later using a system such as the Xenogen 
IVIS 200.
19.6  Advantages
This in vivo vascular network model is ideally suited for 
studies on the cellular and molecular mechanisms of human 
vascular network formation. The assay is amendable to both 
loss-of-function and gain-of-function experiments. For 
example, specific genes of interest can be tested by carry-
ing out shRNA/siRNA knockdown or CRISPR/Cas9 gene 
editing in the ECs and/or the mesenchymal cells prior to 
implantation. Conversely, specific genes can be expressed 
using retroviral or lentiviral constructs, providing a gain-
of-function test strategy. Alternatively, the human cells can 
be treated with drugs prior to implantation, which restricts 
drug exposure to the cell of interest and avoids confound-
ing systemic effects. These types of experiments have been 
used to study human vascular tumors and vascular malfor-
mations [413–415]. Furthermore, Melero-Martin and col-
leagues showed that human ECs can be genetically engi-
neered to provide controlled release of a protein of interest 
from the newly formed human vascular networks. In their 
study, human ECFCs that were genetically engineered to 
overexpress erythropoietin (EPO) were shown to form vas-
cular networks that increased erythropoiesis and corrected 
anemia in the recipient mice [416], revealing the engineered 
network’s potential to serve as a drug delivery device. An 
additional advantage is that the human ECs and mesenchy-
mal cells, as well as host cells, can be easily retrieved from 
the implant at any desired time point and sorted into puri-
fied populations for molecular and biochemical analyses, or 
for transplant into secondary, recipient mice. Finally, it is 
worth noting that hydrogel suspensions of human ECs and 
mesenchymal cells have also been shown to form vascular 
networks in murine ischemic myocardium and ischemic hind 
limbs, providing physiological benefit to those tissues [411, 
412]. This demonstrates that the blood vessel-forming abil-
ity of the cells can be recapitulated in settings beyond the 
subcutaneous implant site.
19.7  Limitations and challenges
Implanting human vascular cells necessitates the use of 
immune-deficient recipient mice, which precludes the use 
of many available transgenic murine models. The use of 
murine cells would solve this, although obtaining robust and 
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phenotype-stable murine ECs remains a challenge. Murine 
mesenchymal cells are less problematic; murine MSCs from 
four different tissue sources have already been shown to sup-
port vessel formation in vivo [402]. Therefore, it should be 
feasible to switch to syngeneic murine cells for implanta-
tion into desired murine strains. Second, this assay is not 
well suited for high-throughput studies because of the rela-
tively large number of human cells required, the expense of 
immune-deficient mice, and the time-consuming analytical 
procedures. Alternatively, in vitro 3D microfluidic models in 
which perfusable human vascular networks form can provide 
a valuable intermediary between this in vivo assay and 2D 
cell culture models [417].
19.8  Concluding remarks
This in vivo vascular network forming assay is technically 
simple, reliable, and experimentally accessible; it provides 
a functional test for assessing the blood vessel-forming 
potential of human ECs in vivo. The assay allows wide ver-
satility in the use of cell sources. The human cells can be 
manipulated genetically and/or pharmacologically prior to 
implantation to address a variety of questions. Human (and 
murine) cells can be retrieved from the implants at desired 
time points for cellular and molecular analyses. The assay 
is also amendable to the use of human ECs from patients or 
ECs genetically engineered to express a human mutation to 
model specific vascular pathologies.
20  Developing mouse retinal vasculature—
tip cells
The developing mouse retina is an extensively used model 
to study angiogenesis. Vessels originate around birth from 
the optic nerve and grow radially to the peripheral retinal 
margin during the first postnatal week as a flat and easily 
imaged plexus. Subsequently, the superficial capillaries start 
sprouting downwards to form the deep and intermediate vas-
cular plexus. The network also undergoes some remodeling, 
and in approximately the third postnatal week, all vascular 
layers are completely mature. Several aspects of vascular 
development can be studied in this system, such as endothe-
lial tip/stalk behavior, sprout anastomosis, lumen formation, 
vessel pruning, network remodeling, formation of arteries 
and veins, and others. The model is particular useful for the 
analysis of genetically altered mice.
20.1  Visualization of cellular markers and gene 
expression
To appreciate spatial relationships and network topology, 
the retinal vasculature is best studied in retinal whole-mount 
preparations. This, however, contains some challenges. Dis-
secting the retina in one piece requires practice. Further-
more, depending on fixation conditions and antibodies used, 
immunohistochemistry can be difficult. The likely reason for 
this is the formation of diffusion barriers at the retina–vitre-
ous interface. Two fixation protocols have emerged minimiz-
ing these problems. The first approach uses fixation for just a 
few minutes in paraformaldehyde followed by a longer incu-
bation in ice-cold methanol (which can also act as storage 
medium) [418]. Alternatively, paraformaldehyde fixation is 
carried out for several hours on ice. Different antibody stains 
may behave differently depending on the fixation method 
used. Furthermore, in situ hybridization (ISH) can also be 
used on retinal wholemounts. Here, care needs to be taken 
to prevent the retina from curling up during the hybridiza-
tion step [419]. By far the most simple and robust method of 
staining the retinal vasculature is based on labeled isolectin 
B4 (IB4), which binds a carbohydrate epitope on mouse 
endothelial cells, but also on microglia and macrophages.
20.2  Analysis of tip cells
Endothelial tip cells are defined by their position at the 
tips of vascular sprouts (Fig. 17). They also have long and 
dynamic filopodia, migratory behavior, and low prolifera-
tive activity. On the other hand, stalk cells, following the tip 
cells, proliferate and form the vessel lumen. Manipulations 
that change the balance between the tip and stalk pheno-
type alter branching frequency of angiogenic sprouts. The 
basis for this concept was set by Gerhardt et al. [420], who 
used lectin labeling (Fig. 17a, b) and ISH against PDGFB 
(Fig. 17c) or VEGFR2 to identify tip cells. The Notch ligand 
DLL4 plays an important role for maintaining the tip cell 
state and is also a tip cell marker. In the search for additional 
tip cell-specific markers, whole genome genetic profiling 
strategies were used [421, 422] and many other useful mark-
ers have emerged such as CD34, apelin (APLN), angiopoi-
etin-2 (ANGPT2), chemokine receptor type 4 (CXCR4), and 
endocan (ESM1) [419–423]. ESM1 is probably the most 
specific tip cell marker in mouse retinal vasculature, labe-
ling additionally only some arterial ECs, whereas labeling 
of CXCR4 is high in tip cells, but also to a lesser extent 
present in some EC of the vessel plexus, in arterial EC and 
in perivascular cells [423].
The actin cytoskeleton provides a driving force for tip 
cell movement during angiogenesis, and labeling F-actin 
with phalloidin [420] is another way of assessing endothe-
lial tip cells, especially by highlighting and counting their 
filopodia. As an indirect method to distinguish tip cells from 
other EC phenotypes, labeling with antibodies against the 
adherens junction protein VE-cadherin, the adhesion pro-
tein PECAM1/CD31 or against proteins in the basal lam-
ina (fibronectin, collagen, laminin) is used in combination 
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with IB4, in which all ECs are labeled, but tip cell filopodia 
exclusively with IB4 [420, 424]. The use of markers of the 
basal lamina is based on the concept that formation of new 
sprouts requires degradation of extracellular matrix to allow 
migration of tip cells, thus showing reduced staining in prox-
imity of tip cells. Indeed, it was recently shown by triple 
labeling of tip cells with F-actin, cortactin, and collagen 
type IV that tip cells use so-called podosomes to degrade the 
extracellular matrix [425]. Labeling with anti-Ki67 or BrdU 
[420, 424] is used as marker of proliferation, a property that 
is greatly reduced in tip cells.
Several transgenic mouse models are also available today 
to specifically study tip cells in the mouse retina. Lifeact-
EGFP labels actin associated with cell–cell junctions, and 
apical and basal membranes, and highlights actin-based 
structures such as filopodia and stress fiber-like cytoplas-
mic bundles [426]. Also, a Cre transgenic strain was devel-
oped (Esm1-CreERT2) [423], mimicking tip cell-specific 
expression of ESM1 in the retina [421]. Combining this 
transgenic strain with the R26-mTmGT/+ Cre reporter gen-
erated, a conditional knockout strain that can be cross-bred 
with global knockout strains for tip cell genes as Cxcr4, or 
stalk cell-specific genes as Notch1, and Jag1 to study tip 
cell fate [423]. Furthermore, mosaic mutant mice can be 
generated by injecting morulas or blastocysts of mice with 
DsRed or eGFP expressing embryonic stem cells that have 
undergone gene targeting. The ability of the mutant embry-
onic stem cells to contribute to EC in the tip position is a 
direct readout of the importance of the mutated gene for EC 
tip cell function. Mosaicism can also be achieved by using 
very low amounts of tamoxifen in tamoxifen-inducible, 
endothelial specific Cre transgenic strains. Interestingly, 
even heterozygous gene deletions, with no phenotype in 
globally targeted mice, can result in a competitive disad-
vantage in a mosaic background, resulting, for example, in a 
reduced proportion of mutant EC in tip position [427, 428].
Tip cell behavior can also be studied in ex vivo and 
in vitro models, which have the advantage over in vivo 
models that they are suitable for an array of interventions 
and readouts and allow a rapid and low-cost screening of 
potential anti-angiogenic molecules. These models, such as 
retinal or dorsal aorta explants, and EC-coated beads embed-
ded in fibrin gels are well suited to study tip cells and are 
described in detail in other chapters of this article. It has 
recently also been demonstrated that tip cells can be identi-
fied in EC monolayer cultures such as primary HUVECs, 
HMVECs and in immortalized endothelial cultures by stain-
ing for CD34, an endothelial and hematopoietic stem cell 
marker, which stains the tips of vascular sprouts but also 
the luminal side of all EC in vivo [429]. In contrast, in vitro 
CD34 reliably and specifically stains endothelial cells with 
almost all characteristics of tip cells in vivo (Fig. 17d). This 
in vitro model of tip cells allows studies into the differentia-
tion and regulation of tip cells, as well as the discovery of 
novel tip cell genes [422].
20.3  Network analysis of retinal vasculature
The size and topology of the developing retinal vasculature 
can be used as a general readout to assess angiogenic pro-
cesses. The overall diameter or the plexus covered during the 
initial expansion phase of retinal vasculature development is 
widely used as an indicator of decreased or increased angio-
genesis. Moreover, branching frequency, branch length, and 
Fig. 17  Identification of tip 
cells. The tip cell is the leading 
cell of an angiogenic sprout 
with long filopodia extensions, 
followed by stalk cells that pro-
liferate and phalanx cells that 
form a matured new capillary. 
a Tip cells in the developing 
mouse retina can be identified 
by staining with isolectin B4 
(IB4). b The mouse retinal vas-
culature (IB4) follows the astro-
cytic meshwork (GFAP) when 
forming the superficial vascular 
plexus during development. c A 
combination of collagen type IV 
IHC (in pink) for general stain-
ing of blood vessels and ISH 
for PDGFB (black) for specific 
identification of tip cells in the 
developing mouse retina. d Tip 
cells in endothelial cell cultures 
are identified by CD34
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vessel diameter are strongly affected by tip/stalk imbalances 
and can easily be assessed by image analysis (e.g., using 
tools in ImageJ or Fiji) [430]. The plexus central to the 
leading front is unstable and remodeled via the pruning of 
capillaries, leading to reduced vessel density. In addition, 
capillary free spaces form in the vicinity of arteries. These 
readouts can indicate changes in vessel stability [431]. Fur-
thermore, artery–vein differentiation is particularly noticea-
ble in the developing retinal vasculature because of the radi-
ally alternating patterning of arteries and veins. Arteries are 
easily labeled with an antibody against alpha smooth mus-
cle actin, which is strongly upregulated in arterial smooth 
muscle cells. Endothelial specific arterial (e.g., ephrin B2 or 
DLL4) and venous markers (e.g., Eph B4) can also be used.
20.4  Limitations and challenges
Retinal whole-mount IHC and ISH can be tricky, and the 
accessibility of antibodies in the retina may be dependent 
on the protein or mRNA targeted. Transgenic reporter mice 
partly overcome these problems greatly reducing back-
ground and show a more equally distributed expression, but 
are not affordable for every laboratory. A further limitation 
to the use of tip cell markers is that none of the current mark-
ers exclusively labels tip cells, as they can also be expressed 
in other EC of the vascular plexus, arteries, or perivascular 
cells. Therefore, identification of tip cells relies mainly on 
their position, morphology, and their filopodial protrusions. 
To confirm the endothelial identity of tip cells, staining with 
multiple antibodies is necessary to distinguish between EC 
and perivascular cell types.
Another major limitation of the developing mouse retinal 
vasculature as a model system is that experimental manipu-
lations are challenging. Although intraocular injections are 
possible, they are prone to artefacts and requires highly 
skilled and experienced operators. Genetic models are more 
robust but usually require an inducible approach (e.g., the 
tamoxifen-inducible Cre-lox system) because the retinal vas-
culature develops postnatally and cannot be studied when 
vascular abnormalities lead to embryonic death. The associ-
ated mouse breeding can be very costly and time-consuming. 
Thus, ex vivo and in vitro assays may be in many instances 
more appropriate as they are faster, cheaper, and ethically 
more responsible. However, more complex network develop-
ment depends on in vivo approaches and can so far not be 
studied in vitro.
20.5  Concluding remarks
The developing retinal vasculature is a very well-defined 
and widely used model to assess vascular phenotypes in 
mutant mice. It has been particularly useful in the study 
of endothelial tip/stalk behavior in physiological context. 
However, inducible genetic tools are usually required and 
the associated mouse breeding makes it a resource and time-
intensive model.
21  Corneal angiogenesis assays
In the early 1970s, the Folkman’s group firstly set up an 
in vivo angiogenesis by exploiting the anatomical features 
of rabbit cornea and in particular the absence of blood vessel 
and the easy access to monitor the neovascularization by a 
slit lamp after implanting tumor cells or tissues or slow-
release pellets containing angiogenic inducers [432]. This 
strategy was further extended to rodents (mouse and rats), 
which are smaller and less expensive than rabbits and allow 
studying specific molecular correlations by taking advan-
tages of using genetic engineered mouse models [433–435]. 
Corneal assays are instrumental to characterize angiogenic 
inducers and inhibitors, interactions between different fac-
tors, and to study cellular and molecular mechanisms of 
angiogenesis [436]. Interestingly corneal assay can also be 
used to study other biological processes. For example, stud-
ies of lymphangiogenesis were made possible through the 
implantation of low-dose bFGF pellets, which allowed the 
visualization of lymphatic vessels through specific molecu-
lar markers [437].
21.1  Assay overview
The protocol is based on the creation of a small pocket in 
the cornea to introduce tissue samples, cells, or slow-release 
pellets incorporating growth factors. Surgical procedures are 
performed on anesthetized animals, in sterile conditions to 
avoid inflammatory reactions and with the help of a stere-
otaxic microscope. Generally, the resins used are etylen-
vinyl acetate (Elvax 40W, 40% by weight ethylene–vinyl 
acetate comonomer content with a “W” amide additive, 
Dupont) or a mixture of sucralfate and poly(2-hydroxyethyl 
methacrylate) (Hydron). To produce slow-release Elvax 40 
pellets, 1 g of the polymer is washed in 100 ml of absolute 
alcohol for at least 15 days and then dissolved in 10 ml of 
methylene chloride to prepare 10% casting stock solution 
(60 min in at 37 °C). Two hundred microliters of this solu-
tion is layered on a Teflon film, and the methylene chloride is 
allowed to evaporate under a laminar flow hood. The result-
ing film of polymer is cut under a stereomicroscope into 
1 × 1 × 0.5 mm pieces, which are used as implants. Ten 
implants (see above) are monitored for 14 days after implan-
tation. The casting solution is eligible for the use when the 
implants performed with a specific casting solution do not 
induce reactive inflammatory injury at microscope and his-
tological examination of the cornea. To incorporate the test 
substance, a predetermined amount of casting solution is 
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mixed with a given amount of the molecule and processed 
as above described. Alternatively, pellet is incubated with 
a solution of the testing molecule dissolved in sterile phos-
phate buffer solution for 40 min at room temperature in a 
plate rotator and then dried in a laminar airflow hood under 
sterile condition.
Elvax-40 containing testing molecules can be stored up 
to 1 month at − 80 °C. Empty pellets of Elvax-40 are used 
as negative control, while positive control contains VEGF-
A (200 ng/pellet). In the case the experiment protocols 
require the use of cells or tissues, it is used to implant 5 
μl of medium containing 2–5 × 105 cells, or a fragment of 
2–3 mg of fresh tissue.
A second resin is hydron stabilized by sucralfate. Ten 
milligrams of sucralfate is added to solutions of sterile saline 
(20–50 μl) containing the appropriate amount of testing sub-
stances (e.g., 0.05 mg VEGF-A as positive control) that are 
then speed vacuumed until the mixture is dry (30–60 min). 
To this suspension, 10 μl of 12% hydron in ethanol is added. 
This suspension is layered on a sterilized 1.5 × 1.5 cm piece 
of nylon mesh (pore size 0.4 × 0.4 mm). Both sides of the 
mesh are covered with a thin layer of hydron and allowed 
to dry in sterile conditions. Then, the fibers of the mesh are 
pulled apart under a microscope, and only uniformly sized 
pellets of 0.4 × 0.4 × 0.2 cm are selected for implantation. 
All procedures are performed under sterile conditions. Such 
pellets can be stored at − 80 °C for 1 month without loss of 
bioactivity.
Pellets are implanted in anaesthetized animals, and the 
eye is further anesthetized with few drops of local anesthetic. 
A central incision (1.5 × 3 mm in rabbit; 1.5 × 1.5 mm in 
mouse or rat) is produced into the corneal 3 mm (rabbit) or 
1–1.5 mm (mouse, rat) from the limbus, and using a von 
Graefe knife (2 × 30 mm), a micropocket is dissected to 
insert the pellet with forceps. This procedure allows the dif-
fusion of test molecule in the tissue, with the formation of 
a gradient for the ECs of limbal vessels. The distance of 
the pocket from the limbus can influence the angiogenic 
response, which depends on the features of the angiogenic 
inducer [438].
Observations of the implants are made with a slit lamp 
stereomicroscope over a set period of time on anaesthetized 
animals. Images are recorded for subsequent analysis. In 
rabbit, an angiogenic response is positive when budding 
of the vessels from the limbal plexus occurs after 3–5 days 
and capillaries progress to reach the implant in 7–10 days. 
Implants with an inflammatory reaction or that are unable 
to induce angiogenesis within 10 days are discarded. The 
angiogenic activity is evaluated on the basis of the angio-
genic score calculated by the formula vessel density/cornea 
x distance from the limbus [439, 440]. The number of posi-
tive implants over the total number is also scored.
In the mouse or in the rat, the vascular response is meas-
ured as the maximal vessel length [441, 442]. By using 
the slit lamp microscope with an ocular grid, the y-axis of 
the reticule is located along limbal vessel directly beneath 
implant. It is possible to refer the eye as a clock with inter-
vals from 1 to 12, and the measurement of the number of 
clock hours with new vessels is performed during each 
observation. Two measurements are obtained for each eye: 
the linear response representing the maximal vessel length 
(an average of the five longer vessels) extending from the 
limbus toward the implant and the circumferential response 
representing the neovascularization zone (measured in clock 
hours). The vessel area is calculated according to this for-
mula: vessel length × clock hour × 0.2π. At the end of the 
experiments, cornea is fixed and analyzed for the presence 
of inflammatory cells and to investigate the vessels features.
21.2  Limitations and challenges
Corneal assays present advantages and disadvantages in 
different species. The rabbit’s size enables an easy manipu-
lation of both whole animal and the eyes, and the inflam-
matory reactions are easily detectable as corneal opacity. 
However, the experimental cost is higher in rabbit than in 
mouse or rat. Multiple observations are easier in rabbit than 
in mouse or rat and can be done in not anaesthetized ani-
mals. Furthermore, the angiogenic response in mouse and 
rat is highly variable and a large number of animals are 
required. Thanks to its size, the rabbit eye offers a large area 
for the placement of stimuli in different forms including the 
presence of two pellets. All species can be also used to test 
the effect of local or systemic drug treatment on the local 
angiogenic response. Obviously, the systemic drug treatment 
of rabbit is more expensive than the treatment of mouse or 
rat. There are some critical steps in performing a successful 
corneal assay. The first issue is the preparation of pellets, 
which need to be uniform, without any inflammatory activ-
ity and able to ensure a good distribution of the angiogenic 
molecule. Surgical procedure is another challenge issue of 
the assay, and it is important to calibrate the appropriate 
depth of the incision to avoid the eye rupture. In mouse, 
this assay permits to induce neo-angiogenesis on different 
genetic backgrounds, which can be useful to evaluate the 
effect of a specific gene on angiogenesis.
21.3  Concluding remarks
Corneal angiogenesis assay, which requires high technical 
competences, represents a powerful tool to monitor and 
quantify in vivo neo-angiogenesis, to test specific drug treat-
ment and the effect of genetic manipulation. To possibility of 
final histological examinations allows an initial description 
of the cellular mechanisms sustaining the process.
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22  Mouse oxygen‑induced retinopathy 
model
Pathological angiogenesis plays a pivotal role in the most 
common causes of blindness including neovascular age-
related macular degeneration (AMD) [443], polypoidal 
choroidal vasculopathy (PCV) [444], or diabetic retinopathy 
and retinopathy of prematurity (ROP) [445]. Animal angio-
genesis models are an essential tool to understand pathways 
involved in physiological and pathological angiogenesis for 
basic comprehension of the biology and to determine the 
basis for in vivo anti-angiogenic drug development in trans-
lational cancer and ophthalmic research. Moreover, they are 
critical in preclinical drug testing.
The oxygen-induced retinopathy (OIR) model was origi-
nally developed to reflect the pathological stages of human 
ROP, vaso-obliteration of retinal vessels with oxygen expo-
sure (phase I), followed by vaso-proliferation (phase II). 
Oxygen exposure of neonatal dogs, cats, rats, and mice cre-
ates a relative hypoxic state in the retina with stimulation of 
growth factors resulting in eventual vaso-proliferation as is 
seen in preterm infants with ROP [446]. A major distinction 
of this model is that mice, rats, dogs, and cats are born with 
incompletely vascularized retinas, similar to humans born 
preterm allowing the study of retinal vascular development. 
Mice are the least expensive and most genetically manipula-
tive animal model and therefore the most commonly used. 
Murine retinal angiogenesis occurs postnatally in a tightly 
regulated, predictable manner similar to humans allowing 
for manipulations seen postnatally in preterm babies such 
as oxygen exposure [445].
Since the introduction of the current mouse OIR model 
in 1994, it has been extensively used in many studies of 
angiogenesis and retinopathy. A Google Scholar search with 
the keywords “oxygen-induced retinopathy mice” revealed 
approx. 45,000 publications with an increase of 9500 publi-
cations in the last year, reflecting the feasibility and practi-
cality of this in vivo model in many areas of vascular biology 
research. The major advantages lies in its reproducibility, 
affordable costs, short duration (10 days), and accessibility 
of the retinal vasculature for isolation, imaging, and inter-
ventions [447, 448]. Further, the well-established platforms 
for creating systemic or conditional transgenic strains and 
access to a wide availability of recombinant proteins and 
antibodies make it a powerful tool for basic angiogenesis 
research.
22.1  Assay overview
The current OIR model was developed by Smith et al. [446] 
and optimized by Stahl et al. in 2009 [449]. In brief, neonatal 
mice with nursing mothers are placed into 75% oxygen from 
postnatal day (P)7 until P12 and returned to room air (21% 
oxygen) from P12 to P17 (Fig. 18a). Due to the high  pO2 
levels during the first hyperoxic phase (P7–P12), retinal ves-
sels stop developing and immature capillaries in the central 
retina regress resulting in a central zone of vaso-obliteration 
(Fig. 18a, b′) [450]. Interestingly, the oxygen-induced vaso-
obliteration (VO) develops very rapidly with peak VO 48 h 
after onset of oxygen exposure [446]. The retina starts revas-
cularizing slowly under remaining oxygen exposure from 
P9 to P12 [446, 451], likely reflecting increasing oxygen 
demands of the developing retina. On return to room air at 
P12, the VO area becomes hypoxic [452] and significant 
upregulation of HIF-1-dependent, pro-angiogenic path-
ways including VEGF ensues resulting in neovasculariza-
tion (NV) with its peak at p17 [453–455] (Fig. 18a, b″). A 
comprehensive step-by-step protocol of this mouse model 
has been published [456].
The two main quantifiable components in the OIR mouse 
model are the NV (maximum at P17) and VO areas. If a 
study is designed to determine the amount of vasculature lost 
during the hyperoxic phase, the VO area can be measured at 
P12 or even as early as P8 by manually outlining the VO in 
an image software such as Adobe Photoshop (Fig. 18c). In 
most cases, NV and VO are measured at P17 when abnormal 
vessel growth is at its peak. It has to be kept in mind that 
the VO area on P17 can differ between experiments with 
same VO area at p12 depending on the extent of vascular 
repair, which can be determined by examining the differ-
ence between VO at P12 and P17. The current method to 
quantify NV is the SWIFT_NV method, which is a com-
puter-aided semiquantitative technique detecting NV tufts 
and clusters on retinal wholemounts using the free NIH soft-
ware ImageJ [449]. In brief, using different macros, retinal 
flat mounts are divided into four quadrants and background 
fluorescence is removed allowing NV structures to stand out 
clearly (Fig. 18c′, c″). This enables the user to set a fluores-
cent threshold marking NV, but not normal vessels. Arti-
facts can be manually excluded during this step. Recently, 
a novel Web-based image analysis tool (http://oirse g.org/) 
has been developed based on deep learning segmentation, 
which greatly facilitates the quantification of NV structures 
[457]. This method greatly improved efficiency, reliability, 
and objectivity compared to the prior methods such as cross-
sectional techniques and whole-mount grading systems 
based on predefined characteristics.
22.2  Limitations and challenges
Despite standardization of the OIR mouse model over the 
last 23 years, several essential factors can result in substan-
tial phenotype variability if not controlled. One of these fac-
tors is postnatal weight gain (PWG) during the OIR period. 
A study from Stahl et al. [458] revealed that pups with poor 
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postnatal weight gain (PWG) (defined as pups weighing 5 g 
or less at P17) have a significantly delayed and prolonged 
vaso-obliteration and NV compared to medium (5–7.5 g) 
and extensive (≥ 7.5 g) PWG. Therefore, the weight of each 
pup at P7 and again at P17 should be measured. Mice below 
6 g and over 7.5 g at P17 should be excluded from the analy-
sis. To avert poor PWG during OIR, several adjustments can 
be considered. We recommend avoiding large litter sizes 
Fig. 18  Mouse model of oxygen-induced retinopathy (OIR). a The 
mouse model of oxygen-induced retinopathy (OIR). Neonatal mice 
and their nursing mother are placed into 75% oxygen from P7 to P12, 
which induces loss of immature retinal vessels, leading to a central 
zone of vaso-obliteration (VO). After returning to room air at P12, 
the central avascular retina becomes hypoxic, inducing vascular 
regrowth with pathologic neovascularization (NV). At P17, the maxi-
mum severity of NV is reached. NV starts to regress shortly after P17 
and almost no VO or NV remains visible by P25. b Retinal whole 
mount stained with isolectin-B4-Alexa (red) displaying a normal 
vascular development at P17 under normoxic condition. b′ OIR P12 
retinal whole mount showing an extensive VO area without NV. b″ 
OIR P17 retinal whole mount showing a decreased VO with NV at 
its maximum. c Quantification of vaso-obliteration (VO) by manually 
outlining the avascular area with image-processing software (Photo-
shop, Adobe Systems) c′ For computer-aided NV quantification, both 
the original image and the VO image generated with Adobe Photo-
shop were imported into NIH’s free-access ImageJ software. The 
SWIFT_NV macroset isolates the red color channel, subtracts back-
ground fluorescence, and divides the VO image into four quadrants. 
c″ SWIFT_NV then allows the user to outline NV tufts but not nor-
mal vessels by setting a fluorescence threshold for each quadrant. The 
macroset then quantifies all NV pixels from all four quadrants, reports 
the result as neovascular total area, and creates an overlay of NV and 
original image
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over eight pups by removing some pups (or if pups are too 
heavy by adding pups to maintain appropriate weight gain) 
and surrogating C57BL/6 pups at P2 or P3 with S129 lactat-
ing mice due to their lower susceptibility to oxygen toxicity 
if weight gain is low. It is important to note that nursing 
mothers are no longer fertile after exposure to OIR. Under 
hyperoxia exposure and especially after transfer to normoxia, 
we found that mothers cannibalize their pups. Therefore, 
we recommend careful handling after return to normoxia as 
stress leads to less lactation and increased cannibalization.
Another important variable, which needs to be consid-
ered, is the phenotype variability between different strains 
and even within one strain due to vendor-related substrain 
differences. These differences can be easily addressed by 
using the same strain from a single vendor. To correct for 
age and genetic heterogeneity as well as environmental dif-
ferences, the use of littermate controls is strongly recom-
mended. When using transgenic mice, controls with exactly 
the same background will help to minimize strain-dependent 
phenotype variability.
Last, it has to be noted that the OIR mouse model does 
not cover all aspects of human ROP since mice are not born 
preterm even though retinal development occurs postnatally 
as it does with preterm infants. Thus, systemic factors result-
ing from preterm delivery are not taken into account, such 
as low IGF-1 seen after preterm birth in humans. Also, mice 
have no macula (the area of acute central vision) and have 
fewer cones than humans. However, vascular development 
is very similar.
22.3  Concluding remarks
The OIR mouse model is a robust, reliable, and quantifiable 
model to investigate developmental and pathological angio-
genesis when variables are carefully controlled.
23  Laser‑induced choroidal 
neovascularization mouse model
Age-related macular degeneration (AMD) is one of the 
major causes of vision impairment in the elderly [459]. 
Although AMD does not lead to complete blindness, loss 
of central vision makes it difficult for patients to recognize 
faces, drive, or read. Nonexudative or non-neovascular AMD 
includes early and intermediate forms of AMD, as well as 
geographic atrophy, in which progressive loss of retinal 
cells leads to some loss of visual function. In 10–20% of 
AMD patients, nonexudative AMD progresses to neovas-
cular AMD, which accounts for ~ 90% of AMD-associated 
vision loss with deterioration of central vision [460]. Neo-
vascular AMD is characterized by choroidal neovasculari-
zation (CNV), with blood vessels from the choriocapillaris 
penetrating through Bruch’s membrane into the normally 
avascular subretinal space [461]. However, in some patients, 
pathological angiogenesis develops from retinal vessels 
known as retinal angiomatous proliferation (RAP). In vitro 
EC culture models of CNV lack complex in vivo cellular 
interactions of photoreceptors, retinal pigment epithelium, 
pericytes, inflammatory cells, and glial cells [462]. There-
fore, reproducible animal models that mimic the pathologi-
cal angiogenesis in the retina and choroid are needed to 
study AMD [463]. No models, however, mimic the aging 
aspects of the disease, nor do non-primates have a macula.
23.1  Laser CNV model advantages and limitations
A laser-induced in vivo model of CNV, first described in 
1979, uses photocoagulation to disrupt Bruch’s membrane, 
inducing the growth of new choroidal vessels into the sub-
retinal area [464]. This model is similar to the majority of 
neovascular AMD in which pathological angiogenesis arises 
from the choroid. However, it differs from AMD as it is 
a wounding model unlike neovascular AMD that is initi-
ated with aging changes. The laser-induced CNV model 
has been used successfully to predict the clinical efficacy of 
anti-vascular endothelial growth factor (VEGF) therapy to 
suppress neovascular growth in AMD [465]. Laser-induced 
CNV has been used in mice, rats, rabbits, pigs, and non-
human primates. Non-human primates’ retinal anatomy 
(with a macula) is most similar to humans, but primates 
are costly to maintain, and rarely develop AMD and only 
do so after decades. Rodent models offer the advantages 
of lower cost but lack an anatomical macula [466]. Several 
gene-targeted mouse models, such as the very low-density 
lipoprotein receptor knockout (Vldlr −/−), superoxide dis-
mutase (SOD) knockout (Sod1 −/−), and apolipoprotein E 
(APOE) e4 transgenic mice, demonstrate some aspects of 
CNV such as spontaneous subretinal neovascular lesions 
[462]. However, these models are difficult to further manip-
ulate genetically to determine pathways involved in AMD 
progression, whereas the laser-induced CNV model can be 
used in transgenic animals to explore the molecular mecha-
nisms of CNV formation.
C57BL/6J mice are usually recommended for laser-
induced CNV experiments, because only pigmented mice 
absorb laser energy well and respond reliably to laser burns. 
Previous studies suggest that both gender and age of ani-
mals influence the outcome of laser-induced CNV [467]. 
In one study, mice of both genders more than 12 weeks old 
developed more severe CNV than mice less than 8 weeks 
old. Gender difference was only significant in 12–16-week-
old mice, but not in the younger 6–8-week-old mice [467]. 
However, Zhu et al. [468] observed larger CNV lesions in 
female mice at 5–8 weeks old. This discrepancy may be 
due to differences in analysis time points and fluorescent 
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methods between the studies. Especially noteworthy, the 
older female mice developed significantly larger CNV 
lesions than both older male and younger female mice. The 
larger area of CNV in older female mice is suggested to be 
related to their high circulating levels of estrogen, which 
increases pro-angiogenic functions of both EC and smooth 
muscle cells in vivo and promotes wound healing in both 
human and animal models. Moreover, compared with the 
younger mice, the lesion area in the older mice had increased 
variability. These studies suggest that mice of either gen-
der weighing 15–23 g at 6–8 weeks of age are optimal for 
the laser-induced CNV model for testing efficacy of drugs, 
although age- and gender-matched mice may be essential for 
specific experiments.
23.2  Assay overview
The general procedure of laser-induced CNV induction 
involves careful mouse anesthesia, mouse positioning, 
laser burn, with optional optical coherence tomography 
and fundus fluorescein angiography, eye dissection, cho-
roid staining and imaging, and CNV lesion quantification 
(Fig. 19a). Only intact eyes (Fig. 19b) without observable 
structural or morphological abnormalities are used for the 
laser-induced CNV model. Eyes with anomalous structures 
(Fig. 19c), cataract, or visible defects of the cornea or fun-
dus are excluded. Mice are anesthetized with a mixture of 
xylazine and ketamine, and pupils are dilated with topical 
drops of Cyclomydril. 2 min after pupil dilation, lubricating 
eyedrops are applied to the cornea. Four laser burns at equal 
distance from the optic nerve (which optimally is approxi-
mately twice the diameter of the optic nerve) are induced 
one by one in each eye by a green Argon laser pulse with 
a wavelength of 532 nm (Fig. 19d). The distance between 
laser burns must be at least double the diameter of the optic 
nerve to avoid fusion of lesions. Major retinal and choroi-
dal vessels should be avoided to prevent potential bleeding. 
The formation of a vaporization bubble immediately after 
laser photocoagulation indicates the success of a laser burn, 
which correlates with rupture of Bruch’s membrane. Opti-
cal coherence tomography immediately after laser photo-
coagulation may be used to confirm the success of the laser 
burn with visible rupture of Bruch’s membrane (Fig. 19e). 
After laser photocoagulation, the eyes are gently rinsed with 
sterile saline to remove the lubricating eyedrops and treated 
with an antibiotic ointment, erythromycin. Mice are then 
placed on a pre-warmed warming plate at 35 °C after the 
laser treatment until they are fully awakened. Mice with or 
without treatment can be subjected to fundus fluorescein 
angiography to evaluate the levels of vascular leakage from 
CNV lesions 6 days after laser burn (Fig. 19f, g). The in vivo 
retinal structure may also be examined by optical coherence 
tomography, if applicable, to determine the cross-sectional 
area of CNV lesions 7 days after laser burns. To measure the 
surface area of CNV lesions, the fluorescence-stained retinal 
pigment epithelium/choroid/sclera flat mounts are imaged 
(Fig. 19h, i) and quantified by researchers masked to treat-
ment. The choroidal CNV samples may also be analyzed for 
RNA or protein.
23.3  Limitations and challenges
The laser-induced CNV model in mice has been often char-
acterized as variable and inconsistent. Establishing a set of 
consistent exclusion criteria is necessary for ensuring reli-
able data analysis. In a typical study, ten mice per group 
with four lesions per eye would optimally provide 80 data 
points for each experimental condition. To account for data 
or mouse loss, including (1) cataract and corneal epithe-
lial edema before laser photocoagulation, (2) unsuccessful 
laser burn without Bruch’s membrane rupture, (3) odd lesion 
shape due to mouse movements during laser induction, (4) 
death of mice post-laser treatment, or (5) damage of the 
CNV lesions during tissue dissection and processing, more 
mice may be needed and should be considered in a power 
analysis to account for an anticipated intervention effect.
To accurately evaluate the laser-induced CNV, some 
lesions should be excluded. Severe hemorrhages will 
cause much larger CNV lesions, whereas choroidal dam-
age will yield a CNV lesion much smaller than the fellow 
CNV lesions in the same eye. First, choroidal hemorrhages 
encroaching on the lesion should be analyzed and classified 
carefully: (1) If the diameter of the bleeding area is less than 
that of the lesion, the lesion will be eligible for inclusion of 
analysis; (2) if the diameter of the bleeding area is more than 
that of the lesion but less than two times of the lesion diam-
eter, the lesion should be excluded from quantification; and 
(3) if the diameter of bleeding area is more than two times 
the lesion diameter, all lesions in the same eye should be 
excluded from analysis. Second, excessive laser burns that 
damage not only Bruch’s membrane but also the choroid and 
retinal pigment epithelium should be excluded. These exces-
sive burns can be seen clearly as a solid “hole” in the bright 
field of choroid imaging. Lesions should also be excluded 
if (1) the lesion is fused with another lesion, (2) the lesion 
is either more than five times larger than the mean of the 
lesions under the same experimental conditions, or (3) the 
lesion is the only one eligible for statistical analysis among 
all lesions in an eye. Previous studies provide the optimal 
settings and conditions to make use of the laser-induced 
CNV model for the goal of improving the consistency and 
reproducibility of experimental results for AMD and other 
pathological angiogenesis research [467].
486 Angiogenesis (2018) 21:425–532
1 3
23.4  Concluding remarks
The laser-induced choroidal neovascularization model is an 
attractive model to study AMD. The model is available in 
many species and is, despite the fact that the initiation of the 
pathology is through wounding and not because of aging, 
suitable for the development of drugs for the treatment of 
AMD.
24  Transparent window preparations 
for angiogenesis studies in mice
Our ability to observe living tissues with the microscope 
improved dramatically in the 1920s when Sandison began 
implanting transparent windows over wounds in rabbit ears. 
This allowed him to view the underlying tissue noninva-
sively and longitudinally [469, 470]. In the 1940s, Algire 
modified Sandison’s method to visualize the dorsal skin in 
mice [471]. With this powerful tool, he was able to perform 
detailed studies of angiogenesis during wound healing and 
Fig. 19  Experimental flowchart of the image-guided laser-induced 
CNV model and data collection. a Overview of the procedure for 
CNV induction involving mouse preparation and followed by experi-
mental treatment, sample preparation, and analysis. b Representative 
image of normal fundus (Green check mark). c Representative image 
of anomalous structure (white arrow) in the eye, which is not suit-
able for laser photocoagulation (Red X). d Representative image of 
normal fundus with four laser burns shown as bright white spots. e 
Representative image of a successful laser burn (white arrow) with 
3D optical coherence tomography. f, g Representative ocular fundus 
fluorescein angiography images at 5 and 10 min after the injection of 
fluorescent dye at day 6 after laser burn. h Representative images of 
flat-mounted choroid with IB4 staining at day 7 after laser photocoag-
ulation. Scale bar: 200 μm. ON: optic nerve. (i) Higher magnification 
of the laser-induced CNV lesion highlighted in panel H. Scale bar: 
50 μm. Reproduced with permission from [467]
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Table 3  Angiogenesis assays and vascular analysis
References
Development of novel imaging techniques
Direct measurement of interstitial diffusion and convection of albumin using fluorescence photobleaching [707]
Tumor induction of VEGF promoter activity in stromal cells [506]
Interstitial pH and  pO2 gradients in solid tumors in vivo [505]
In vivo measurement of gene expression, angiogenesis, and physiological function in tumors [487]
Two-photon fluorescence correlation microscopy to reveal transport in tumors [498]
Quantum dots to spectrally distinguish multiple species within the tumor milieu in vivo [490]
Three-dimensional in vivo microscopy using optical frequency domain imaging [485]
Simultaneous measurement of RBC velocity, flux, hematocrit, and shear rate in vivo [495]
In vivo validation of MRI vessel caliber index with intravital optical microscopy in a mouse brain tumor model [515]
Video-rate resonant scanning multiphoton microscopy [496]
Next-generation in vivo optical imaging with short-wave infrared quantum dots [708]
Analysis of vessel function
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment [501]
Effect of tumor–host interactions on distal angiogenesis and tumor growth [709]
Kinetics of vascular normalization in response to VEGFR2 blockade [510]
pH/pO2
Calibration and application of fluorescence ratio imaging of pH gradients [503]
Noninvasive measurement of microvascular and interstitial oxygen profiles [504]
Simultaneous in vivo high-resolution measurements of interstitial pH and  pO2 gradients [505]
Extracellular matrix and interstitial transport
Fluorescence photobleaching with spatial Fourier analysis for measurement of diffusion [502]
Dynamic imaging of collagen in tumors in vivo using second-harmonic generation [491]
In vivo imaging of ECM remodeling by tumor-associated fibroblasts [492]
Angiotensin inhibition enhances drug delivery by decompressing tumor blood vessels [500]
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy [481]
Immune cells
VEGF and bFGF regulate natural killer cell adhesion to tumor endothelium [497]
Ly6Clow monocytes drive immunosuppression and confer resistance to anti-VEGFR2 therapy [511]
Analysis of lymphatic vessel function
Conventional and high-speed intravital multiphoton laser scanning microscopy [508]
Lymphatic metastasis in the absence of functional intratumor lymphatics [710]
A genetic Xenopus laevis tadpole model to study lymphangiogenesis [711]
Investigation of the lack of angiogenesis in the formation of lymph node metastases [486]
Drug delivery, nanoparticles
Vascular normalization improves the delivery of nanomedicines in a size-dependent manner [499]
Compact high-quality CdSe-CdS core–shell nanocrystals with narrow emission linewidths and suppressed blinking [489]
Magneto-fluorescent core–shell supernanoparticles [712]
Engineered vasculature
Tissue engineering: creation of long-lasting blood vessels [407]
Paradoxical effects of PDGF-BB overexpression in EC in vivo [713]
Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis [509]
Generation of functionally competent durable engineered blood vessels from human pluripotent stem cells [398]
Mathematical analysis of angiogenesis
Scale-invariant behavior and vascular network formation in normal and tumor tissue [517]
Cancer, angiogenesis, and fractals [519]
Scaling rules for diffusive drug delivery in tumor and normal tissues [518]
Assessing therapies
Herceptin acts as an anti-angiogenic cocktail [714]
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma [478]
Vascular endothelial protein tyrosine phosphatase inhibition in tumor vasculature and metastatic progression [512]
A cerebellar window for intravital imaging of medulloblastoma in mice [479]
Tissue isolation chambers
Implantable tissue isolation chambers for analyzing tumor dynamics in vivo [493]
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tumor growth. Intravital imaging techniques have provided 
unprecedented insight into tumor vessel formation and 
function [472–474]. By implanting transparent windows in 
various anatomical locations in the mouse, it is possible to 
observe angiogenesis associated with tumor development, 
wound healing, and immune/inflammatory responses with 
high resolution, and in the native microenvironment. To 
date, transparent window preparations in mice have been 
developed to observe angiogenesis and lymphangiogenesis 
in the dorsal skin [475], brain [476, 477], cerebellum [478, 
479], liver [480, 481], lung [482], pancreas [483, 484], 
breast [485], and lymph node [486], Table 3.
24.1  Development and capabilities
Advances in intravital microscopy have come with the 
development of new window models, but also with inno-
vations in microscopy. Multiphoton laser scanning micro-
scopes provide high resolution, 3D images of vessel anat-
omy, gene expression, and network topology, even in deeper 
regions of tumors [487]. More recently, frequency domain 
optical coherence tomography (OCT) imaging has been 
applied in window chambers to improve depth penetration 
and contrast, providing unprecedented images of vascula-
ture noninvasively and longitudinally [485]. Another imag-
ing technology, short-wave infrared imaging (SWIR), has 
been adapted from the defense industry to improve imaging 
depth penetration and reduce scattering [488]. The devel-
opment of novel probes for improving contrast has also 
improved the ability to monitor angiogenesis in vivo [489, 
490]. Furthermore, advanced imaging technologies such as 
second-harmonic generation imaging allow us to see impor-
tant components of the angiogenic process such as ECM 
fibers [491]. This ability has improved our understanding 
of the involvement of matrix components in the angiogenic 
process [491–493].
Chronic window preparations allow analysis of vessel 
function, including hemodynamics [494–496], immune cell 
trafficking [497], transport of materials in the vascular and 
interstitial spaces [472, 487, 498–501], the binding kinet-
ics of drugs in vivo [502], and other microenvironmental 
parameters such as perivascular pH and  pO2 [503–505]. 
Using intravital reporters, it is possible to study spatiotem-
poral expression of genes [506], to quantify vessel struc-
ture, function, and dynamics [485, 493], and to probe the 
abnormal organization, structure, and function of angio-
genic vasculature (e.g., hyper-permeability, heterogeneous, 
and compromised blood flow) [475, 477, 487, 507, 508]. 
When combined with sophisticated imaging and analysis 
techniques, we can quantify blood velocity, hematocrit, and 
shear rate in vivo [495].
Intravital microscopy through transparent windows has 
been used to study many aspects of neovascularization and 
vessel dynamics (Fig. 20). In addition to tumor angiogenesis 
and wound healing, they have been valuable for understand-
ing the integration of engineered tissue grafts into existing 
vascular beds [398, 407]. By following various cell popula-
tions as angiogenic host vessels make new connections with 
those of the graft, it is possible to understand the cellular 
mechanism of anastomosis [509].
Intravital imaging also allows assessment of therapies that 
affect the vasculature. For example, it is possible to quantify 
the abnormalities in structure and function that are hallmarks 
of tumor angiogenesis, and then assess how these abnormali-
ties change when the vasculature is normalized with anti-
angiogenic or anti-fibrotic therapies [478, 500, 508–513]. 
Intravital optical microscopy [514] has also been useful for 
calibrating clinical imaging modalities in patients [515].
With information about the structure and dynamics of the 
angiogenic network, it is possible to analyze performance 
and efficiency of the vasculature at a deeper level. These 
analyses allow for further probing of the pathophysiology of 
Fig. 20  Tumor angiogenesis imaging. Vasculature in the brain (left) and the dorsal skin (right) visualized using IR frequencies to image deeper 
into tissue; blood flow creates the contrast, so it is noninvasive (from [485])
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tumor angiogenesis and the implications of abnormal vascu-
lature for drug and nutrient delivery [516–519].
Microfabrication technologies popularized in the past 
two decades have allowed the design and implementation 
of more sophisticated chamber designs. By creating custom-
designed window chambers from polydimethylsiloxane, a 
clear, biocompatible polymer, it is possible to control the 
interactions between host and implanted tissues and to 
improve imaging by partially constraining the growing tis-
sues [493] (Fig. 21).
24.2  Advantages of intravital microscopy/chronic 
window chambers for angiogenesis studies
Intravital microscopy in window chambers is characterized 
by the following features: (1) It allows studies in an in vivo 
Fig. 21  MMTV tumor vasculature in the cranial window pillar TIC. 
a MPLSM/SHG image of the indicated region in the bright-field 
image (b). Near the edge of the PDMS, the vasculature extends radi-
ally into the central chamber. At this time point (day 7 after implan-
tation), the vasculature is mature and has normal morphology in the 
regions far from the tumor. Four feeding arterioles (red arrowheads) 
and three venules (blue arrowheads) are indicated. These vessels have 
significant flow and have acquired smooth muscle cells in their walls 
(red, αSMA+-DsRed). Note that the arterioles generally have more 
αSMA signal than the venules, as expected. c The vasculature near 
the growing tumor has dramatically different morphology and flow, 
as observed in other animal models and human tumors. The tumor 
was not fluorescently labeled in this group, but is visible as the mass 
extending from the central tumor (T) in b (from [493])
Fig. 22  Imaging of vasculature in the cranial window preparation. 
Vascular sprouts entering a cranial window tissue isolation cham-
ber. Time sequence of new vasculature (green) migrating toward the 
top left into a cranial window TIC, past the edge of the PDMS disk 
(dashed line) (imaged using MPLSM and SHG). Alignment of col-
lagen fibers (white) is evident, and alpha-SMA+ cells can be seen 
on the PDMS surface (red). The vasculature (green, FITC-dextran) 
extends by forming perfused loops and sprouts. As the matrix remod-
els, the vessels also remodel as they advance. a: D1: day 1, D3: day 3, 
D6: day 6 post-TIC implantation. A pillar structure, which defines the 
height of the chamber, is indicated with * (from [493])
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microenvironment, while ex vivo or in vitro studies require 
more extensive validation; (2) it enables visualization and 
measurement of the dynamics of the same vessels and cells 
as the new vasculature forms and changes in response to 
various treatments (Fig. 22); (3) it permits a variety of func-
tional studies of angiogenic vessels which are being increas-
ingly recognized in the angiogenesis field; (4) it allows dis-
section of the role of various mechanical (shear stresses, 
hoop stresses, etc.) and biochemical signals known to govern 
angiogenesis, (5) it allows investigation of the role of differ-
ent organ microenvironments on vessel formation and func-
tion; and (6) a wide range or reagents are readily available 
for the murine system (Abs, genetic manipulation, etc.).
24.3  Limitations and challenges of intravital 
microscopy and window chambers
Intravital microscopy and window chambers experience some 
limits: (1) They are labor-intensive, making screening stud-
ies expensive; (2) creating the window may cause transient 
inflammation and inappropriate implantation of the window 
can induce tissue damage; the use of compromised windows 
affects angiogenesis in the windows (wound healing response); 
(3) for single-photon microscopes, depth penetration is limited 
to a few cell layers due to light scattering. Multiphoton micro-
scopes permit deeper imaging but still limited to a few hundred 
micrometers. OCT, Doppler OCT, and SWIR permit deeper 
imaging, but are more expensive; (4) commercially available 
advanced imaging techniques are very expensive and the most 
advanced imaging techniques are not widely available.
24.4  Concluding remarks
Optical microscopy provides the high-resolution imaging 
needed to distinguish cell dynamics, ECM components, and 
intracellular features. By placing transparent windows over 
various organs in animal models, we can take advantage of 
optical microscopy to follow the formation of new vasculature 
noninvasively for time periods of weeks or months. This ena-
bles studies of neovascularization in normal processes such as 
wound healing and diseases such as cancer and allows detailed 
analyses of responses to drugs that target blood vessels.
25  The RIP1‑Tag2 transgenic mouse model
The RIP1-Tag2 mouse model was one of the earliest onco-
genic mouse models used in pioneering studies by Hanahan 
and Folkman to identify and characterize the angiogenic 
switch and multi-step progression to pancreatic neuroendo-
crine tumors. Due to its high vascularity, and synchronous 
and rapid tumor development, it became a valuable preclini-
cal tool for developing and evaluating response and relapse 
from anti-angiogenic therapy from its earliest stages to the 
current day. Studies in the RIP1-Tag2 model predicted effi-
cacy and helped to motivate clinical trials that led to the 
approval of two compounds, everolimus and sunitinib, for 
human pancreatic neuroendocrine tumors (PNET) in 2011.
25.1  The angiogenic switch
The RIP1-Tag2 mouse was developed by Douglas Hanahan 
as a result of his interest in using newly developed transgenic 
technology to use a well-characterized rat insulin promotor 
to express a viral oncogene, SV40 T antigen, in the beta 
cells of the pancreatic islets of Langerhans in order to study 
oncogenic transformation of normal tissues [520]. The first 
transgenic mice died at an early age from hypoglycemia, 
consequent to the rapid proliferation of beta-islet cells, 
which produced high insulin levels. Tumors from viable 
mice were characteristically bright red and highly vascular-
ized, and it was immediately proposed that this was likely 
the result of what was later called the “angiogenic switch,” 
which Judah Folkman had postulated, must occur for tumors 
to grow beyond a small size [521]. But when and how is 
this switch activated? Co-culture of the total islet population 
with EC in a collagen matrix resulted in proliferation and 
migration of EC toward only a small subset of “angiogenic” 
islets to form capillary tubes, elegantly confirming that the 
angiogenic switch occurred in hyperplastic islets prior to 
tumor formation [522]. This also implies that a soluble fac-
tor [521], later identified as VEGF through multiple lines 
of evidence, was critical. In normal adult mammals, the 
vasculature is quiescent, and new blood vessels are formed 
through angiogenesis, wherein new capillaries sprout from 
existing vessels in a process largely driven through VEGF 
signaling. Hanahan and Folkman proposed that this angio-
genic switch is a discrete early step in tumorigenesis and 
that the stages of progression that characterize RIP1-Tag2 
tumorigenesis, where progressively smaller subsets of quies-
cent islets sequentially become hyperplastic, angiogenic, and 
finally progress to invasive carcinomas (Fig. 23a), also exist 
in human tumors [523]. In contrast to the popular hypoth-
esis at that time that the angiogenic switch is induced by 
upregulation of pro-angiogenic factors, RT-PCR analysis 
of all VEGF ligands and their receptors, flt-1 and flt-2, as 
well as acidic fibroblast growth factor (FGF1) indicated that 
their expression levels were similar in islets before and after 
the angiogenic switch [524, 525]. The fact that normal non-
transgenic islets already contained high levels of various 
pro-angiogenic factors suggested another mechanism in the 
activation of angiogenesis. Indeed, the switch from vascular 
quiescence to an angiogenic state involved the matrix met-
alloproteinase MMP-9, which was secreted by infiltrating 
myeloid cells. MMP-9 rendered ECM-sequestered VEGF 
bioavailable to its receptor, thus triggering an angiogenic 
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switch; this identification was confirmed using co-culture 
studies of angiogenic islets derived from MMP-9 KO RIP1-
Tag2 mice and EC in collagen matrices—in contrast to wild-
type islets, the MMP-9 KO islets did not induce EC capillary 
formation [526]. The result that VEGF-A is a pivotal factor 
in the angiogenic switch was further confirmed with an islet 
beta cell-specific knockout of VEGF-A in RIP1-Tag2 mice, 
which impaired both angiogenic switching and subsequent 
tumor growth [525].
25.2  Preclinical and clinical studies
These and many other concurrent studies identifying the 
VEGF/VEGFR2 axis as a powerful therapeutic target led to 
the development of numerous anti-angiogenic compounds. 
Sarah Parangi and colleagues were the first who used the 
RIP1-Tag2 model to perform preclinical studies with a 
combination of three early compounds with anti-angio-
genic activity—AGM-1470, the antibiotic minocycline, 
Fig. 23  RIP1-Tag2 mouse model. a Multi-step progression to tumors 
in RIP-Tag2. Although oncogene expression begins during embry-
onic development (E8.5), the pancreatic islets initially have a normal 
anatomical and histological appearance (“normal” stage). Begin-
ning at 4–5  weeks of age, hyperplastic and dysplastic islets begin 
to appear to comprise about 50% of islets by 10 weeks. Angiogenic 
islets appear beginning around 6  weeks of age, and represent 10% 
of all islets at 10.5 weeks. Angiogenic islets are recognized by their 
dilated blood vessels and microhemorrhages. Tumors form begin-
ning at 9–10 weeks and represent 2–4% of all the islets by 14 weeks. 
About half of the tumors at end stage evidence either focal or wide-
spread invasion to the surrounding acinar tissue. RIP-Tag2 mice die 
at approximately 14 weeks of age primarily due to hyperinsulinemia. 
b Anti-angiogenic Therapy Response and Relapse. Tumors treated 
with anti-angiogenic therapy using an RTK inhibitor starting at 
12–15  weeks “Response,” or 12–20  weeks “Relapse,” when vessels 
have significantly rebounded. Tumors are stained with anti-insulin in 
blue, vessels are stained with anti-CD31 in red, and surrounding exo-
crine pancreas is stained with amylase in green
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and interferon alpha/beta [527]. The combination can reduce 
tumor growth, but not prevent it, and was an early preclini-
cal success for anti-angiogenic therapy that helped to propel 
this class of inhibitors into the clinic [527]. The rapid and 
synchronous multi-step tumor progression that character-
ized the RIP1-Tag2 model made it then ideal for designing 
three different trial formats (Fig. 23a): early treatment at 
the hyperplastic stage to block the angiogenic switch com-
mencing prior to tumor formation (prevention trial), treat-
ment of mice bearing small tumors to determine whether 
tumor growth and progression can be stopped (intervention 
trial), and treatment of mice with substantial tumor bur-
den and near death to test whether drugs can induce tumor 
regression and promote survival benefits (regression trial). 
These trials were first tested with AGM-1470, batimastat 
(BB-94), Fc-endostatin, Fc-angiostatin, or a combination 
of the latter two compounds and produced distinct efficacy 
profiles in the various trial formats [528]. These studies sug-
gested that those anti-angiogenic compounds needed to be 
fine-tuned to target specific stages of disease progression 
and that combinatorial strategies can broaden the effects 
and enhance survival. Subsequent studies illustrating the 
importance of targeted therapies that disrupt both tumor EC 
and pericytes brought this notion to fruition in combination 
therapy trials with two different Sugen inhibitors, SU5416 
and SU6668, that target VEGFR2 and PDGFR, respec-
tively [529]. While the VEGFR inhibitor SU5416 was most 
potently effective against early-stage disease, SU6668 was 
shown to block further growth of end-stage tumors suggest-
ing that PDGFR+pericytes in tumors present a complimen-
tary target to EC for efficacious anti-angiogenic therapy. 
Combination therapies of these compounds were more 
efficacious against all stages of islet carcinogenesis than 
either single agent [529]. Congruently, subsequent studies 
with sunitinib (SU11248), which targets both VEGFR2 and 
PDGFR, showed remarkable efficacy in preclinical studies 
in RIP1-Tag2 mice and produced increased survival relative 
to monotherapy targeting VEGFR2 [530]. Collectively, these 
studies were used to incentivize the use of sunitinib in clini-
cal trials for PNET. These clinical trials produced an impres-
sive extension in progression-free survival that leads to the 
approval of sunitinib in 2011 [531], along with everolimus 
that primarily targets mTOR signaling. Interestingly, mTOR 
inhibitors also are very efficacious and produced increased 
survival in the RIP1-Tag2 model [532]. Thus, the RIP1-Tag2 
model predicted the beneficial effects of both sunitinib and 
everolimus. However, significantly increased overall survival 
of RIP1-Tag2 mice, but not PNET patients treated with these 
inhibitors, can be reflective of the consequence of the dif-
ferent life spans of mouse versus human (approximately 
15 weeks versus 70 years); therefore, a relatively short life 
extension can be significant. Also, preclinical studies in the 
RIP1-Tag2 mice are confounded by the fact that tumors are 
multifocal and that mice die from hypoglycemia, with rela-
tively low (collective) tumor burdens and little metastasis 
relative to that characteristic of other mouse tumor models or 
human cancer. However, it is also noticed that evaluation of 
overall survival in clinical studies is confounded by the fact 
that placebo-treated PNET patients (unlike RIP1-Tag2 mice) 
elect to “cross-over” to the treatment cohort, likely reducing 
the calculated overall survival benefit in patients [533].
25.3  RIP1‑Tag2 versus PNET tumors
Another major complication in interpreting preclinical stud-
ies using the RIP1-Tag2 mouse lies in fundamental biologi-
cal differences from PNET. Tumors in the RIP1-Tag2 model 
are rapidly progressive and rarely form metastases, in con-
trast to the more indolent PNET tumors, although a subset 
of PNET tumors is more aggressive and metastasized [534]. 
Further, the tumor gene driving RIP1-Tag2 oncogenesis is 
a viral protein that interferes with p53 and retinoblastoma 
tumor suppressor function, while the genes associated with 
human PNET are predominantly chromatin-remodeling 
genes, DNA repair genes, mTOR-PI3K pathway genes, and 
menin mutations [534]. Notwithstanding these differences, 
expression profiling of human PNET tumors split them into 
three distinct groups, and remarkably two of them corre-
spond to expression profiles identified in RIP1-Tag2 tumors 
[535]. Interestingly, human PNET tumors rarely adapt to 
culture, and while many cell lines from RIP1-Tag2 tumors 
(βTC cell lines) have been generated, they are surprisingly 
difficult to culture in comparison with other mouse tumor 
cell lines in spite of their aggressive growth in vivo.
25.4  Adaptation to anti‑angiogenic therapy
The RIP1-Tag2 mouse represents a powerful model to 
assess therapeutic response and relapse to anti-angiogen-
ics due to their very synchronous tumor progression, and 
this has made it a potent model to study adaptation to anti-
angiogenic therapy. The response phase is characterized by 
tumor stasis and markedly reduced vascularity and vessel 
normalization blocking hemorrhage formation that pro-
duces whitish tumors, while the angiogenic relapse phase 
is characterized by tumor regrowth and revascularization 
(Fig. 23b). McDonald and colleagues investigated the kinet-
ics and mechanisms underlying vessel regrowth upon with-
drawal of anti-angiogenic therapy and found that although 
two different VEGFR inhibitors, AG-013736 or AG-028262, 
significantly regressed tumor vasculature, they left behind 
empty sleeves of pericyte-covered basement membrane 
which functioned as a scaffold for rapid revascularization 
after treatment withdrawal. They concluded that targeting 
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pericytes and the sleeves of basement membrane appeared 
to be an important strategy to produce an enduring response 
to anti-VEGF therapy [536]. Casanovas et al. [537] per-
formed preclinical studies in the RIP1-Tag2 model, which 
demonstrated that after a period of response to continuous 
anti-VEGFR2 monotherapy, tumors rebounded although 
blockade of VEGFR2 signaling persisted. They found that 
the mechanism for regrowth was induction of alternative 
pro-angiogenic factors, including the fibroblast growth factor 
family (FGF) and ephrins. In addition, the response phase 
is characterized by the angiostatic and immunostimulatory 
polarization of myeloid cells that contributes to pruning and 
normalization of the vasculature [538]. Tumors respond to 
these changes by activating and repolarizing myeloid cells 
to an angiogenic and immunosuppressive phenotype and by 
initiating an adaptive immune response by upregulating the 
negative immune checkpoint regulator, programmed cell 
death ligand PDL1; both immune adaptations limited the 
efficacy of VEGF/VEGFR inhibitors [538–540]. Another 
form of evasion from anti-angiogenic therapy that was 
characterized in the RIP1-Tag2 model (and glioblastoma) 
is that of increased invasion and metastasis following phar-
macological and genetic targeting of the VEGF signaling 
axis [530], the consequence of increased hypoxia induced 
by vascular fallout. While increased invasion has not yet 
been found in PNET treated with anti-angiogenic therapy, it 
appears bevacizumab treatment can cause increased invasion 
in a subset of patients with glioblastoma multiforme [541], 
again highlighting the predictive power of this model.
25.5  Limitations and challenges
In spite of the fact that preclinical studies in the RIP1-Tag2 
model predicted the efficacy of two approved therapies, the 
model is multifocal, rapidly progressive, and driven by a 
viral oncogene unlike its human counterpart. Because some 
PNET patients progress on available targeted therapies, it 
is desirable to further develop biomarkers of therapeutic 
response together with Patient Derived Xenograft (PDX) 
models from resistant tumors in humanized mouse mod-
els in order to identify beneficial secondary or concurrent 
therapies [533].
25.6  Concluding remarks
The RIP1-Tag2 model of beta islet-cell carcinogenesis has 
been instrumental in studying mechanistic underpinnings 
of tumor angiogenesis and in revealing adaptations to the 
environmental stresses elicited by anti-angiogenic therapies, 
leading to valuable insights and predictions regarding clini-
cal successes and failure.
26  The MMTV‑PyMT breast cancer model
The MMTV-PyMT mouse breast cancer model was 
described in 1992 by Guy, Cardiff, and Muller [542] and has 
been broadly employed for studying several aspects of breast 
cancer progression, such as the regulation of angiogenesis, 
cancer cell intravasation and dissemination, and metastatic 
colonization. In this transgenic model, the polyomavirus 
middle T antigen (PyMT) is expressed in the mammary 
epithelium from the long terminal repeat (LTR) promoter 
of the mouse mammary tumor virus (MMTV). The trans-
forming activity of the PyMT is dependent on its association 
with several oncogenic proteins, resulting in the multifocal 
growth of mammary adenocarcinomas that metastasize to 
the lung [542].
26.1  Tumor angiogenesis in MMTV‑PyMT mice
Lin et  al. have examined breast cancer progression in 
MMTV-PyMT mice [543–545]. Early malignant transition 
occurs between 8 and 12 weeks of age and is associated 
with increased nuclear pleomorphism, peri-acinar infiltra-
tion by leukocytes, and angiogenesis [544]. The angiogenic 
switch—the conversion of a quiescent, non-angiogenic vas-
culature into one that is actively growing and infiltrative—
generally demarcates the malignant progression of benign 
lesions [5]. Although the transition from hyperplasia to the 
adenoma/mammary intraepithelial neoplasia (MIN) involves 
the enlargement of the tumor mass in MMTV-PyMT mice, 
the density of functional blood vessels remains constant in 
these premalignant stages and is comparable to that of nor-
mal mammary glands [545].
A change in blood vessel distribution and density occurs 
during the transition from premalignant to malignant stages. 
In early adenocarcinomas, the acinar structures are replaced 
in the core of the lesion by small solid nodules displaying 
increased nuclear pleomorphism and cytologic atypia [545]. 
A high-density vascular network becomes evident in the 
solid nodular area, whereas surrounding premalignant acini 
are not associated with angiogenesis. Therefore, the develop-
ment of adenocarcinomas, but not premalignant adenoma/
MIN, is accompanied by angiogenesis in MMTV-PyMT 
mice. Of note, both high- and low-density vascular networks 
are found in early or late adenocarcinomas [545]. Variation 
in the features and density of blood vessels in transgenic 
(autochthonous) tumors is likely controlled by a multitude of 
parameters, including the spatiotemporally regulated expres-
sion of pro- and anti-angiogenic factors and inflammatory 
mediators, as well as biophysical forces, which dynamically 
control vessel functionality, growth, and regression in dis-
tinct tumor microenvironments [5].
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26.2  Role of macrophages in MMTV‑PyMT tumor 
angiogenesis
Monocytes and macrophages have been implicated in 
MMTV-PyMT tumor angiogenesis and progression [543, 
545]. MMTV-PyMT mice carrying a homozygous muta-
tion in the colony-stimulating factor-1 (Csf1) gene (Csf1op/op) 
recruit fewer tumor-associated macrophages (TAMs) than 
Csf1-proficient mice [543]. The macrophage-deficient 
phenotype of MMTV-PyMT/Csf1op/op mice is associated 
with delayed tumor progression (decreased incidence of 
invasive adenocarcinomas and pulmonary metastasis) and 
defective tumor angiogenesis [543, 545]. Conversely, the 
genetic overexpression of Csf1 in the mammary epithelium 
of MMTV-PyMT mice results in the premature accumula-
tion of macrophages around hyperplastic lesions and adeno-
mas and accelerates both the development of an angiogenic 
vasculature and tumor progression [545]. These findings are 
consistent with results obtained using a macrophage-deplet-
ing CSF1 receptor (CSF1R) inhibitor [546] and agree with 
studies in other mouse tumor models, such as RIP1-Tag2 
transgenic mice [547].
Conditional overexpression of vascular endothelial 
growth factor-A (Vegfa) in the mammary epithelium of 
4–6-week-old MMTV-PyMT mice was sufficient to induce 
the formation of enlarged, angiogenic blood vessels around 
premalignant acini [548]. Also, VEGF-A overexpression res-
cued macrophage infiltration, stimulated the formation of a 
high-density vascular network, and restored tumor progres-
sion in MMTV-PyMT/Csf1op/op mice [548]. These findings 
suggested that macrophages can promote tumor angiogen-
esis in MMTV-PyMT mice, at least partly, through VEGF-
A [548]. In another study, conditional deletion of Vegfa 
specifically in myeloid-lineage cells, which encompass 
macrophages, altered vascular patterning in MMTV-PyMT 
mice [549]. This phenotypic conversion involved decreased 
vessel tortuosity and density and increased pericyte cov-
erage, which are consistent with an attenuated angiogenic 
response. While overall VEGF-A levels were unabated by 
loss of myeloid-derived VEGF-A (likely due to substantial 
VEGF-A production by cancer cells), the phosphorylation 
of endothelial VEGF receptor 2 (VEGFR2) was decreased 
in the tumors [549]. These findings suggest that myeloid 
cells, or subsets thereof, provide a non-redundant source of 
bioactive and pro-angiogenic VEGF-A in the perivascular 
microenvironment of MMTV-PyMT tumors. Macrophages 
enwrap angiogenic blood vessels in MMTV-PyMT tumors 
[550, 551], which may explain the importance of mac-
rophage-derived VEGF-A for tumor angiogenesis [549]. 
However, it should be noted that attenuation of angiogenesis 
does not necessarily translate into tumor inhibition. Indeed, 
Stockmann et al. observed accelerated tumor progression 
in MMTV-PyMT mice with myeloid-specific Vegfa dele-
tion [549]. This finding can be attributed to the “normal-
ized” structure of the blood vessels, which may have led to 
improved tumor oxygenation and cancer cell growth [552].
Besides VEGF-A, TAMs secrete additional pro-angio-
genic factors [5]. For example, the genetic deletion of Wnt7b 
in TAMs reduced the expression of WNT/β-catenin mito-
genic target genes in vascular endothelial cells and decreased 
the MVD in MMTV-PyMT adenocarcinomas [553].
MMTV-PyMT mice have also been instrumental for 
studying macrophage–vascular interactions in the mammary 
tumors. The genetic inactivation of Tie2/Tek in TAMs did 
not block their recruitment to tumors, but impaired their 
ability to associate with immature blood vessels and sus-
tain tumor angiogenesis [551]. Further to supporting angio-
genesis, perivascular TAMs enhance vascular permeability 
through VEGF-A, which facilitates cancer cell intravasation 
and metastasis in MMTV-PyMT mice [554]. The association 
of macrophages with tumor blood vessels is increasingly rec-
ognized as an important determinant for early breast cancer 
metastasis in both MMTV-PyMT mice and patients with 
breast cancer [554–556].
26.3  Anti‑angiogenic therapy in MMTV‑PyMT mice
The pharmacological inhibition of VEGF-A signaling atten-
uates tumor angiogenesis in both transgenic MMTV-PyMT 
mice and mice carrying orthotopic MMTV-PyMT tumor 
transplants [557, 558]. More marked anti-angiogenic effects 
are observed when VEGF-A and angiopoietin-2 (ANGPT2) 
are neutralized concomitantly in the mammary tumors [557, 
558]. Dual VEGF-A and ANGPT2 blockade also leads to 
substantial tumor inhibition and significantly extends the 
survival of transgenic MMTV-PyMT mice [558]. Further 
to suppressing tumor angiogenesis and abating the density 
of the vascular network, combined VEGF-A and ANGPT2 
blockade normalized the structure of the blood vessels 
that survived in viable tumor regions and facilitated the 
extravasation and perivascular accumulation of activated, 
interferon-γ (IFNγ)-expressing  CD8+ T cells [558]. These 
tumor phenotypes were likely due to the complementary 
actions of ANGPT2 and VEGF-A inhibitors on the tumor 
microenvironment: Whereas VEGF-A blockade has more 
marked vascular-pruning activity, at least acutely [559], 
ANGPT2 blockade limits angiogenesis [551] and enforces 
the maturation and stabilization of the remaining vessels, 
making them permissive to T cell extravasation and traffick-
ing [560, 561]. Thus, MMTV-PyMT mice provide a useful 
model for studying the kinetics of angiogenesis inhibition 
and vascular normalization in response to anti-angiogenic 
drugs.
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26.4  Limitations and challenges
Although angiogenesis has been extensively studied in 
primary adenocarcinomas, little is known of the mecha-
nisms controlling vascularization of pulmonary metastases 
in MMTV-PyMT mice. Because macroscopic pulmonary 
metastases become evident only in aging mice (12–16 weeks 
of age), the development of multifocal primary tumors may 
impose significant constraints on the investigator’s abil-
ity to examine metastatic lesions whose mass would be 
large enough to stimulate angiogenesis. In this regard, it is 
increasingly appreciated that metastatic tumors may rely, 
at least partly, on vessel co-option and be less dependent 
on angiogenesis than primary tumors [562]. Further studies 
are required to establish whether pulmonary metastases that 
develop in MMTV-PyMT mice vascularize through angio-
genesis, vessel co-option, or both.
27  Tumor implantation models
27.1  Implantation of angiogenic tumors
Tumors may be implanted in mice as xenografts or in a 
syngeneic context. Implantation may also be done subcu-
taneously or orthotopically at the correct organ site where 
the tumor usually grows. There are many angiogenic tumor 
models to cite only a few such as glioma (U87 human glio-
blastoma, mouse GL261 glioma), breast (MDA-MB-231, 
66cL4 mouse mammary tumor), lung (Lewis lung car-
cinoma, human LNM35 lung) melanoma (B16 mouse 
melanoma), prostate (human prostate CWR22Rv1 tumor) 
[563]. Tumor cells may be injected as single-cell suspen-
sion, embedded in matrix such as matrigel or implanted 
as spheroids or organoids. Cells may be transduced with a 
suitable reporter construct (such as luciferase), and tumor 
development may be followed by imaging. Usually at a given 
time point, animals are killed and tumors are processed for 
immunohistochemistry, RNA expression analysis, or protein 
detection (immunoblot). The angiogenic response is ana-
lyzed by immunohistochemistry or immunofluorescence 
using appropriate antibodies for endothelial cells (CD31, 
CD34) or pericytes (alpha2SM actin, desmin). This analysis 
will give information about vessel density, vessel size distri-
bution, and vessel quality (tight or loose pericyte coverage). 
The angiogenic response is usually high in the viable core 
of the tumor. At the invading front, tumor cells may use 
preexisting vessels for invasion.
It is of note that tumors may exhibit different angiogenic 
responses when they are either implanted in orthotopically 
or subcutaneously as it has been shown in the case of astro-
cytomas [564].
27.2  Detection of “non‑angiogenic” tumors, which 
rely instead on “vessel co‑option”
While there is an overwhelming body of preclinical/experi-
mental and clinical evidence accumulated over 40 years 
showing the importance of sprouting neo-angiogenesis in 
tumor growth, progression, and metastasis, it is increas-
ingly appreciated that there are many circumstances in 
which tumors can grow and expand without inducing any 
new blood vessel capillaries. This realization has major 
implications for understanding some of the clinical efficacy 
limitations including failures of anti-angiogenic drugs. Thus, 
new blood vessels can be formed by a process of the “split-
ting” of existing vessels, a process known as intussusception, 
as discussed above. Or, certain tumors, especially neural 
crest-derived cancers, may form blood forming channels by 
“vasculogenic mimicry” whereby tumor cells line the vessel 
lumen, rather than authentic host EC. However, the most 
dominant manifestation of non-angiogenic tumors is likely 
“vessel co-option” and it is particularly prominent in vascu-
lar-rich organs that are the most common sites of metastatic 
disease, namely lung, liver, lymph nodes, and brain [117].
Broadly speaking, vessel co-option refers to the ability 
of tumors to parasitize preexisting blood vessels of the tis-
sue, bypassing the requirement of developing new ones. 
The modern era of vessel co-option may have begun in 
1996–1997 with the publication of two pathology reports by 
Pezzella and colleagues. Therein, a pattern of tumor growth 
of non-small cell lung cancer and lung metastases was rec-
ognized which made use of alveolar air spaces for expansion 
and alveolar vessels for blood supply without any indication 
of angiogenesis [121, 565]. Histopathological descriptions 
of similar growth pattern in the lungs and analogous patterns 
in the brain and liver date to the late 1800s and early 1900s. 
The distinction between so-called newly formed versus pre-
existing blood vessels was noted in the past, but the biologi-
cal significance of each form was generally not appreciated. 
This has changed in the era of anti-angiogenic therapy—for 
example, targeting the vascular endothelial growth factor 
(VEGF) pathway to impair and cause regression of new 
vessel sprouts does not deplete preexisting vessels. Tumor 
exploitation of vessel co-option has recently been shown to 
account for instances of intrinsic and acquired resistance 
to anti-angiogenic drugs, both preclinically [122, 566, 567] 
and clinically [119]. Moreover, growth patterns associated 
with vessel co-option are emerging as important for patient 
prognosis [120, 568].
There is currently no “assay” as such to quantitate the 
extent of vessel co-option in tumors. Conventional measure-
ment of tumor microvessel densities (MVD) within tumors 
has high potential for error when one considers that nor-
mal tissue vessel densities—as well as tumors where cancer 
cells surround these vessels—may be high [569]. Rather, 
496 Angiogenesis (2018) 21:425–532
1 3
histopathological analysis is currently used with certain 
key features being looked for. Some examples are briefly 
described below; more detailed descriptions can be found 
elsewhere [117, 569].
27.3  Some “hallmarks” of detecting vessel 
co‑option in tumors growing within the lungs, 
liver, and brain
Though the histological structures of these organs are dis-
tinct, tumors within these sites that co-opt preexisting blood 
vessels—either as part of its overall mass or throughout—
often have some of the following features:
1. The architecture of the normal host tissue is preserved 
within the tumor. This is in contrast to angiogenic 
tumors, which tend to destroy the surrounding tissue. 
Tissue architecture preservation has been aided by 
immunohistochemistry for basement membrane and 
epithelial markers showing continuity of form across 
the tissue–tumor interface.
2. Lack of surrounding capsule or desmoplastic tumor 
boundary. Angiogenic tumors often form defined masses 
or nodules, a symptom of the inflammatory response of 
the host to the tumor, but this is lacking in “purely” ves-
sel co-opting tumors.
3. Invasive, infiltrative, and replacing tumor growth. 
Minimal compressive tumor growth and compression 
of normal tissue structures. Rather, tumor cells tend to 
Fig. 24  Visualization of vasculature in transplanted mouse models. 
Immunofluorescence and immunohistochemical staining of forma-
lin-fixed mouse lung samples to enable differentiation between ves-
sel co-option and angiogenesis in tumors. a, b Vessel co-opting 
tumors are observed in spontaneously formed lung metastases from 
mice with orthotopically implanted then surgically resected MDA-
MB-231/LM2-4 breast tumors. In a sections are stained for alveolar 
cell marker podoplanin, EC marker CD34 and nuclei marker DAPI. 
Tumor cells can be seen filling alveolar spaces along the border and 
incorporating alveolar capillaries into the tumor core. In b is the cor-
responding section stained for HLA human cell marker and hema-
toxylin to show the presence of tumor cells with respect to host 
stroma and lung parenchyma. A bronchiole is also seen to be taken 
into the tumor and gradually filled with tumor cells. The tumor bor-
der is irregular. c, d Angiogenic growth is observed in spontaneously 
formed lung metastases from mice bearing intra-renal implanted 
RENCA tumor cells that later underwent nephrectomy. Sections are 
stained for alveolar and bronchial epithelium cell marker cytokeratin 
7, EC marker CD34 and nuclei marker DAPI. RENCA tumors grow 
in “cannonball” shape, compressing lung tissue and excluding them. 
The lung–tumor interface of another nodule is shown at high mag-
nification in d. Lung tissue is compressed or “pushed” aside to allow 
tumor expansion. The tumor border is smooth, and microvessels are 
not associated with alveolar epithelium within the tumor. Scale bar 
represents 200  µm. Regions in dashed boxes are expanded on the 
right. “T” = tumor. Arrow = columnar bronchial epithelium
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infiltrate along preexisting vessels, often in direct con-
tact with epithelial–endothelial basement membranes. 
Epithelial cells may become destroyed or stripped from 
their vessels during this process. Tumor borders are 
irregular.
4. Incorporation of characteristic cells and structures of 
the tissue into the tumor. Parenchymal epithelial cells 
(e.g., lung pneumocytes, liver hepatocytes, neuralglia) 
and larger intact structures (e.g., lung bronchioles and 
large vessels in the lungs, portal triads in the liver) are 
taken up into the expanding infiltrative tumor mass and 
get locked into the tumor.
5. Maintained vessel morphology and marker expression. 
Co-opted vessels are known to be remodeled by sur-
rounding tumor tissue and therefore may not in all cases 
appear “normal.” Newly recruited co-opted vessels in 
particular may maintain morphological and molecular 
characteristics of tissue endothelium (e.g., GLUT-1 and 
p-glycoprotein endothelial expression in brain tumors).
6. Low rates of endothelial cell proliferation relative to 
angiogenic tumors. Specific molecular markers of co-
opted blood vessels are not currently known; thus, sev-
eral criteria are used to distinguish between vessel sub-
types and differential growth patterns of tumors. Vessel 
co-option was first identified in tumors from patients; 
however, experimental mouse models have also been 
shown to recapitulate the growth patterns observed in 
human tumors.
The major question now for future studies is whether 
“anti-vascular” therapeutic strategies can be developed that 
target co-opted vessels, in addition or instead of angiogenic 
vessels, without impacting the normal vasculature; some 
possibilities have recently emerged, for example using anti-
body–drug conjugates [570].
Shown in Fig. 24 are preclinical examples of both ves-
sel co-opting and angiogenic tumors. Lung metastases from 
mice with breast cancer cell (MDA-MB-231/LM2-4) vs. 
kidney cancer (RENCA). The former develops purely non-
angiogenic vessel co-opting lung metastases, whereas the 
latter forms both angiogenic (shown here) and vessel co-
opting lung metastases. Staining for lung-specific epithelial 
and EC markers shows the architecture of blood vessels in 
lung tissue and metastases. In vessel co-opting lung metasta-
ses, alveolar cells surrounding capillaries are taken up by the 
expanding mass at the tumor border, but alveolar epithelial 
cells are gradually shed from vessels toward the tumor center 
while capillaries remain.
27.4  Limitations and challenges
Implantation models are generally very useful in deciphering 
mechanisms of the tumor angiogenesis and the role of given 
angiogenesis stimulator or inhibitor, receptors or modulating 
intracellular factors. The only drawback is that the adaptive 
immune system in xenotransplantations is absent and thus 
the data must be interpreted with care. The other challenge 
is the implantation site. Usually, it is better to orthotopically 
implant tumor cells since the correct host tissue is present 
in this case. Another challenge is whether or not to implant 
cell suspensions or spheroids. Spheroids seem in many cases 
better suited because they already adopt a 3D tissue configu-
ration which preserves some of their genetic program that is 
encountered in a 3D tissue.
Co-optive growth may be induced by anti-angiogenic 
therapy as it is encountered in glioblastoma for instance. 
Thus, a switch from angiogenesis to co-option may occur in 
this case. It would be important to develop therapies against 
co-opted vessels but this may be damaging because there 
are for the moment no specific markers discovered for co-
opted vessels.
27.5  Concluding remarks
Tumor implant models are of great value to decipher tumor 
vessel interactions. Despite several limitations, this is still 
important methodology that is useful in characterizing many 
molecular mechanisms of tumor angiogenesis.
28  Mouse hind limb ischemia model
Peripheral arterial disease (PAD) is caused by atherosclero-
sis and occlusion of peripheral blood vessels and results in 
intermittent claudication or in more severe stage in critical 
limb ischemia. The prevalence of PAD increases with age, 
affecting 6% of individuals aged 50–60 years, and 10–20% 
of individuals aged > 70 years [571, 572]. In the upcom-
ing years, the number of PAD patients will increase even 
more due to the aging of the population and the increase in 
number of patients with obesity and type 2 diabetes. Unfor-
tunately, current therapies for improving the perfusion of 
the lower limbs in patients with PAD are hardly effective 
[573, 574]. Therefore, much effort has been put in the last 
decade in defining new strategies to improve the blood flow 
to the lower extremities and to promote blood vessel growth. 
These strategies that are based on the concept of therapeutic 
neovascularization are often also called therapeutic angio-
genesis or more general, neovascularization [573].
Neovascularization comes in three anatomical and physi-
ological forms; angiogenesis, arteriogenesis, and vasculo-
genesis [574]. Angiogenesis describes an expansion of the 
microvasculature, because of sprouting of EC from preex-
isting capillaries, followed by their proliferation, migration, 
and capillary formation and is mainly hypoxia driven [246]. 
By contrast, arteriogenesis describes the remodeling of 
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existing arterioles into collateral arteries so that they can 
deliver more blood flow to the limb [575]. Finally, adult vas-
culogenesis describes the incorporation of circulating (pro-
genitor) cells into the regenerating microvasculature [573]. 
In PAD, neovascularization primarily occurs in the form of 
arteriogenesis or collateral formation, although angiogenesis 
in more distally located ischemic areas does occur.
To test new therapeutic approaches to induce neovascu-
larization, as well as unraveling the complex cellular and 
molecular mechanisms involved in the regulation of the neo-
vascularization process, mouse models mimicking critical 
Fig. 25  Laser Doppler perfu-
sion imaging and angiography 
of blood flow. Analysis of blood 
flow recovery in time by laser 
Doppler perfusion imaging (left 
panels) and angiography (right 
panels)
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limb ischemia have been developed. Although these models 
may vary in crucial aspects, commonly they are referred to 
as the mouse hind limb ischemia model. Being in vivo mod-
els they are complex and not always straightforward to inter-
pret, but they faithfully reproduce the physiology of blood 
recovery in PAD after stenosis of the original conduit. In this 
section, we will discuss the critical aspects of the variations 
in the use of the mouse hind limb ischemia model, their 
consequences for interpretation of the data obtained, and the 
limitations and pitfalls in their use.
28.1  Mouse model for hind limb ischemia
Couffinal et al. were among the first to describe a mouse 
model for hind limb ischemia [576]. They induced acute 
hind limb ischemia by ligating the proximal end of the femo-
ral artery, and the distal portion of the saphenous artery, 
followed by excision of ligated part of the femoral artery and 
attached side branches. The recovery of blood flow in the 
ischemic limb due to angiogenesis and arteriogenesis was 
monitored by laser Doppler perfusion imaging (LDPI) [576], 
Fig. 25. Subsequently, many groups used similar approaches 
and variants of this model [577, 578]. Surgical procedures 
range from a single ligation of the femoral or iliac artery 
[579–581] to a complete excision of the artery [576] and 
sometimes even the vein and the nerve were dissected as 
well [582, 583]. Several excellent review papers have been 
written on these variations in the hind limb ischemia model 
[584–587]. When choosing a particular variant of the mouse 
hind limb ischemia model for a study, it is important to 
define the goal of the study. For instance, when testing new 
pro-arteriogenic approaches, there should be an appropriate 
therapeutic window in which an improvement of blood flow 
recovery can be monitored. In mice that rapidly form new 
collaterals, for example, C57BL/6 mice with a single ligation 
of the femoral artery, it is difficult to monitor an increase 
toward an even faster collateral formation [588], and there-
fore a model with more severe injury is required [589, 590]. 
On the other hand, such a fast model is ideal for mechanistic 
studies in which the effects of the deficiency or inhibition 
of crucial factors on blood flow recovery are studied [591, 
592]. The fast recovery model is also associated with less 
animal discomfort.
Another crucial question is which aspect of neovascu-
larization will be studied. Arteriogenesis is the remodeling 
of preexisting arterioles to larger diameter collateral blood 
vessels required for restoring the blood flow to the distal 
ischemic parts of the limb, whereas angiogenesis is the 
sprouting of new (capillary) vessels into the ischemic tissue. 
One can imagine that the excision model to induce hind limb 
ischemia results in the disruption of the preexisting arteri-
oles in the adductor muscle, and thus the presumed substrate 
for collateral formation. In pro-angiogenic intervention, 
however, severe ischemia in the calf muscles in the excision 
model is warranted.
A good comparison of the various models has also been 
hampered by the lack of a proper description of the anatomy 
of the blood vessels in the mouse limb. Hopefully the recent 
excellent description of the arterial anatomy of the murine 
hind limb by Kochi et al. [593] will contribute to a bet-
ter understanding of the outcomes of the different ischemia 
models.
28.2  Variants of the surgical procedure to induce 
mouse hind limb ischemia
General aspects of the surgical procedures Before surgery, 
mice are anaesthetized with an intraperitoneal injection of a 
combination of midazolam, medetomidine, and fentanyl. In 
all models, the femoral vein and nerve are preserved. After 
surgery, the skin is closed with 6/0 Ethilon sutures (proce-
dures adapted from [585]).
Single electrocoagulation of femoral artery Directly after 
incision of the skin in the left inguinal region, the subcu-
taneous fat pad in the thigh becomes visible and is pulled 
aside distally. After dissection of the artery from the nerve 
and vein, ischemia is induced by electrocoagulation of the 
left femoral artery, proximal to the superficial epigastric 
artery. Electrocoagulation results in complete occlusion of 
the artery. After electrocoagulation, the proximal end of the 
artery moves proximally into the surrounding tissue and the 
distal end moves distally, so there will be a distance of a few 
millimeters between both ends after the surgical procedure.
Single electrocoagulation of iliac artery A larger skin 
incision in the inguinal region is made for this procedure. 
Furthermore, there is no need to cleave the fat pad. For expo-
sure of the iliac artery, a retroperitoneal approach is used. By 
carefully moving the peritoneum proximally with a cotton 
swab, a good exposure of the iliac artery is possible. In addi-
tion, preparation of the artery from the vein is necessary. The 
internal iliac artery serves as a landmark; direct proximally 
of the internal iliac artery an electrocoagulation of the com-
mon iliac artery is performed.
Double electrocoagulation of both femoral artery and 
iliac artery For a double coagulation model, both com-
mon iliac artery and femoral artery are electrocoagulated. 
First, an electrocoagulation of the common iliac artery is 
performed followed by electrocoagulation of the femoral 
artery. These coagulations are at the same anatomical levels 
as in the single electrocoagulation procedures of the femoral 
artery and the iliac artery.
Total excision of femoral artery The upper thigh is 
exposed through an inguinal to knee incision. A proximal 
part of the femoral artery is removed after double ligation. 
Then, all side branches are isolated and coagulated. The dis-
tal ligation site is at the popliteal artery level distal from the 
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saphenous artery bifurcation. The whole artery in between 
is removed.
28.3  Analysis of blood flow recovery 
and neovascularization
Traditionally, blood flow recovery is analyzed by Laser 
Doppler Perfusion Imaging (LDPI) where the flow in the 
footpads of the ligated and contralateral limb is measured 
and expressed as the ratio between the ligated and unligated 
footpad. The restoration of the blood flow in time is used as 
a readout for neovascularization (angiogenesis and arterio-
genesis combined) in the ischemic limb.
Next to the LDPI-based flow analysis, immunohistochem-
ical analyses of the neovascularization are used. Usually, the 
angiogenic response is studied in the distal part of the limb, 
the ischemic calf muscle (gastrocnemius), using EC staining 
(CD31, von Willebrand is in absolute numbers per area or as 
number of blood vessels related to number of myocytes). In 
addition, the arteriogenic response, (i.e., newly formed col-
lateral arteries) is commonly studied in the adductor muscle. 
They are usually stained with alpha smooth muscle actin to 
demonstrate the arterial nature, whereas size and location 
are indicative of their collateral nature.
In addition to these two commonly used methods to moni-
tor the neovascularization in the ischemic limb of the mouse, 
sometime a functional test is used in which the use of the 
foot and limb is analyzed for instance by assessment of the 
plantar/dorsiflexion [594]. In the more severe models, necro-
sis of toes or even feet ensues, leading to auto-amputation. 
Semiquantitative scores have been developed and used to 
assess efficacy of interventions. Moreover, the increased sen-
sitivity of current imaging methods may represent a major 
step forward. For example, the use of micro-CT analysis 
(which previously was typically used as a postmortem pro-
cedure due to the low sensitivity and lack of good contrast 
agents [585], has now become a method for in vivo imag-
ing of the microvasculature [595], enabling the analysis of 
the neovascularization over time. Recently, it was demon-
strated by Hendrikx et al. [596] that single photon emission 
computed tomography perfusion can be used to analyze 
neovascularization processes in the mouse hind limb, even 
with such a resolution that they can demonstrate that LDPI 
analysis underestimates the revascularization processes in 
this model.
28.4  Limitations and challenges
One of the major limitations of the currently used hind limb 
ischemia model is the acute nature of the ischemia, whereas 
in the patients with peripheral artery disease the ischemia 
develops gradually. Although an interesting approach 
for gradual induction of ischemia in mice using ameroid 
constrictors has been described by Yang et al. [597], this 
model has not received large follow-up.
The capacity for vascular regeneration and neovascu-
larization differs strongly between commonly used mouse 
strains [598, 599]. For many years, it has been known that 
C57BL/6 mice have a stronger neovascularization capacity 
than Balb/c mice [581, 600] and only recently, it has been 
discovered that this difference in regenerative response is 
linked not only to a difference in the preexisting collateral 
bed in the various strains [598] but that it also can be attrib-
uted to a specific gene locus in chromosome 7 of the mouse 
[601–604]. Because of their slow regenerative response, 
Balb/c mice are frequently used for hind limb ischemia stud-
ies, on the assumption that this slow response better mim-
ics the situation in patients with PAD that display a poor 
regenerative capacity. A recent study by Nossent et al. [605] 
compared the mRNA expression pattern of angiogenesis and 
arteriogenesis related genes in the hind limb of C57BL/6 
and Balb/c mice. This showed that in Balb/c mice a stronger 
upregulation of pro-angiogenic and pro-arteriogenic genes 
can be observed when compared to C57BL/6 mice, despite 
the poorer regenerative phenotype in Balb/c mice. These 
findings suggest that rather than a more accurate model 
of human critical limb ischemia, Balb/c mice lack a thus 
far unknown factor that is crucial for vascular regenerative 
response.
Since inflammation and the immune system play an 
important role in the regulation of the angiogenic and arte-
riogenic responses in the hind limb ischemia model and 
several immune cells including monocytes, T cells, and NK 
cells are crucial in neovascularization [579, 581, 591, 592, 
606–609], the use of immune-compromised mouse strains 
for cell therapy approaches with human cells is not ideal 
and the results of these studies should be interpreted with 
caution. This becomes even clearer when the fate of injected 
cells, and their rapid disappearance even from syngeneic 
mouse is taken into account [609]. A very comprehensive 
review on the use of various immunocompromised mouse 
strains in hind limb ischemia models for human cell therapy 
validations has recently been published by Thomas et al. 
[594] and provides valuable information on the choice of 
the proper model.
Last but not least, a major limitation for most of the hind 
limb ischemia mouse studies is that they are performed in 
healthy young mice, whereas the PAD patients usually are 
older, and have atherosclerosis, type-2 diabetes, or other 
comorbidities. These comorbidities strongly affect the neo-
vascularization responses in mice [610, 611]. Moreover, 
induction of vascular remodeling may also affect the under-
lying atherosclerotic disease leading to arterial occlusion. 
This phenomenon is described as the Janus phenomenon of 
neovascularization by Epstein et al. [612].
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28.5  Concluding remarks
Many variants of the mouse hind limb ischemia model are 
used; researchers should be aware of the different options, 
select the model that fits best the goal of their experiments, 
and properly describe the type of model used. It should also 
be noted that although this model is commonly referred to 
as an angiogenesis model, the mode of neovascularization is 
a true combination of collateral formation and angiogenesis.
29  Large animal models for myocardial 
angiogenesis
There is little doubt that large animal models are needed for 
translational and preclinical studies of myocardial angio-
genesis. Advantages of large animal models over smaller 
animals are that the heart better resembles human heart in 
size, anatomy, and function. Also, the same imaging equip-
ment and treatment strategies, including similar dosage, can 
be used. Due to ethical reasons and a good resemblance to 
human, sheep and pigs are nowadays most widely used large 
animals in myocardial angiogenesis studies. Recent develop-
ments in these models are briefly described in this chapter.
29.1  Acute ischemia models
Acute myocardial ischemia models have been widely used, as 
they are rather easy to replicate in large number of animals. 
It will also be easy to make interventions if any arrhythmias 
occur. The models used are either surgical or catheter-based, 
very consistent, and variation between the animals is usually 
low. In surgical models, manipulation of the coronary arteries 
from a thoracotomy opening to induce ischemia is a widely 
used method [613]. However, from the thoracotomy open-
ing, surgery affects the potential therapeutic approaches as 
pericardial attachments complicate further interventions and 
make it difficult to evaluate possible effusate accumulation, 
which often complicates pro-angiogenic therapies.
On the contrary to surgical models, catheter-based endo-
vascular models leave much of the heart intact and post-oper-
ational complications are much less frequent. Widely used 
catheter-based ischemia models include ischemia–reperfu-
sion model [614], infarction due to an intracoronary injected 
solution [615] and intracoronary coil occlusion [616].
29.2  Chronic ischemia models
A healthy animal has several mechanisms to respond to 
acute ischemia, which chronically ischemic patients may 
not have anymore. This has led to the development of more 
slowly developing occlusion and ischemia models to coun-
teract and expand these adaptation mechanisms and to better 
mimic the lack of necrosis, acute inflammation and strong 
endogenous angiogenic stimuli, which takes place in acute 
ischemia models [617].
Very widely used gradual obstruction model is a surgi-
cal ameroid constrictor model [618]. However, as a surgical 
model, this has the same disadvantages as described above.
Endovascular models have also been recently developed. 
Catheter-based models include the use of copper stents 
[619], copper-plated stents [620], or oversized steel stents 
[621], where in-stent restenosis causes stenosis in the coro-
nary artery. However, in these stent models, the stenosis 
size is variable, and its development cannot be controlled. 
There is also a ligated hourglass-shaped stent-graft model 
[622], but in this model, the exact time of total occlusion is 
not known. A recent bottleneck stent model can be varied 
for either reversible myocardial ischemia or ischemic car-
diomyopathy [623], depending on if the stent is allowed to 
occlude in this model. Occlusion is controlled by gradual 
reduction of antiplatelet and antithrombotic therapy.
29.3  Non‑ischemic heart failure models
In addition to ischemic heart failure models, non-ischemic 
models of heart failure have been developed that might be 
used to study neovascularization as a therapeutic approach 
for the improvement of cardiac function. In a recent model, 
heart failure is induced by chronic pulmonary hypertension 
[624]. To induce left ventricular hypertrophy and heart fail-
ure, different variations of aortic banding have been used 
[625]. Pacing models to induce heart failure have also been 
extensively used [626].
29.4  Myocardial stainings
Immunohistochemical stainings are used to histologically 
detect the effects of angiogenesis. Hematoxylin–eosin staining 
is used for tissue morphology characterization. Endothelial 
cells can be stained with PECAM-1, which is also known as 
CD31. Lymphatic endothelium can be stained with LYVE-1 
or PROX-1. These pericytes, the smooth muscle cells sur-
rounding blood vasculature, are stainable with α-SMA.
29.5  Challenges and limitations
Large animal models are the last translational step from 
bench to the first clinical trials. Therefore, using these 
models requires careful planning. Efficient delivery of the 
therapeutic agent, be it cellular, viral, or growth factor-based 
therapy, is a very critical factor for successful treatments. 
Earlier, mainly intramyocardial injections were used as 
these can provide robust and efficacious transduction, but 
more recent studies have used intracoronary infusion and 
retrograde coronary sinus infusion to achieve more global 
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transduction of the heart. These new delivery methods bring 
along new challenges to achieve efficacious transduction for 
angiogenetic therapies.
In large animal pro-angiogenic studies, study endpoints 
must be carefully decided. Therapeutic angiogenesis itself is 
not the de facto aim. These neovessels should be functional 
and enhance myocardial function. Therefore, functional anal-
yses should have a significant role in evaluating the effects 
of pro-angiogenic therapies. Previously, microspheres have 
been used for the evaluation of myocardial perfusion, but 
with improved technology, imaging modalities such as com-
puted tomography (CT), magnetic resonance imaging (MRI), 
and positron emission tomography (PET) should play more 
prominent roles as real-time perfusion, anatomical and func-
tional imaging can be performed simultaneously (Fig. 26). 
These modalities also allow for a long-term follow-up, as 
imaging can be performed sequentially, providing a better 
understanding of the long-lasting effects of the treatments.
Potential limitation of angiogenic therapies is the poten-
tial effect of the treatment on neural networks of the heart. 
It is entirely possible that the pro-angiogenic therapies 
also induce alterations in nerves producing arrhythmias. 
As a result, potential sudden deaths and other potential 
arrhythmia-based problems should be carefully monitored. 
Also, large animals do not have comorbidities that the 
patients might possess. For instance, reactions to angiogenic 
stimuli significantly vary in the ischemic and normoxic myo-
cardium. Rapid growth of heart also causes challenges, as 
relatively young tissue is more resistant to injury and can 
regenerate better than tissues in elderly patients.
29.6  Concluding remarks
Large animal models are invaluable in neovascularization 
studies, as they most closely resemble human patients. The 
model must be carefully selected, and further thought must 
be given when deciding suitable endpoints, which should 
nowadays include functional imaging studies.
30  Guidelines for purity of recombinant 
proteins in angiogenesis assays
This brief section aims to provide a few practical guide-
lines for purity requirements of recombinant proteins. 
Indeed, many proteins are tested in the in vitro and in vivo 
Fig. 26  Perfusion imaging is crucial in detecting functional changes 
in the vasculature. In normoxic pig myocardium 6 days after intramy-
ocardial AdVEGF-B186 and AdVEGF-DΔNΔC gene transfer, myocar-
dial perfusion is increased at stress conditions in the treated region 
(gt) as measured with PET. Color scale is absolute; darkest blue is 
0  ml/min/g, green is 1.5  ml/min/g, and deepest red is 3.0  ml/min/g 
or over (a–c). In control AdCMV group, relative perfusion, i.e., the 
ratio of absolute perfusion in the gene transfer area to that of the 
control anteroseptal area, did not increase at stress, whereas with 
both AdVEGF-B186 and AdVEGF-DΔNΔC, the relative perfusion was 
higher in comparison with the control group. Relative perfusion at 
rest was 12 and 13% and at stress 40 and 34% higher for AdVEGF-
B186 and AdVEGF-DΔNΔC, respectively d, e. Ad, adenoviral; CMV, 
cytomegalovirus; ctrl, control anteroseptal area; gt, posterolateral 
gene transfer area [654]
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angiogenesis assays described throughout this article, 
including pro- and anti-angiogenic cytokines or growth 
factors and antibodies. Antibodies, owing to their long sys-
temic half-life, are widely used in preclinical in vivo models. 
While in the majority of cases reliable commercial sources 
ensure high quality of reagents and hence reproducibility of 
experimental results, at times controversial or unexpected 
findings have emerged that may be, at least in part, traced 
back to purity and quality control issues.
30.1  Endotoxin
One of the major confounders and a key source of variabil-
ity, both in vitro and in vivo, is represented by endotoxin or 
lipopolysaccharide (LPS) contamination [627, 628]. LPS is 
an integral part of the outer cell membrane of Gram-nega-
tive bacteria and is released following bacterial lysis. LPS 
consists of a lipid component, known as Lipid A, a core 
oligosaccharide and a long heteropolysaccharide chain, the 
O-specific chain, representing the surface antigen (O-anti-
gen). The O-antigen is strain specific. Lipid A is the most 
conserved component of endotoxin and is responsible for 
the majority of the biological effects attributed to LPS [628, 
629]. LPS is heat stable and is not destroyed under regular 
sterilizing conditions. The limulus amebocyte lysate (LAL) 
assay is commonly used for the detection of endotoxin, 
and LAL kits are available from many manufacturers. This 
assay is based on a cell lysate of the horseshoe crab Limulus 
polyphemus that coagulates in the presence of even very low 
levels of endotoxins. Endotoxin levels are expressed as units 
(EU): 1 EU is generally equivalent to 100 pg of LPS.
It is now well established that LPS interacts with toll-
like receptor(TLR)-4 [630]. This is a key pathway in innate 
immunity [631]. Upon activation, TLRs signal as dimers, 
complexing via their intracellular Toll/interleukin-1 receptor 
(TIR) domains with a family of adaptor proteins in TLR-
specific patterns. This results in the activation of multiple 
downstream pathways in a cell-type specific fashion [632]. 
It is also well established that, besides LPS, a variety of 
endogenous and exogenous ligands can have agonistic or 
antagonistic effects on TLR4, accounting for a wide variety 
of biological effects [631].
30.2  Effects of endotoxin in angiogenesis assays
LPS can have diverse effects in angiogenesis-related assays. 
It can induce both cell injury and activation in cultured 
endothelial cells, even at very low concentrations [633, 634]. 
In vivo, LPS has been reported to induce tumor angiogenesis 
[635] and metastasis as well as tumor invasion [636]. On the 
other hand, a variety of studies have shown the opposite, i.e., 
anticancer effects of LPS in mouse models and in humans 
[637]. Indeed, as above noted, TLR4 stimulation can activate 
multiple signaling cascades, including the MAP kinase and 
NF-kB pathways [632]. These pathways may activate the 
secretion of proinflammatory cytokines, such as IL-6 and 
IL-8, or anti-inflammatory type I IFNs, including IFN-γ. 
To further complicate the picture, it has been reported that, 
depending on p53 status, TLR4 stimulation may have oppo-
site effects on promotion of breast cancer cell growth [638].
A common misconception is that only proteins expressed 
in bacteria can be contaminated by LPS. In reality, a variety 
of sources have been found to be contaminating [628]. Tap 
water, air and people’s fingers can lead to endotoxin contami-
nation. It has been reported that one of the most common 
sources of endotoxin is laboratory water since distillation 
and deionizing columns do not remove endotoxin [628]. 
Pyrogen-free water is helpful, but LPS can be still introduced 
by inadequate handling of containers during washing proce-
dures. A variety of chemical reagents and buffers are also 
potential sources of endotoxin [628]. It is not uncommon to 
find high levels of endotoxin in biological products such as 
albumin, collagen or gelatin. Indeed, it has been argued that, 
unless specific steps to prevent LPS contamination have been 
taken and the LPS level is indicated, one should assume that 
a reagent is almost certainly contaminated [628]. Therefore, 
LPS levels ideally should be tested routinely and certainly 
whenever unexpected results are obtained.
In biotech settings, the generally acceptable LPS levels 
for antibodies or other protein reagents to be tested in pre-
clinical studies are < 1 EU (~ 100 pg)/mg protein. Achiev-
ing such low levels requires significant planning and taking 
Fig. 27  Effects of imidazole on endothelial cell proliferation. BCECs 
(bovine choroidal microvascular endothelial cells) were cultured in 
the presence of low-glucose DMEM in the presence of 10% bovine 
calf serum as previously described [645]. Elution buffer was tested 
up to a final concentration of 5 mM imidazole, with or without 10 ng/
ml VEGF165. Note that the concentration of imidazole typically used 
to elute His-tagged proteins is 500  mM. After 5-6  days, cell prolif-
eration was determined by fluorescence readings at 590 nm. Asterisks 
denote significant differences compared to no addition (0) groups by t 
test (***p < 0.001, **p < 0.01)
504 Angiogenesis (2018) 21:425–532
1 3
multiple steps to prevent contamination [628], besides the 
usual chromatographic steps aimed at achieving high purity 
of the recombinant protein. Treatment of columns and equip-
ment with 1 N NaOH for 1 h (> 10 h when using 0.1 N 
NaOH) is typically employed to inactivate LPS. Methods 
to remove LPS in contaminated preparations have also been 
described, although their success is relatively mixed [629].
It is noteworthy that even some relatively recent contro-
versies in the tumor angiogenesis field might be attributed, 
at least in part, to LPS (or other contaminants). For example, 
Paez-Ribes and colleagues reported in 2009 the unexpected 
finding that the anti-VEGFR2 monoclonal antibody DC101 
promotes invasiveness and metastasis in the Rip-Tag model of 
insulinoma [530]. This finding was in conflict with previous 
studies reporting inhibition of invasiveness by DC101 in other 
models [639] and with subsequent reports that did not confirm 
induction of tumor invasiveness and metastasis by DC101 in 
the Rip-Tag model [557, 640]. While the DC101 employed 
in the majority of studies was purified and distributed by 
ImClone Systems [641], Paez-Ribes and colleagues purified 
the antibody themselves from supernatants of hybridoma cells 
that had been deposited at the American Tissue Culture Col-
lection [530]. Unfortunately, the authors did not describe any 
steps to remove LPS nor did they report the LPS levels in their 
preparations of DC101 [530]. Given the high doses of DC101 
required for in vivo studies (100 mg/kg/week), it is conceiv-
able that even a relatively modest contamination may affect 
the results. It remains to be determined whether LPS was truly 
responsible for the reported tumor invasiveness.
However, LPS is by no means the only confounder in angi-
ogenesis-related assays. Commonly used reagents or contami-
nants, for example detergents employed to solubilize samples 
or misfolded or aggregated proteins, can have major effects on 
endothelial cells. In the course of earlier studies in which we 
screened libraries of secreted proteins to identify growth stimu-
lators and inhibitors [642], we observed a surprisingly high rate 
of inhibitory “hits” using an early version of the library [643]. 
However, the majority of these “hits” could not be confirmed 
using more stringently purified proteins. It became apparent 
that basal or VEGF-stimulated endothelial cell growth could 
be easily inhibited by a variety of impurities, as above noted. 
Imidazole, the buffer typically employed to elute His-tagged 
protein bound to Nickel columns, a common procedure to purify 
recombinant proteins, was also found to have profound effects 
in endothelial cell proliferation assays. Figure 27 illustrates the 
effects of imidazole on proliferation of bovine microvascu-
lar endothelial cells. As little as 3 mM significantly inhibited 
VEGF-stimulated endothelial cell growth. At 4–5 mM imida-
zole, there was a dramatic inhibition of both basal and VEGF-
stimulated endothelial cell growth. Considering that 500 mM 
is the concentration of imidazole commonly used to elute pro-
teins from Nickel columns, a several hundred-fold final dilution 
or, preferably, a buffer exchange is advisable before adding the 
sample to endothelial cells. It has been suggested that similar 
issues might account for the opposite reports by two groups on 
the effects on endothelial cell growth of VEGF-Ax, a VEGF 
isoform arising from read through translation [644, 645].
30.3  Concluding remarks
It is clear from the above that contamination of reagents can 
have major effects in both in vitro and in vivo assays. The 
most well-known contaminant with major consequences is 
bacterial endotoxin, or LPS. Endotoxin is not only present in 
recombinant preparations but can be co-purified from many 
other sources. Next to endotoxin, other contaminants can 
have major effects as well. It is therefore required to check 
compound preparations for the presence of contaminants and 
take action for purification when necessary.
31  Conclusions
This paper describes a large number of assays and analysis 
methods that can be used for the assessment of angiogen-
esis. A proper interpretation of these assays is warranted for 
obtaining relevant mechanistical insight into the sequence of 
angiogenesis processes in different tissues and under chang-
ing conditions. We have aimed to provide insight into the use 
and interpretation of the mostly used assays and have tried 
to provide the reader with the challenges, limitations, and 
pitfalls in making use of these assays.
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